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Abstract  
 
Introduction: Malignant Pleural Mesothelioma (MPM) is an incurable malignancy with severe 
symptoms. It is challenging to diagnose and with limited treatments.  
The studies described here aim to determine the diagnostic accuracy of four biomarkers in MPM, 
identify factors to aid prognosticating, and test the efficacy of a novel intervention, early specialist 
palliative care (SPC).  
Methods: In the biomarker study ELISA evaluated SMRP, Fibulin-3, Osteopontin and HMGB-1 
concentrations in MPM patients.  
Regression analysis assessed the ability of a series of patient factors from a retrospective MPM 
patient cohort to predict prognosis. 
The RESPECT-Meso study was a randomised controlled trial assessing early SPC versus standard 
care in a 1:1 ratio on quality of life (QOL) in 174 MPM patients.  
Key findings: The biomarker study revealed effusion SMRP levels were significantly higher in 
MPM patients compared to benign and other malignant effusions (3170nM/L vs 210nM/L vs 
428nM/L, p<0.001). SMRP predicted MPM with an AUC of 0.93 (0.86-0.99) giving 95% sensitivity 
and 86% specificity at a threshold of 1150nM/L. 
In the analysis of prognostic factors patient age, smoking status, chest pain, weight loss, PLT 
count, Urea and Adjusted Calcium were independently associated with survival. Being a current 
smoker carried the highest hazard ratio 3.42 (1.11, 4.2) p=0.03.  
The RESPECT-Meso study was unable to demonstrate a difference in QOL with early SPC 
compared to standard care with a 1.8 mean difference between groups (95%CI: -4.9 to 8.5; 
p=0.59). 
Conclusions: This body of work evaluating three components of MPM care concludes, SMRP as a 
biomarker with a significant ability to predict MPM from other causes of pleural effusion in a real 
world clinical setting. Seven prognostic factors identified may aid clinicians to better 
prognosticate when planning treatments in MPM. Finally the results of the RESPECT-Meso study 
are reassuring of the exiting care pathway for MPM.  
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1. Introduction to Malignant Pleural Mesothelioma 
Malignant pleural mesothelioma (MPM) is a rare cancer predominantly caused by asbestos which 
affects the pleura, a thin membrane of cells which lines the lungs and chest wall (Woolhouse et 
al., 2018). The focus of this chapter is to give a detailed overview of MPM including its 
epidemiology, aetiology, clinical presentation, diagnosis and finally how it is currently managed. 
1.1 Epidemiology of MPM 
The incidence of MPM differs across different countries worldwide, varying from 7 per million in 
Japan to 40 per million in Australia annually. In Europe the incidence is 20 per million (Scherpereel 
et al., 2010). These differences are related to the differences in historical asbestos imports and its 
use. Factors such as the long latency period of 30-40 years between asbestos exposure and 
manifestation of the disease (BTS, 2007) diagnostic practices, and awareness of the disease may 
also influence reported incidence rates (Scherpereel et al., 2010). 
Although MPM is perceived to be a rare disease attributing to less than 1% of all cancers 
diagnosed in the UK, combined data from the office for national statistics, Welsh cancer 
intelligence and surveillance unit, information services division Scotland, and the Northern Ireland 
cancer registry have shown that there were 2,717 new cases of MPM in the UK in 2014. Of these 
84% were men and 16% were women, giving a male to female ratio of 5:1. The crude incidence 
rate shows that there are 7.0 new mesothelioma cases for every 100,000 males in the UK, and 1 
for every 100,000 females(CRUK, 2015b). 
The UK now has the highest death rate from MPM in the world (Rake et al., 2009) and predictions 
continue to forecast this figure increasing up to 2015 and possibly 2020 (Hodgson, McElvenny, 
Darnton, Price, & Peto, 2005; Peto, Decarli, La Vecchia, Levi, & Negri, 1999; Peto, Hodgson, 
Matthews, & Jones, 1995). The projected lifetime risk of MPM for a UK male born in the 1940s is 
0.59%, or approximately 1 in 170 of all deaths (Hodgson et al., 2005). A review into the burden 
from MPM in Great Britain by the Health and Safety Executive published in 2017 (HSE, 2017) 
reported 2542 deaths from MPM in 2015 with a similar number in the preceding three years. The 
latest projects are in line with 2500 deaths per year until the end of this decade (Figure 1). These 
figures are supported by the number of new cases assessed for Industrial Injuries Disablement 
Benefit (IIDB) which was 2170 in 2016. 
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Figure 1: MPM annual deaths, IIDB cases and projected future deaths to 2030 in GB (HSE, 2017). 
 
As in the UK the incidence of MPM worldwide is also on the rise (Table 1), and although the 
reason for this is not entirely clear it is likely to represent the local trends of asbestos use (Volker 
Neumann, Löseke, Nowak, Herth, & Tannapfel, 2013). Certainly for the UK these figures would 
appear to be an underestimate as previously described which may be the case in other countries. 
However this data gives a good indication of the disease burden likely to be encountered in the 
future. 
Table 1: Predicted peak incidence years and incidence at peak for mesothelioma in various countries. 
Country Incidence at peak 
(new cases per million per year) 
Peak years(s) Predicted deaths per 
year at peak 
United Kingdom 38 2016 2040 
France 20 2020-2040 1300 
Germany 20 2015-2020 1600 
Australia 40 2010 1000 
 
MPM is a disease of adults and with an age range of 35 to 98 years and a median of 75 years at 
diagnosis as reported in the 2016 mesothelioma National Lung Cancer Audit (NLCA) report (NLCA, 
2016). There are significant differences in the MPM death rate between different age groups 
(Figure 2). Men aged over 70 have the highest rates and will continue to follow an upward trend 
whilst rates in men aged 65 and below are falling. Age specific death rates from MPM in females 
are generally an order of magnitude lower than for males but follows a similar pattern (HSE, 
2017). 
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Figure 2: Male MPM death rates by age and time period 1968-2015 (HSE, 2017). 
 
The higher MPM death rates noted in older male populations (Figure 2) may be explained by the 
very long latency period, and so time to manifest itself between first exposure to asbestos and 
death from mesothelioma. One review of over 20 epidemiological studies which documented 
latent periods reported a median latency of 32 years, very few cases with latency of less than 20 
years and nearly one-third of cases with latency of more than 40 years. A more recent British 
study has reported a mean latency of 41 years (range 15–67) (Scherpereel et al., 2010). 
MPM is in the main a disease of men with 2542 male deaths in 2015 compared to only 407 female 
deaths during this time (HSE, 2017). The incidence of death in men and women from MPM is 
demonstrated in Figure 3. Whilst mesothelioma deaths in males are expected to peak this decade, 
the peak in females is expected to be well beyond 2020 at about a quarter of the level of the male 
peak (HSE, 2017). This is because historically exposure to asbestos was far more common in 
occupations with a male predominant workforce, leading to a much higher incidence of 
mesothelioma among males than females. According to the French National Mesothelioma 
Surveillance Program, the risk fraction attributable to occupational asbestos exposure is more 
than 80% in males and less than 40% in females (BTS, 2007). 
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Figure 3: Male and female MPM deaths 1968-2015 (HSE, 2017). 
 
1.2 Aetiology of MPM: Asbestos exposure 
The name “asbestos” derives from Greek meaning inextinguishable or unquenchable and is now 
recognised as the most common cause of MPM. Asbestos refers to a group of six silicate minerals 
which are able to form very thin fibres and of which chrysotile, amosite, and crocidolite are 
commonly used in industry (Røe & Stella, 2015). Chrysotile also known as white asbestos is the 
most used type of asbestos, consisting of fine silky curly fibres formed in sheets, and found 
commonly throughout the world. Chrysotile is considered less bio-persistent in the lungs than 
amphiboles. Amosite and crocidolite also respectively known as brown and blue asbestos have 
straight brittle fibres with a chain-like structure and were both commonly used in naval and ship 
building industries. Amosite mainly occurs in South Africa, whereas crocidolite occurs in many 
locations such as Australia, South Africa, Bolivia, the former Soviet Union, and Canada (NCRI, 
2010).  
Asbestos fibres are extremely resistant to heat and almost indestructible by physical force. 
Crushed asbestos forms soft fine filaments that can be spun into lightweight strong fibres which 
had multiple industrial and domestic uses (Levin, Kann, & Lax, 2000). These properties led to the 
development of the asbestos industry from 1890 onwards with certain industries and occupations 
such as shipyard workers, railway carriage builders, plumbers, gas fitters, joiners and electricians 
coming into contact with particularly high concentrations of asbestos. Evidence from two British 
studies suggested that the proportion of MPM in males directly attributable to asbestos exposure 
may be as high as 85% (BTS, 2007; Yates, Corrin, Stidolph, & Browne, 1997). 
Para occupational exposure resulting in MPM has also been described in wives and children of 
asbestos workers through exposure and inhalation of asbestos dust from their work clothes 
(Howel et al., 1997; Scherpereel et al., 2010). MPM resulting from close vicinity to deteriorating 
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asbestos materials from commercial and domestic premises has been reported (Hillerdal, 1999; 
Wagner, Sleggs, & Marchand, 1960). Cases of non-occupational or environmental mesotheliomas 
have also been linked to ‘‘natural’’ asbestos exposure in areas of the world where asbestos exists 
as a geological component of the soil such as in Turkey, Corsica, Cyprus and New Caledonia and 
also in people living close to asbestos mines or factories (Scherpereel et al., 2010). 
The ancient Greeks and Romans first noted that asbestos damaged the lungs of slaves who wove 
it into cloth. The first studies to establish the association between asbestos and MPM were 
published in the 1960 (Wagner et al., 1960). Prior to controls on asbestos exposure introduced in 
the 1970s, industrial asbestos exposure was widespread in the United Kingdom (UK). The 
maximum use of asbestos in the UK occurred in the 1960s and 70s. Despite this a much larger 
workforce involved with lagging and construction continued to be exposed until the early 1980s 
(Rake et al., 2009). In the UK, amosite and crocidolite were banned in 1985 but imports of 
chrysotile were not banned until 1999 (F. J. Brims, 2009; Turner, Newall, Tweedale, & Hansen, 
2000). As a result of health and safety legislation all types of asbestos and its importation has now 
been banned in most European countries (NCRI, 2010). However despite the evidence 
surrounding the lethal effects of asbestos, its production and use continues in many medium and 
low resource countries putting their populations at increased risk of asbestos-related illnesses. 
This is due to the low cost of this material and poor understanding of and lack of resources for its 
safe handling and disposal. At present Russia and Canada are the largest exporters of asbestos in 
the world and India and Thailand are the largest importers (NCRI, 2010).   
1.2.1 Other causes of MPM 
Erionite and therapeutic irradiation have been recognised to be potential risk factors for MPM as 
has genetic predisposition. A study looking at familial clusters of MPM suggested that genetic 
predisposition does seem to influence mineral fibre carcinogenesis in Turkey where erionite is 
implicated for a high incidence of the disease (Scherpereel et al., 2010). However familial 
clustering of mesothelioma may be explained by shared environmental factors rather than 
genetic factors. A recent Swedish study (Ji, Sundquist, & Sundquist, 2016) which to date is the 
only  population based piece of work looking at familial risk in mesothelioma identified a 
significantly increased risk of developing MPM in individuals with siblings and parents already 
diagnosed with MPM. No association was seen between spouses which further strengthens the 
argument for a genetic link. 
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1.3 Pathogenesis of MPM 
MPM is a solid, locally aggressive tumour of the pleura that encases and invades the lung 
parenchyma leading to clinically significant morbidity and eventually death. Inhaled asbestos 
fibres migrate to the pleura. There the asbestos fibres induce acute inflammatory responses at 
the site of deposition leading to mediation of inflammatory cytokines, recruitment of 
macrophages and neutrophils, and airway epithelial cell proliferation (Bibby et al., 2016). There 
are repeated cycles of damage, repair and inflammation. Oxygen free radicals released by 
asbestos fibres during this process causes intra-cellular DNA damage and abnormal repair. The 
asbestos fibres penetrate mesothelial cells generating DNA mutations. These mesothelial cells 
release inflammatory cytokines which then create a microenvironment for tumour growth. 
Asbestos can also induce phosphorylation of various protein kinases leading to the expression of 
proto-oncogenes which in turn leads to abnormal cell proliferation. 
Based on prognostic significance the World Health Organisation (WHO) has classified MPM into 
one of three main types. These are epithelioid, sarcomatoid and biphasic (mixed) (Travis WD, 
2004). Epithelioid mesothelioma is the most common subtype and accounts for approximately 
60% of MPM. Epithelioid tumours contain polygonal, oval or cuboidal cells that can often mimic 
reactive mesothelial cell proliferations that occur in response to various types of injury. 
Sarcomatoid MPM account for about 10-20% of mesotheliomas (BTS, 2007; F, 2010) and consist 
of spindle cells that can mimic malignant mesenchymal tumours such as malignant fibrous 
histiocytoma, leiomyosarcoma or synovial sarcoma. Sarcomatoid MPM is more aggressive 
compared to epithelioid MPM and rarely appears to have the ability to metastasise to bone which 
is otherwise unusual in mesothelioma (BTS, 2007). Biphasic MPM contain a mixture of epithelioid 
and sarcomatoid areas within the same tumour and account for about 30% of mesotheliomas. 
MPMs are arbitrarily classified as biphasic when there is at least 10% of each component (Bibby et 
al., 2016; Husain et al., 2009).  
 
1.4 Clinical presentation of MPM 
Presenting symptoms in MPM are often an insidious onset of dyspnoea or chest pain. In the early 
stages, dyspnoea is usually caused by the build-up of pleural effusions. A pleural effusion is an 
increase in the normal volume of fluid contained between the inner or visceral pleura and the 
outer or parietal pleura during the normal physiological state. The visceral pleura lines the lung 
and the parietal pleura lines the rib cage, mediastinum and diaphragm. The pleural fluid acts as a 
lubricant and allows the lung to move in and out smoothly during respiration. In MPM there can 
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be a pathological increase in this fluid compressing the lung and altering lung mechanics leading 
to dyspnoea. As MPM progresses the pleura becomes thickened and encases the lung resulting in 
increased dyspnoea by further restricting lung expansion (BTS, 2007). This process is depicted as a 
cartoon in Figure 4. 
                                           
Figure 4: Diagram showing the transition from a normal lung to one with pleural mesothelioma (CRUK, 
2015a). 
 
Weight loss and fatigue are also commonly seen and a study examining quality of life (QOL) in 
MPM patients receiving chemotherapy demonstrated that 92% of patients have 3 or more 
physical symptoms at presentation with fatigue (94%), dyspnoea (89%), appetite loss (87%) and 
pain (85%) being the most prominent (Hollen, Gralla, Liepa, Symanowski, & Rusthoven, 2004). A 
more recent retrospective study evaluating the symptom burden in MPM found pain, weakness, 
poor appetite, poor well-being and dyspnoea to be the most frequent symptoms with the highest 
intensity (Mercadante, Degiovanni, & Casuccio, 2016). 
MPM can also occasionally be incidentally found on radiological imaging as an asymptomatic 
pleural effusion, pleural thickening or pleural mass. Finger clubbing may occur and is more 
commonly seen in mesothelioma than any other asbestos related disease. Bilateral disease is rare 
at presentation but not uncommon in the terminal phases of the disease. Patients rarely may also 
present with pneumothorax (BTS, 2007).  
MPM usually progresses by local extension rather than haematogenous spread. However, post-
mortem studies from patients with mesothelioma suggest metastases are surprisingly common 
although, they are rarely detected clinically (Rhian et al.). 
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1.5 Current diagnostic pathway for MPM 
The current diagnostic pathway uses a combination of clinical history, examination, radiology and 
pathology and is outlined in Figure 5 (BTS, 2007). Presenting symptoms of MPM can frequently be 
non-specific and insidious in onset with a latency period between exposure to asbestos and 
disease. Therefore even in the presence of previous asbestos exposure, clinical manifestations 
alone should not be used to make a diagnosis (BTS, 2007). 
 
Figure 5: The current diagnostic algorithm for malignant pleural mesothelioma. (MM=Malignant 
mesothelioma, CXR=Chest X-ray, CT=Computer Tomography, MDT=Multi-disciplinary meeting, 
PET=Positron emission tomography, US=Ultrasound) (BTS, 2007). 
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1.5.1 Imaging in MPM 
Chest radiographs usually show a unilateral pleural effusion or pleural thickening but these 
findings alone should not be used to make the diagnosis of MPM (Scherpereel et al., 2010). Chest 
computer tomography (CT) can help identify evidence of previous asbestos exposure by the 
presence of pleural plaques. Contrast-enhanced CT can also exhibit certain features such as 
nodular pleural thickening, mediastinal pleural thickening, parietal pleural thickening of more 
than 1 cm and circumferential pleural thickening which can help differentiate between benign and 
malignant pleural disease. These features have specificities of 94%, 94%, 88% and 100%, 
respectively, and sensitivities of 51%, 36%, 56% and 41%. The accuracy of these criteria for the 
detection of pleural malignancy has since been confirmed in several prospective studies (C. 
Hooper, Lee, & Maskell, 2010). Despite these advances in diagnosing pleural malignancy the 
differentiation between MPM and metastatic pleural malignancy remains difficult as they both 
share these CT features and therefore is unsuitable for definitive diagnosis of MPM (C. Hooper et 
al., 2010; Scherpereel et al., 2010). 
Certain features on thoracic ultrasound can also help distinguish malignant from benign pleural 
disease with a  sensitivity of 79% and specificity of 100%, but is again is unable to differentiate 
between MPM and metastatic disease to the pleura (C. Hooper et al., 2010).  
Magnetic Resonance Imaging (MRI) is equal to CT in its ability to differentiate between benign and 
malignant pleural disease but may be useful in situations when CT is contraindicated. However 
access to MRI is still somewhat restricted and therefore except when contrast-enhanced CT is 
contraindicated such as in allergy to contrast or renal failure MRI is of limited use (C. Hooper et 
al., 2010).  
Positron emission tomography-computed tomography (PET-CT) combines high resolution CT with 
an injection of a radioactive metabolic tracer, 18-fluorodeoxyglucose (FDG) which accumulates in 
areas of increased metabolic activity (Bibby et al., 2016). As FDG uptake is reliant on metabolic 
activity false negatives can occur in early disease and in tumours with a low proliferation rate 
(Bibby et al., 2016). Although FDG uptake has been shown to be greater in malignant pleural 
effusions, the value of PET-CT in distinguishing between benign and malignant disease is limited 
by false positives caused by pleural inflammation including pleural infection and following talc 
pleurodesis. Therefore PET-CT imaging is not currently recommended in the routine diagnosis of 
pleural mesothelioma but may be useful for monitoring response to treatment and assessing 
prognosis (C. Hooper et al., 2010). 
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1.5.2 Pathological diagnosis in MPM 
Pleural effusion is usually the first clinical sign of MPM. Therefore cytological examination which is 
the examination of the cellular component of pleural fluid is often the first diagnostic examination 
to be carried out. Previous studies examining the diagnostic rate for malignancy in pleural fluid 
cytology have reported a mean sensitivity of about 60% (C. Hooper et al., 2010). For MPM the 
sensitivity of pleural fluid cytology is lower and can be as low as 20% (Rakha et al., 2010). Many 
cytological features of MPM such as intercellular windows, variation in cytoplasmic staining, and 
low nuclear-to-cytoplasmic ratios are also shared between reactive and malignant epithelioid 
mesothelial cells (Husain et al., 2009). Therefore due to this high risk of diagnostic error cytology 
alone should not be used to diagnose MPM and the joint 2010 European Respiratory Society and 
the European Society of Thoracic Surgeons (ERS/ESTS) guidelines on the management of MPM 
recommend cytological suspicion is followed by tissue confirmation for definitive diagnosis of 
MPM (Scherpereel et al., 2010).  
The British Thoracic Society (BTS) and the ERS/ESTS guidelines both state that thoracoscopy 
should be the preferred diagnostic investigation in order to obtain a tissue diagnosis (C. Hooper et 
al., 2010; Scherpereel et al., 2010). Thoracoscopy uses an endoscope which is an illuminated optic 
instrument that is inserted through an incision made in the chest wall. It allows complete visual 
examination of the pleura, providing the opportunity to obtain multiple, deep biopsies for 
histology and will provide a diagnosis in more than 90% of cases (Roberts, Neville, Berrisford, 
Antunes, & Ali, 2010). Despite these advances in the investigation of MPM, diagnosis still remains 
challenging with less than 5% of patients with MPM being diagnosed at an early stage 
(Pantazopoulos, Boura, Xanthos, & Syrigos, 2013). 
This is because although these diagnostic procedures ensure a high level of tissue diagnosis with 
good quality biopsy specimens, these procedures are relatively invasive and may not be suitable 
for all. Therefore less invasive novel methods of diagnosis are much needed and are likely to have 
a major impact on the speed of diagnosis. A growing body of research is evaluating biomarkers as 
a much less invasive mode for diagnosis and is investigated in more detail in chapter two. 
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1.5.3 Staging in MPM 
The stage of a cancer describes its size and spread. This information is important as it gives insight 
into the prognosis of a patient suffering with cancer and will also inform appropriate treatment 
options.  
The lung cancer TNM staging system was initially used to stage MPM. Recently a new staging 
system proposed jointly by the International Association for the Study of Lung Cancer (IASLC) and 
the International Mesothelioma Interest Group (IMIG) (Figure 6) has been adopted. This has been 
accepted by the Union for International Cancer Control (UICC) and the American Joint 
Commission on Cancer (AJCC) both for the clinical and pathological staging of MPM (H. Pass et al., 
2016). Despite recent developments in the field, staging MPM is challenging due to limitations in 
currently available imaging methods with regard to accurately assessing tumour size and nodal 
involvement (Scherpereel et al., 2010). Unlike certain cancers for which a surgical cure is sought, 
MPM cannot be surgically cured. Therefore staging is perceived by some cancer multi-disciplinary 
meetings (MDT) to be more of an academic interest until staging data has more influence on 
management. 
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Figure 6: The International staging system for MPM (H. Pass et al., 2016). 
 
 
1.6 Treatment for MPM 
When considering potential therapeutic strategies in addition to factors such as MPM type and 
MPM stage some consideration must also be given to patients’ level of fitness. Many available 
treatments are associated with potentially toxic side effects.  Therefore, when considering 
treatments patient tolerability must be evaluated in order to avoid harm. This is determined by 
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assessing the patient’s level of fitness.  Patient Performance Status (PS) is a recognised and widely 
used tool which enables clinicians to assess patient fitness. The most widely used PS is the Eastern 
Cooperation Oncology Group (ECOG) PS (Sørensen, Klee, Palshof, & Hansen, 1993). A numerical 
figure is assigned on a scale of 1-5 depending on the patient’s level of fitness. This scale is outlined 
below; 
 PS 1- Fully active, 
PS 2- Restricted in physically strenuous activities. Able to perform work of a sedentary nature, 
PS 3- Ambulatory and capable of all self-care but unable to carry out any work activities, 
PS 4- Need assistance with self-care, 
PS 5- Deceased 
In this next section currently available treatments for MPM and their evidence base is described.  
1.6.1 Surgery in MPM 
Surgical options for MPM are available but lack a sound evidence base. Extra-pleural 
pneumonectomy (EPP) is a radical surgery performed with curative intent in MPM. EPP involves 
the removal of the pleura, lung, ipsilateral diaphragm, and often pericardium. The MARS trial 
(Treasure et al., 2011) was a multicentre randomised feasibility study assessing clinical outcomes 
in patients assigned to EPP versus no EPP. In the study EPP was associated with a high rate of 
morbidity causing the study to conclude that radical mesothelioma surgery in the form of EPP 
offered no benefit and possibly caused harm to patients. 
Another type of radical surgery in MPM is extended pleurectomy/decortication (EPD) or lung 
sparing pleurectomy. This procedure involves stripping the outer parietal pleura, the inner visceral 
pleura with the diaphragm and/or pericardium aiming for total macroscopic clearance of tumour. 
The MARS2 trial (Waller & Dawson, 2017) which is currently underway and has been designed to 
assess the ability to recruit to a trial comparing EPD and standard chemotherapy with no EPD and 
standard chemotherapy in patients with MPM. 
Partial pleurectomy has also been assessed in MPM. The MesoVATS study (Rintoul et al., 2014) 
was an open label randomised controlled trial comparing video assisted thoracoscopic surgical 
partial pleurectomy with talc pleurodesis. Video assisted thoracoscopic surgery (VATS) is when 
the lung is approached through a number of small incisions between the ribs allowing a surgeon 
to perform a pleurectomy where the both parietal and visceral pleura is removed. The intention is 
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purely palliative by debulking the tumour. Talc pleurodesis which is a widely used method for 
managing symptomatic pleural effusions involves inserting a chest tube into the pleural space, 
removing the accumulated fluid, allowing the lung to re-inflate, and then inserting talc, which 
encourages the parietal and visceral pleura to stick together. MesoVATS was unable to show a 
survival benefit with surgery. Complication rates and length of hospital stay were also higher with 
surgery. Thus based on currently available evidence, attempts at major debulking surgery are not 
recommended outside of clinical trials at present. 
1.6.2 Radiotherapy in MPM 
Retrospective and uncontrolled series have demonstrated that radiotherapy can help with pain 
relief for patients with MPM and is widely used as a palliative measure (BTS, 2007). However due 
to the diffuse nature of MPM and the potential toxicity to lung and adjacent organs radical 
radiotherapy is of limited use. A retrospective review of 123 patients with MPM receiving hemi-
thoracic radiotherapy post lung sparing pleurectomy found 10% severe lung toxicity and 1.5% 
mortality at 1 month implying that radical radiotherapy was not suitable with the lung in situ 
(Gupta et al., 2005). Another study evaluating hemi-thoracic radiotherapy post neoadjuvant 
chemotherapy followed by EPP concluded that there was no role for hemi-thoracic radiotherapy 
in this setting (Stahel et al., 2015).  
Prophylactic irradiation of surgical procedure site to prevent tumour seeding along the tract 
causing subcutaneous chest wall metastasis has been widely practiced (Boutin, Rey, & Viallat, 
1995; Bydder et al., 2004). However a recent UK based multicentre randomised controlled trial 
concluded against the routine use of prophylactic radiotherapy in this setting (Clive et al., 2016). 
At the time of writing the PIT study another trial evaluating the role of prophylactic procedure 
tract site radiotherapy had completed recruitment and was awaiting publication (Bayman et al., 
2016). 
Radiotherapy for symptom palliation is also used. To date although there is no role for whole 
hemi-thoracic radiation for symptom management the latest BTS guidance does recommend 
palliative radiotherapy in the context of localised pain caused by MPM (Woolhouse et al., 2018).  
1.6.3 Systemic therapy in MPM 
Chemotherapy may be suitable for certain patients but despite the large volume of evidence 
assessing its efficacy, MPM has proved extremely resistant to many chemotherapy agents. A 
systematic review of use of chemotherapy in patients with MPM pooled the results from 111 
phase II studies and indicated that only single agent cisplatin and combinations containing 
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cisplatin resulted in response rates of >20% (Ellis, Davies, Evans, Haynes, & Lloyd, 2006). Following 
this result the EMPHASIS trial demonstrated how a chemotherapy regime combining cisplatin and 
pemetrexed improved survival from 9.3 with cisplatin alone to 12.1 months (Vogelzang et al., 
2003) and has since become the standard worldwide. More recently the MAPS trial has shown 
that combining Bevacizumab with cisplatin and pemetrexed can improve survival from 14 months 
to 18 months (Zalcman et al., 2016). However this drug is not yet available on the National Health 
Service (NHS).  
To date there is no agreed consensus on a second line chemotherapy for MPM and active 
research is ongoing for further chemotherapy and immunotherapy agents for patients with MPM.  
1.6.4 Symptom control 
Nearly all patients with MPM experience a significant ongoing burden of physical, social and 
emotional symptoms during the relentless progression of their condition until death. Pain, 
dyspnoea, weakness, anorexia and sense of poor well-being are common symptoms with three 
quarters of patients experiencing pain. These symptoms also appear to be associated with the 
highest intensity. Despite this and a reasonably well defined prognosis many patients suffer from 
a lack of access to palliative care services until the late stages of their illness (Mercadante et al., 
2016). The National Institute for Health and Care Excellence (NICE) has highlighted the 
importance of symptom control and has described supportive care as encompassing information 
giving, self-help and support, user involvement, symptom control, psychological support, social 
support, spiritual support, rehabilitation, complementary therapies, palliative care, end-of-life and 
bereavement care (NICE, 2004). At present there is a sparsity of evidence evaluating symptom 
control specifically in MPM. In chapter four the symptom burden in MPM is explored further. The 
importance of optimal symptom control and developing existing services aimed to better manage 
symptoms in MPM is then investigated through the design of a randomised controlled trial (RCT) 
(Gunatilake et al., 2014).  
 
1.7 An unmet need 
The diagnosis and management of MPM is complex. Diagnosis can be difficult as a result of its 
indolent clinical features which are non-specific. Even once clinical suspicion has been aroused 
confirmation of the diagnosis can be challenging with clinical teams relying on a combination of 
radiological features and various biopsy techniques which are not always suitable. As a result 
patients may need to undergo lengthy periods of surveillance and repeated testing in order to 
finally arrive at a diagnosis which is inevitably delayed. Once a diagnosis of MPM is made it is 
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important that the management is tailored to the individual patient. Although MDTs are 
experienced in making these decisions, there is limited insight into patients’ prognosis which 
should be a key factor in deciding which treatment would be best suited. A better understanding 
of each patient’s prognosis based on prognostic factors specific to each patient would enable 
better patient tailored care. From previous published data it is also apparent that MPM is 
associated with a significant early symptom burden. Yet patients rarely have access to palliative 
care services until later on in the disease process which is often too late. This would suggest an 
unmet need for better early specialist symptom control for patients with MPM. 
On reviewing the existing MPM care pathways it is clear that the currently available expertise in 
MPM diagnosis, prognosticating in MPM and management of the symptom burden in MPM is 
sub-optimal. In this piece of work I have attempted to take an in depth look at these three 
components of MPM care and strived to seek improvements so that a higher standard of care 
might be delivered to patients with MPM in the future. Figure 7 demonstrates how these might 
further enhance the existing care pathway for MPM. 
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Figure 7: Algorithm for diagnosis and management of MPM including anticipated use of a novel 
biomarker test, a novel prognostic tool and early better integrated SPC. (CT=Computer tomography, 
IPC=Indwelling pleural catheter, LAT=Local anaesthetic thoracoscopy, MDT=Multi-disciplinary meeting, 
MPM=Malignant pleural mesothelioma, PET=Positron emission tomography, US=Ultrasound).  
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2. A prospective comparison of serum and pleural fluid biomarkers in 
the diagnosis of Malignant Pleural Mesothelioma 
2.1 Review of the literature 
2.1.1 Early diagnosis of MPM 
Differential diagnosis and early detection are the greatest challenges in making a diagnosis of 
MPM. The difficulty in making an early diagnosis arises due to its non-specific symptoms and the 
limitations in sensitivity/specificity of current biological and radiological techniques.  Diagnosis 
based on clinical suspicion of MPM alone is insufficient to initiate treatment.  
The long delays associated with seeking confirmation of the diagnosis may often result in disease 
progression leading to worse patient PS. A patient’s PS is a factor which has a major influence on 
treatment. PS is used as a standardised surrogate for patient fitness. Patients with a PS of 0-1 are 
considered fit enough to receive anti-cancer treatments whilst patients with a PS of 2 need more 
individualised assessment. Data gathered as part of the 2014 LUCADA mesothelioma report 
showed that only 54% of patients present with a PS of 0-1 (NLCA, 2014) (Figure 8). This would 
suggest that many patients are denied these treatments as a result of worse PS at time of 
diagnosis.  
 
Figure 8: PS at time of MPM diagnosis according to 2014 National lung cancer audit report (NLCA, 2014). 
 
Delays in diagnosis will also cause patients and carers considerable anxiety, discomfort, and 
ultimately may result in patients not being able to receive optimal treatment (NLCA, 2016).  
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Once a diagnosis of MPM is confirmed patients are eligible to then claim compensation 
(Woolhouse et al., 2018). An early diagnosis of mesothelioma is therefore not only important for 
making early decisions about treatment, but also to ensure patients and their families receive 
timely compensation. Although clinical teams appreciate this urgency, despite good adherence to 
referral targets and timely investigations less than 5% of patients with MPM are diagnosed early 
(Scherpereel et al., 2010).  
2.1.2 Novel diagnostic tests 
A diagnostic test such as a serum or pleural fluid biomarker could significantly improve the 
current diagnostic pathway (figure 7). Such a test would be less invasive and may be of great 
benefit for those patients where current diagnostic strategies have been inconclusive or 
inappropriate. It would also have the potential for a much earlier diagnosis which is a major 
challenge at present. 
2.1.3 Clinical role of biomarkers 
A biomarker is a measurable characteristic that reflects the severity or presence of some disease 
states including cancer. Biomarkers can be a molecule, a process, or a substance that is altered 
quantitatively or qualitatively in pre-cancerous or cancerous conditions and is detectable by an 
assay. It is usually a protein, but can also be DNA, mRNA, or a process such as apoptosis, 
angiogenesis or proliferation and may be either produced exclusively by the cancerous tissue 
itself or by surrounding tissue in response to growth of the cancer (Hayes et al., 1996). 
Today certain tumour markers are used to further support diagnosis and monitoring treatment of 
several types of cancer. Sensitive markers facilitate early diagnosis and therefore early 
therapeutic intervention that generally offers a better prognosis. Biomarkers also have a role in 
predicting prognosis, assessing response to treatment as well as disease relapse.  
Several tumour makers have already been investigated in different types of cancer specifically for 
early diagnosis and have shown considerable success. Alpha-fetoprotein for liver, testicular and 
other germ-cell tumours, CA125 for ovarian cancer, prostatic specific antigen in prostate cancer, 
and oestrogen and progesterone receptors in management of breast cancer are some examples 
(Schrohl et al., 2003).  
Biomarkers are becoming increasingly popular throughout the field of diagnostic medicine as they 
support the future goals for more personalised diagnoses and treatments of disease (Deakin, 
2009). Biomarkers are considerably cheaper and less invasive than conventional investigations 
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such as thoracoscopy, and therefore offer the potential to save cost whilst also increasing patient 
choice and limiting the need for invasive tests with the potential risks. 
2.1.4 Biomarkers for MPM 
An ideal biomarker for MPM would need to predict development of mesothelioma in asbestos 
exposed individuals, and differentiate MPM and non-MPM pleural disease. It would need to be 
useful in all histological subtypes and correlate with disease extent allowing monitoring of 
treatment response and also assessing prognosis. It should also be measurable in biological 
samples obtained from non-invasive or minimally invasive tests and have an acceptable cost. 
Finally the perfect biomarker should have 100% sensitivity and specificity for mesothelioma. Such 
a biomarker in serum or pleural fluid would significantly simplify the diagnostic algorithm for 
MPM aiding early diagnosis and enabling more treatment options to be initiated with greater 
success.  
Although a variety of biomarkers for mesothelioma have been studied, and despite some 
promising early results to date there are no reliable biomarkers for the diagnosis of MPM. The 
most widely studied biomarkers are soluble mesothelin related peptide (SMRP), osteopontin and 
fibulin-3. Yet a number of other biomarkers have also been assessed but only in exploratory 
studies with potential for further evaluation.  
2.1.5 Soluble Mesothelin Related Peptide (SMRP) 
The most researched biomarker in MPM is soluble mesothelin related peptide. SMRP is the 
circulating form of a 40kDa membrane bound glycoprotein whose levels are raised in MPM. The 
mesothelin precursor consists of two proteins, the membrane bound mesothelin protein and 
megakaryocyte potentiating factor. Although mesothelin is usually bound to the cell membrane, 
abnormal splicing event leads to the circulating SMRP (Cui, Jin, Zhai, Tong, & Shi, 2014).  
SMRP has been shown to be expressed in normal mesothelial cells and although overexpressed in 
MPM it is also raised in pancreatic, ovarian, lung, sarcomas and gastrointestinal cancers (B. W. 
Robinson et al., 2003). SMRP has been found to be present in human serum and pleural fluid and 
hence much interest has been expressed in its potential utility as a biomarker for MPM 
(Pantazopoulos et al., 2013). 
The diagnostic accuracy of serum SMRP for detection of mesothelioma has been extensively 
studied. Despite numerous studies evaluating SMRP in serum demonstrating high specificity for 
differentiating MPM from healthy controls, patients with other malignancies and asbestos 
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exposed patients the sensitivity of SMRP has been inadequate. This inability to exclude MPM to 
date is a major limiting factor to its value as a biomarker. 
A Chinese group (Luo et al., 2010) published results of the first meta-analysis reporting on the 
overall  diagnostic accuracy of serum SMRP in MPM. This work revealed that SMRP had a 
specificity of 90% and sensitivity of 61% for differentiating MPM from other pulmonary disease.  
SMRP had a specificity of 92% for differentiating patients with MPM from healthy subjects but 
again the sensitivity was only marginally improved, 64%. While these results suggested that SMRP 
could  play a role in the diagnosis of MPM the low sensitivity values remain a major limitation to 
its use in clinical practice (Luo et al., 2010).  
Work done by Hollevoet et al who conducted an individual patient data meta-analysis evaluating 
SMRP concluded that despite low sensitivity values a positive value with a high specificity cut off 
could be used as an additional tool in the diagnostic arsenal for mesothelioma and as incentive to 
do further investigations (Hollevoet et al., 2012).  
Pleural fluid SMRP values are much higher than serum SMRP concentrations. Pleural fluid SMRP 
has been investigated to a much lesser extent than in serum. Although a diagnostic test based on 
pleural fluid sampling would be more invasive compared to serum sampling this would still be 
much preferred and less invasive compared to the current gold standard which is thoracoscopy 
and pleural biopsy. Cui et al reviewed the literature on SMRP in serum and pleural fluid for 
diagnosing MPM (Cui et al., 2014). In total 30 publications determining human SMRP in either 
serum or pleural fluid for its diagnostic accuracy were reviewed. Serum SMRP was evaluated in 23 
studies and pleural fluid SMRP was evaluated in 12 studies. A meta-analysis of the data 
demonstrated a pooled specificity of 87% and 85% and sensitivity of 61% and 79% in serum and 
pleural fluid respectively.  
2.1.6 Osteopontin 
Osteopontin is another promising biomarker for MPM. Osteopontin is an extracellular 
glycoprotein that is not only involved in non-mineral bone matrix formation, but is also a primary 
cytokine in mediating type I immune responses. It has been implicated in regulating metastatic 
spread by tumour cells. Osteopontin has also been found to be over-expressed in several human 
neoplasms such as lung, breast, prostate, colon, ovarian cancer and melanoma (Pantazopoulos et 
al., 2013). 
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Osteopontin has been implicated in cell-signalling pathways that are associated with asbestos 
induced carcinogenesis and studies have demonstrated that serum or plasma osteopontin levels 
might be able to distinguish patients with MPM from those who have benign pleural disease 
associated with asbestos exposure (H. I. Pass et al., 2005). Pass et al also demonstrated that 
serum osteopontin had a sensitivity of 77.6% and specificity of 85.5% for distinguishing patients 
with MPM from subjects exposed to asbestos (H. I. Pass et al., 2005). Unfortunately data so far 
suggests that osteopontin seems to be unable to reliably distinguish between MPM, pleural 
metastatic carcinoma and patients with benign pleural lesions from asbestos exposure (Grigoriu 
et al., 2007). 
Due to these inconsistencies associated with the diagnostic utility of osteopontin Hu et al 
attempted to establish the diagnostic accuracy of osteopontin for MPM (Hu, Liu, Liu, Ding, & Hu, 
2014). A meta-analysis including eight studies investigating the overall diagnostic role of 
osteopontin in the diagnosis of MPM gave a specificity of 81%, while the sensitivity was only 57%. 
However the meta-analysis was limited by several factors. Only five studies on osteopontin were 
included with only a limited number of patients. Furthermore it was not clear whether serum or 
plasma is best for testing and studies included used both specimens for testing which is likely to 
have influenced the result. This study concluded that more robust studies were required to 
rigorously assess the diagnostic power of osteopontin.  
2.1.7 High-Mobility Group Box 1 
High-Mobility Group Box 1 (HMGB1) is a member of the high-mobility group protein super-family 
and acts as an extra cellular signalling molecule associated in a variety of biological processes such 
as transcription, DNA repair, proliferation, and inflammation (Tabata et al., 2013).  
HMBG1 is present in the nucleus and passively released from necrotic cells and actively secreted 
from cells during inflammation. It’s activity has been identified in several disease states including 
cancers including melanoma, colon cancer, breast cancer and lung cancer (Tang, Kang, Zeh, & 
Lotze, 2010). MPM involves the malignant transformation of mesothelial cells which originate 
from mesenchymal cells. Previous work has shown that exposure to asbestos can lead to necrosis 
of the mesothelial cells. This leads to the release of HMGB1 eventually resulting in the secretion 
of Interleukin-1b and this inflammatory cascade is known to be linked with asbestos related 
carcinogenesis (Sun, Vaynblat, & Pass, 2017)  
A recent single study (Tabata et al., 2013) evaluating serum HMGB1 in MPM showed significantly 
higher levels of HMGB1 in patients with MPM compared with non-MPM patients with a previous 
43 
 
history of asbestos exposure. Although the specificity was 100% the sensitivity of serum HMGB1 
for MPM was low (34.4%). Further work evaluating hyperacetylated HMGB1 which is an isoform 
of HMGB1 demonstrated a sensitivity and specificity of 100% in differentiating MPM from benign 
effusion including patients with asbestos exposure at a cut off of 2ng/ml (Napolitano et al., 2016). 
This would suggest high levels of HMGB1 may be supportive of a diagnosis of MPM (Sun et al., 
2017). This is the only study which has evaluated serum HMGB1 as a biomarker for MPM. To date 
the role of pleural fluid HMGB1 as a biomarker for MPM has not been studied. 
2.1.8 Fibulin-3 
Fibulin-3 is a highly conserved protein in the extracellular glycoprotein fibulin family. It is encoded 
by the gene epidermal growth factor-containing fibulin-like extracellular matrix protein 1 
(EFEMP1) on chromosome 2p16 (Zhang & Marmorstein, 2010). Gene expression of EFEMP1 is low 
in normal tissues. The expression of fibulin-3 is localised to condensing mesenchyme, where it 
mediates cell to cell and cell to matrix communication and is inversely related to cell growth. 
Gene silencing of EFEMP1 has been reported in a number of cancers, including mesothelioma, 
lung, prostate, colorectal and breast cancers (H. I. Pass et al., 2012).  
Pass et al 2012 demonstrated that plasma fibulin-3 had a sensitivity of 96.7% and a specificity of 
95.5% for the detection of mesothelioma at a cut-off of 52ng/ml. Effusion fibulin-3 had a 
sensitivity of 83.8% and specificity 92.4% (H. I. Pass et al., 2012). This was a significant 
improvement on the sensitivity and specificity quoted for any other biomarkers for this disease. 
However to date these results are yet to be replicated. A study by Creaney et al comparing the 
utility of fibulin-3 versus mesothelin, in isolation or in combination reported a sensitivity of only 
22% and specificity of 95% for plasma fibulin-3 at the previously reported threshold of 52ng/ml 
(Creaney et al., 2014). In this study by lowering the threshold to 29ng/ml the sensitivity was 
improved to 48% with a specificity of 71%. Unlike the high sensitivity and specificity in the 
previous study (Watzka et al., 2011) here the difference in pleural effusion fibulin-3 levels was not 
significant. Also as previously observed there was no correlation between plasma and pleural 
effusion fibulin-3 levels.  
Fibulin-3 may also have a prognostic use and Creaney et al demonstrated that fibulin-3 
concentrations were higher in MPM patients with the sarcomatoid and biphasic histological sub-
types compared to the epithelioid sub-type (Creaney et al., 2014). Furthermore there is a negative 
linear relationship between survival and pleural fluid fibulin-3 levels but not serum or plasma 
fibulin-3 levels (Creaney et al., 2014; Kirschner et al., 2015). This poor correlation between fibulin-
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3 levels in matched plasma and effusion samples has been noted in both patients with MPM and 
non-MPM (H. I. Pass et al., 2012). Therefore further studies are required to elucidate the basis of 
the discrepancy between these studies. 
2.2 Aim 
The current MPM diagnostic pathway is complex and time consuming. The aim of this research 
was to identify a biomarker test which could detect MPM. This would cut out several steps in the 
current pathway and allow for a more timely diagnosis and initiation of earlier treatment.  
2.3 Method 
2.3.1 Objectives 
• To determine whether a chosen panel of 4 biomarkers including fibulin-3, osteopontin, 
HMGB1 and SMRP were elevated in the serum and pleural fluid of patients with MPM 
compared to patients with pleural effusions associated with metastatic cancer and benign 
pleural effusions (BPE) in Portsmouth, and determine the accuracy and local cut-off 
values.  
• To determine whether any of these chosen biomarkers could be utilised either alone or in 
combination as a robust biomarker for MPM. 
2.3.2 Study design 
This was a diagnostic accuracy study using a case-control design with samples obtained from 
consecutive cases. The work took place at Queen Alexandra Hospital (QAH), Portsmouth. 
I was responsible for the design of this study and developed the study protocol as well as the 
study case reporting form (CRF), patient consent form and patient information sheet (PIS). I 
liaised closely with the REC, study sponsor, and the study statistician. 
At the end of the sample collection period serum and pleural samples were categorised into 3 
groups; MPM, metastatic cancer and benign pleural effusions (BPE). Samples from patients in 
whom the diagnosis was uncertain at the time of analysis were withdrawn to prevent 
contamination of the analysis. Biomarker testing was performed on all serum and pleural fluid 
samples for which consent had been obtained. 
2.3.3 Study population 
Biomarker levels were measured in serum and pleural effusions from patients presenting to QAH, 
Portsmouth between June 2014 and August 2015 suspected or confirmed with the following; 
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1. Patients with malignant pleural mesothelioma (MPM). 
2. Metastatic cancer defined as: 
a. Histological or cytological proven pleural malignancy. 
OR 
b. Otherwise unexplained pleural effusion in the context of clinically proven cancer   
elsewhere. 
OR 
c. Radiologically proven pleural malignancy as diagnosed in normal clinical practice on 
thoracic CT in the absence of histological or cytological proof. 
3. Patients with benign pleural effusions (BPE). 
2.3.4 Eligibility criteria 
All patients presenting with a pleural effusion in which pleural fluid sampling was clinically 
indicated were considered for inclusion. Patients with a chest drain or indwelling pleural catheter 
in situ for management of their pleural effusion were also considered for inclusion to the study.  
All participants had to be aged 18 years or above and have the ability to provide written informed 
consent in English and comply with study procedures. There were no specific exclusion criteria for 
this study. 
2.3.5 Ethical and Research approval 
Ethical approval for this research was granted on the 16th of April 2014 by the National Research 
Ethics Service (NRES) Committee London - Camberwell St Giles (Research Ethics Committee (REC) 
reference number: 14/LO/0628 (Appendix 1)). The project was granted local site approval by 
Portsmouth Hospitals NHS Trust (PHT), Research and Development Department on the 6th of 
June 2014 (Reference number PHT/2014/18 (Appendix 2)). This work was funded by the PHT 
Research and Development department’s research fund. 
2.3.6 Sample collection and storage 
Sample searches were performed on a regular basis by a nominated biomedical scientist using the 
laboratory information system to identify all pleural effusions and their respective, matched 
serum samples within 2 week either side of pleural fluid collection that had been received by the 
Blood Sciences Department Laboratory for routine analysis.  
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The Respiratory Research Nurse or Research Medical Officer (RMO) was then contacted to obtain 
retrospective consent from the patients from whom these samples were obtained. Where 
possible potential participants were also prospectively identified by the respiratory department 
and consented prior to routine pleural fluid and serum sampling.  The patients were provided 
with verbal and written information about the study in the form of a PIS. Patients were given as 
much time as necessary to make their decision about entering the study, and given adequate 
opportunity to ask questions prior to obtaining their informed consent to participate in the study. 
Patients were informed that they would not directly benefit from the results of this study, but 
that the results aimed to improve patient care in the future. If consent was not achieved, patients 
were reassured that their routine care and investigations would not be affected by their decision 
not to participate. An Excel data sheet maintained on a Trust computer account in the 
translational oncology research centre was created to record patient information and the 
eventual diagnosis. 
All biomarker testing on pleural effusions were performed on samples that were taken as part of 
routine patient care and no further pleural fluid samples were obtained specifically for the 
purposes of this project except in patients with a chest drain or indwelling pleural catheter in situ 
for management of their pleural effusion. If routine sampling of blood was not planned and there 
were no stored serum samples, a further venepuncture to obtain 4mls of blood was necessary 
with the patients consent. Permission for this was granted by the REC. 
2-3ml aliquots were taken from pleural effusion samples before routine tests are performed. 
Pleural fluid was then centrifuged at 3000rpm for 10 minutes. Serum aliquots were obtained from 
the patient using the same venepuncture as required for routine blood sampling. These were then 
centrifuged at 3000rpm for 10 minutes and paired with the pleural fluid sample as soon as 
possible. Patient samples were then labelled with a sequential laboratory number that was 
assigned to the particular patient and only linked to specimens related to this study. A record of 
the laboratory number designation for each patient was stored in a database accessible only to 
designated staff in the Translational Oncology Research Centre. Serum and pleural fluid samples 
were then stored in the laboratory -80°C freezers for later batch analysis as recommended by the 
enzyme-linked immunosorbent assay (ELISA) kit manufacturers after completion of sample 
collection. 
2.3.7 Sample analysis 
At the end of the sample collection period 64 serum and 98 pleural fluid samples were collected. 
Of the 64 serum and 98 pleural fluid samples 10 and 27 were respectively discarded as consent 
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from these patients could not be obtained for their use. The remaining 54 serum and 71 pleural 
fluid samples were then divided based on aetiology into the 3 categories MPM, metastatic cancer 
and BPE (Table 2). 
Table 2: Samples collected for analysis. 
 
 
 
Serum 
 
Pleural fluid 
MPM 11 20 
Metastatic cancer 23 29 
BPE 20 22 
 
All analysis took place in the combined Blood Sciences Laboratory at QAH, Portsmouth. The ELISAs 
for each reagent, SMRP, osteopontin, fibulin-3 and HMGB1 were performed according to 
protocols (appendices 3-6) adapted by the Blood sciences Laboratory at QAH from the 
manufacturer’s instructions.  An overview of the ELISA method is given below. 
A standard 96 well plate, with colourimetric detection was used for the quantitative 
measurement of the 4 different biomarkers in serum and pleural fluid using specific ELISA kits. All 
4 assays used 2 antibodies, which were identified as the capture antibody; reagent A and 
detection antibody-enzyme conjugate; reagent B. Reagent A which coated the standard ELISA 
microplate wells bound to the biomarker. Reagent B which is conjugated to an enzyme was added 
and detected and then captured the biomarker molecule. A substrate solution was then added. 
The enzyme catalysed the oxidation of the substrate solution changing colour. The 
spectrophotometric micro-titre then measured the optical density of light with a wavelength of 
450nm within 30 minutes of adding the stop solution. The optical density of 450nm correlated 
with the concentration of biomarker in the sample. 
2.3.8 Statistical analysis 
A statistician was assigned for statistical analysis. In the initial analysis fibulin-3, HMGB-1, 
osteopontin and SMRP values were measured in serum and pleural fluid of the patients in the 
three original groups MPM, metastatic cancer and benign disease. Due to the distribution of the 
biomarkers, the Kruskal-Wallis test was performed to compare the biomarker values between the 
three groups. 
The main outcome was defined as the ability of the four biomarkers to detect patients with MPM. 
Effusions associated with metastatic cancer and BPE were combined and considered as a ‘non-
MPM’ group. The four biomarkers of interest were tested on both serum and pleural fluid. Each of 
these was measured on a continuous scale, and each was found to have a positively skewed 
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distribution.  Due to the distribution of the biomarkers, the analysis was performed using the 
Mann-Whitney test. The predictive ability of each biomarker to determine MPM was then 
examined by calculating the area under the receiver operating curve (ROC). 
For biomarkers found to be associated with MPM, the ROC curve results were used to choose cut-
off points to predict patients with MPM. Two different approaches were used. The first cut-off 
point was chosen to give the best combination of sensitivity and specificity. The second cut-off 
point was chosen to give a high sensitivity (>90%). At each cut-off the sensitivity, specificity, 
positive and negative predictive values were calculated.  
The joint association of the biomarkers on the likelihood of MPM was then examined. This 
analysis was performed using multiple logistic regression (MLR) with the biomarkers as the 
predictor variables and MPM and non-MPM as the outcome measure. Due to the skewed 
distribution of the biomarkers, these were analysed on the log scale. A backwards selection 
procedure was performed to retain only the significant biomarkers in the final model. If more 
than one biomarker was found to be statistically significant the area under the curve (AUC) of the 
combined variables was calculated. 
A further analysis was performed to demonstrate whether the biomarkers were predictive of 
MPM, when metastatic cancers were omitted from the analysis, i.e. comparing the MPM group 
with the benign group. Although a combination of clinical judgment and conventional imaging can 
be used to often exclude metastatic cancer, differentiating between MPM and BPE remains a 
challenge.  
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2.4 Results 
2.4.1 Demographics 
54 serum and 71 pleural fluid samples were included in the final analysis. Demographic data was 
provided for the benign disease group, metastatic cancer group, MPM group and collectively for 
all subjects. Pleural fluid samples were analysed from 20 patients with histologically confirmed 
MPM all of which were of the epithelioid histological sub-type. 29 pleural fluid samples were 
analysed from patients with metastatic cancer. Of these 16 were lung cancer, 3 ovarian cancer, 3 
non-Hodgkin lymphoma, 2 breast cancer, 2 oesophageal cancer, 1 sarcoma, 1 bladder cancer and 
1 vulval cancer. Finally 22 pleural fluid samples from benign effusions were analysed. Of these 
patients serum was analysed from 11 MPM patients, 23 metastatic cancer patients and 20 
patients with BPEs. The demographic data from which serum and pleural fluid was sampled is 
summarised in Table 3 and Table 4 respectively. Categorical variables were summarised by the 
number and percentage in each group, whilst the mean and standard deviation was used for age 
which was the only continuous variable and had a normal distribution. 
Table 3: Patient demographics of serum samples. 
Factor BPE 
(n=20) N (%) 
Metastatic Cancer 
(n=23) N (%) 
MPM 
(n=11) N (%) 
All subjects 
(n=54) N (%) 
     
Male sex 12 (60%) 11 (48%) 9 (82%) 32 (59%) 
Age at consent (*)  69 ± 14 71 ± 9 76 ± 7 72 ± 11 
Comorbidity 12 (60%) 16 (70%) 8 (73%) 36 (67%) 
COPD 0 (0%) 2 (9%) 2 (18%) 4 (7%) 
Asthma 3 (15%) 3 (13%) 1 (9%) 7 (13%) 
PE 0 (0%) 1 (4%) 0 (0%) 1 (2%) 
ILD 0 (0%) 1 (4%) 0 (0%) 1 (2%) 
Bronchiectasis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Cardiac failure 5 (25%) 3 (13%) 0 (0%) 8 (15%) 
Hypertension 7 (35%) 10 (43%) 7 (64%) 24 (44%) 
Liver disease 3 (15%) 1 (4%) 0 (0%) 4 (7%) 
CKD 2 (10%) 3 (13%) 1 (9%) 6 (11%) 
Asbestos exposure 4 (20%) 11 (48%) 7 (64%) 22 (41%) 
Previous cancer 2 (10%) 12 (52%) 2 (18%) 16 (30%) 
Current chemo 0 (0%) 5 (22%) 1 (9%) 6 (11%) 
Current radio. 0 (0%) 4 (17%) 1 (9%) 5 (9%) 
Pleural infection 3 (15%) 1 (4%) 0 (0%) 4 (7%) 
Serum markers 0 (0%) 1 (4%) 1 (9%) 2 (4%) 
     
(*) Mean ± standard deviation reported 
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Table 4: Patient demographics of pleural fluid samples. 
Factor BPE 
(n=22) N (%) 
Metastatic Cancer 
(n=29) N (%) 
MPM 
(n=20) N (%) 
All subjects 
(n=71) N (%) 
     
Male sex 13 (59%) 14 (48%) 16 (80%) 43 (61%) 
Age at consent (*)  70 ± 14 73 ± 10 76 ± 7 73 ± 11 
Comorbidity 13 (59%) 21 (72%) 16 (80%) 50 (70%) 
COPD 0 (0%) 3 (10%) 3 (15%) 6 (8%) 
Asthma 2 (9%) 3 (10%) 1 (5%) 6 (8%) 
PE 0 (0%) 2 (7%) 0 (0%) 2 (3%) 
ILD 0 (0%) 1 (3%) 0 (0%) 1 (1%) 
Bronchiectasis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Cardiac failure  (27%) 4 (14%) 0 (0%) 10 (14%) 
Hypertension 9 (41%) 13 (45%) 15 (75%) 37 (52%) 
Liver disease 2 (9%) 1 (3%) 0 (0%) 3 (4%) 
CKD 2 (9%) 3 (10%) 1 (5%) 6 (8%) 
Asbestos exposure 6(27%) 15 (52%) 13 (65%) 34 (48%) 
Previous cancer 4 (18%) 16 (55%) 5 (25%) 25 (35%) 
Current chemo **0 (0%) 5 (17%) 3 (15%) 8 (11%) 
Current radio. 0 (0%) 5 (17%) 2 (10%) 7 (10%) 
Pleural infection 3 (14%) 1 (3%) 0 (0%) 4 (6%) 
Serum markers 0 (0%) 1 (3%) 1 (5%) 2 (3%) 
     
(*) Mean ± standard deviation reported 
2.4.2 Serum data – 3 groups 
Each biomarker was measured in serum for all three groups. A comparison of the biomarker 
values in serum are summarised in Table 5. The median value and inter-quartile range for each 
biomarker in serum is given for patients with MPM, patients with metastatic cancer and patients 
with BPE. The p-values demonstrating the significance of the difference between groups is also 
included. This analysis showed no significant difference between the three groups for any of the 
biomarkers examined. These results are also graphically illustrated by boxplots (Figure 9).  
 
Table 5: Summary of biomarker concentrations in serum. 
Test BPE 
Median (IQR) 
Metastatic Cancer 
Median (IQR) 
MPM 
Median (IQR) 
P-
value 
     
Fibulin-3 (ng/ml) 2.6 (1.5, 4.4) 2.0 (1.0, 3.3) 1.5 (0.6, 5.1) 0.57 
HMGB-1 (pg/ml) 689.0 (497.0, 
955.0) 
724.0 (604.0, 
992.0) 
671.0 (384.0, 
1068.0) 
0.80 
Osteopontin (ng/ml) 19.0 (13.0, 24.0) 22.0 (14.0, 30.0) 13.0 (9.0, 25.0) 0.15 
SMRP (nmol/L) 2.1 (1.1, 2.8) 1.8 (1.4, 2.7) 2.8 (1.6, 3.2) 0.17 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 9: Graphical illustrations of the difference in biomarkers values for serum shown by boxplot. 
2.4.3 Pleural fluid data – 3 groups 
The four biomarkers were then measured in pleural fluid for each group. A summary of the values 
including medians, interquartile ranges and p-values are included in Table 6. Again there was no 
significant difference between the three groups for fibulin-3, HMGB-1 or osteopontin. However, a 
highly significant difference was observed for SMRP. The highest values were found in the MPM 
group with a median of 3170nmol/L. SMRP median values were lower in the other two groups, at 
428nmol/L in the metastatic cancer group and 210nmol/L in the group with benign disease (Table 
6). This is further presented by boxplot (Figure 10). 
 
Table 6: Summary of biomarker concentrations in pleural fluid. 
Test BPE 
Median (IQR) 
Metastatic Cancer 
Median (IQR) 
MPM 
Median (IQR) 
P-value 
     
Fibulin-3 (ng/ml) 58 (32, 85) 38 (12, 94) 47 (31, 86) 0.770 
HMGB-1 (pg/ml) 1783 (1219, 2650) 2103 (1601, 3215) 1788 (1329, 2115) 0.220 
Osteopontin (ng/ml) 63 (50, 78) 70 (57, 85) 67 (52, 81) 0.580 
SMRP (nmol/L) 210 (110, 599) 428 (194, 776) 3170 (2253, 4026) <0.001 
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(a) Fibulin-3 
 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 10: Graphical illustration of the biomarker results for pleural fluid from each category shown by 
boxplots. 
2.4.4 Serum data for MPM and non-MPM 
The ability of the four biomarkers to differentiate MPM from pleural effusions of other cause was 
tested next. The biomarker values were therefore analysed based on the presence of MPM or no 
MPM (non-MPM). The values of the four biomarkers in serum of patients with MPM and non-
MPM are given in Table 7. Due to the distribution of the biomarkers, the median and inter-
quartile ranges were used as summary measures. The p-values from the Mann-Whitney test, and 
the area under the ROC curves presented with corresponding confidence intervals were also 
reported. 
 
Table 7: Summary values for biomarkers in serum of patients with MPM and non-MPM. 
Test Non-MPM 
Median (IQR) 
MPM 
Median (IQR) 
P-
value 
AUC 
(95% CI) 
     
Fibulin-3 (ng/ml) 2.3 (1.3, 6.6) 1.5 (0.6, 5.1) 0.42 0.60 (0.30, 0.89) 
HMGB-1 (pg/ml) 721.0 (545.0, 962.0) 671.0 (384.0, 1068.0) 0.69 0.54 (0.32, 0.76) 
Osteopontin (ng/ml) 21.0 (14, 27) 13.0 (9.0, 25.0) 0.11 0.66 (0.46, 0.86) 
SMRP (nmol/L) 1.8 (1.2, 2.7) 2.8 (1.6, 3.2) 0.06 0.68 (0.51, 0.86) 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 11: Graphical illustration in the form of boxplots for Fibulin-3(a), HMGB-1(b), Osteopontin(c) and 
SMRP(d) values in serum for MPM and non-MPM. 
 
The biomarker values for MPM and non-MPM are represented as boxplots (figure 11). None of 
the four biomarkers were strongly associated with MPM. There was some evidence that MPM 
patients had higher SMRP values than non-MPM patients, although this difference was only of 
borderline statistical significance (p=0.06).  
ROC curves were calculated for each biomarker. SMRP gave an area under the ROC curve (AUC) of 
0.68, suggesting that it might have some predictive ability. The ROC curves for all 4 biomarkers 
including SMRP for MPM are shown in the Figure 12.  
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 12: ROC curves demonstrating the AUC for fibulin-3, HMGB1, osteopontin and SMRP 
differentiating MPM from non-MPM in serum. 
 
The predictive ability of SMRP for detecting MPM in serum was further examined, by evaluating 
the diagnostic ability at specific cut-points. The chosen cut-point and diagnostic performance are 
summarised in Table 8. Only a single cut-off was considered for serum levels due to the lower 
predictive ability of this variable. A serum SMRP concentration of 2.28nmol/L enabled a sensitivity 
73% and specificity of 67% for MPM. 
  
Table 8: Cut-points and diagnostic performance of SMRP in serum for MPM. 
Statistic 
 
Cut-off value 
  
2.28 
 
73% 
67% 
36% 
91% 
Cut-off (nmol/L) 
 
Sensitivity (%) 
Specificity (%) 
Positive Predictive Value (%) 
Negative Predictive Value (%) 
 
 
An additional set of analyses used logistic regression to jointly examine the effect of the four 
biomarkers on MPM in serum. A backwards selection approach was then used to retain only the 
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statistically significant variables. The analysis results are summarised in Table 9. This analysis 
suggested that, as in the initial analyses, none of the four biomarkers were significantly associated 
with MPM, and therefore no variables were included in the final model.   
Table 9: Summary of analysis; logistic regression of biomarker concentrations in serum for MPM. 
Model 
 
Test Odds Ratio (95% CI) (*) P-value 
    
Full model Fibulin-3 0.67 (0.25, 1.78) 0.43 
 HMGB-1 3.88 (0.79, 19.1) 0.10 
 Osteopontin 0.34 (0.06, 1.84) 0.21 
 SMRP 1.47 (0.54, 3.97) 0.45 
    
Final model - - - 
    
(*) Odds ratios given for 1-unit increase on log scale 
 
2.4.5 Pleural fluid data for MPM and non-MPM 
A summary of the values for fibulin-3, HMGB-1, osteopontin and SMRP in pleural fluid of patients 
with MPM and non-MPM are given in Table 10. Again due to the distribution of the biomarkers, 
the median and inter-quartile ranges were used as summary measures. The p-values from the 
Mann-Whitney test and the area under the ROC curves presented with corresponding confidence 
intervals are included. 
 
Table 10: Summary of the values for biomarkers in pleural fluid of patients with MPM and non-MPM. 
Test non-MPM 
Median (IQR) 
MPM 
Median (IQR) 
P-value AUC 
(95% CI) 
     
Fibulin-3 (ng/ml) 55 (18, 94) 47 (31, 86) 0.980 0.50 (0.36, 0.64) 
HMGB-1 (pg/ml) 2068 (1269, 2773) 1788 (1329, 2115) 0.170 0.60 (0.47, 0.74) 
Osteopontin (ng/ml) 67 (50, 84) 67 (52, 81) 0.720 0.53 (0.38, 0.68) 
SMRP (nmol/L) 396 (150, 761) 3170 (2253, 4026) <0.001 0.93 (0.86, 0.99) 
     
 
The results indicated that there was no statistically significant difference in the values of fibulin-3, 
HMGB-1 and osteopontin between patients with MPM and without MPM. However, SMRP values 
were significantly different in the MPM and non-MPM groups. Patients with MPM had a SMRP 
median value of 3170nmol/L which was much higher than the median value of 396nmol/L seen in 
patients without MPM (p<0.001).  The values for fibulin-3, HMGB-1, osteopontin and SMRP in 
pleural fluid for MPM and non-MPM are represented as boxplots in Figure 13. SMRP was found to 
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have a high predictive ability for determining MPM, with an area under the curve (AUC) of 0.93. 
The ROC curves for all four biomarkers are shown below (Figure 14).  
 
(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 13: Graphical illustration in the form of boxplots for Fibulin-3(a), HMGB-1(b), Osteopontin(c) and 
SMRP(d) values in pleural fluid for MPM and non-MPM. 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 14: ROC curves demonstrating the AUC for fibulin-3, HMGB1, osteopontin and SMRP 
differentiating MPM from non-MPM in pleural fluid. 
 
The predictive ability of SMRP for detecting MPM was further examined, by evaluating the 
diagnostic ability at specific SMRP concentration thresholds. Two different cut-off points were 
considered for pleural fluid SMRP. The analysis suggested that the first cut-off of 1440nmol/L gave 
similar values for sensitivity (90%), and specificity (88%). The second cut-off of 1150nmol/L was 
chosen to give a higher sensitivity (95%) but specificity was slightly lower (86%). The chosen cut-
point and diagnostic performance are summarised in Table 11. 
 
Table 11: Cut-points and diagnostic performance of pleural fluid SMRP for MPM. 
Statistic 
 
Cut-off 1 Cut-off 2 
  
1440 
 
90% 
88% 
74% 
96% 
 
1150 
 
95% 
86% 
72% 
98% 
Cut-off (nmol/L) 
 
Sensitivity (%) 
Specificity (%) 
Positive Predictive Value (%) 
Negative Predictive Value (%) 
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Logistic regression was then used to jointly examine the effect of the four biomarkers on MPM in 
pleural fluid. A backwards selection approach was used to retain only the statistically significant 
variables.  The full model (with all variables) and the final model from the selection procedure are 
shown in the Table 12. Only SMRP was significantly associated with MPM. The values reported are 
the change in the odds of MPM for a one unit increase in each biomarker on the log scale. 
The final model suggested that a one-unit increase in SMRP on the log scale was associated with 
the odds of MPM increasing by a factor of 10.  
 
Table 12: Summary of analysis; logistic regression of biomarker concentrations in pleural fluid for MPM. 
Model 
 
Test Odds Ratio (95% CI) (*) P-value 
    
Full model Fibulin-3 0.58 (0.20, 1.67) 0.310 
 HMGB-1 0.24 (0.03, 2.16) 0.200 
 Osteopontin 11.60 (0.36, 365) 0.170 
 SMRP 17.50 (4.01, 76.4) <0.001 
    
Final model SMRP 9.87 (3.29, 29.6) <0.001 
    
(*) Odds ratios given for 1-unit increase on log scale 
2.4.6 Serum data – MPM vs. BPE 
Differentiating between MPM which is in the main caused by asbestos and benign pleural 
effusions (BPE) and in particular benign asbestos pleural effusions can be challenging. Although 
certain radiological features may help increase diagnostic suspicion of malignancy further testing 
is often necessary for fear of delaying a potential cancer diagnosis. A biomarker test with the 
ability to differentiate between malignant and benign asbestos pleural disease would be 
extremely useful negating the need for repeated invasive pleural biopsies. With this in mind a 
further analysis was performed to demonstrate whether the biomarkers were predictive of MPM, 
when metastatic cancers were omitted from the analysis, thus comparing the MPM group with 
the BPE group. 
A summary of the values of fibulin-3 HMGB-1, osteopontin and SMRP in patients with MPM and 
BPE are given in Table 13. Due to the distribution of the biomarkers, the median and inter-quartile 
ranges were used as summary measures. The p-values from the Mann-Whitney tests, and the 
area under the ROC curves (presented with corresponding confidence intervals) are also reported.  
Again the results suggested that none of the four biomarkers were strongly associated with MPM. 
There was some evidence that MPM patients had higher SMRP values than benign patients, 
although this difference was only of borderline statistical significance (p=0.06). The value of each 
biomarker for the MPM and benign groups are represented in boxplots (Figure 15).  
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Table 13: Summary of biomarker concentrations in serum for MPM and BPE. 
Test BPE 
Median (IQR) 
MPM 
Median (IQR) 
P-value AUC 
(95% CI) 
     
Fibulin-3 (ng/ml) 2.6 (1.5, 4.4) 1.5 (0.6, 5.1) 0.35 0.62 (0.31, 0.93) 
HMGB-1 (pg/ml) 689.0 (497.0, 
955.0) 
671.0 (384.0, 
1068.0) 
0.93 0.51 (0.27, 0.74) 
Osteopontin (ng/ml) 19.0 (13.0, 24.0) 13.0 (9.0, 25.0) 0.30 0.61 (0.38, 0.84) 
SMRP (nmol/L) 2.1 (1.1, 2.8) 2.8 (1.6, 3.2) 0.06 0.70 (0.51, 0.90) 
     
 
(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 15: Graphical illustration in the form of boxplots for Fibulin-3(a), HMGB-1(b), Osteopontin(c) and 
SMRP(d) values in serum for MPM and BPE. 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 16: ROC curves demonstrating the AUC for fibulin-3, HMGB1, osteopontin and SMRP 
differentiating MPM from BPE in serum. 
 
The ROC curves for all four biomarkers were calculated (Figure 16). The predictive ability of SMRP 
for detecting MPM in serum was further examined, by evaluating the diagnostic ability at specific 
cut-points. A single cut-off was considered for serum levels due to the lower predictive ability of 
this variable. The cut-off was to give the best combination of sensitivity and specificity (Table 14). 
The results suggested that at the ‘best’ cut-off which was at a SMRP concentration of 2.28nmol/L 
gave a sensitivity of 73% and specificity of 70%%.  
 
Table 14: Cut-points and diagnostic performance of SMRP in serum for MPM compared to BPE. 
Statistic 
 
Cut-off 
  
2.28 
 
73% 
70% 
57% 
82% 
Cut-off (nmol/L) 
 
Sensitivity (%) 
Specificity (%) 
Positive Predictive Value (%) 
Negative Predictive Value (%) 
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Logistic regression was then used to examine the effect of the four biomarkers in combination for 
MPM in serum. A backwards selection approach was used to retain only the statistically 
significant variables. The analysis results are summarised in Table 15. The results are given for the 
‘full’ model, which includes all predictor variables, and then for the final model containing only 
the significant variables.  
 
Table 15: Summary of analysis; logistic regression of biomarker concentrations in serum for MPM 
compared to BPE. 
Model 
 
Test Odds Ratio (95% CI) (*) P-value 
    
Full model Fibulin-3 0.52 (0.16, 1.73) 0.29 
 HMGB-1 4.46 (0.60, 32.8) 0.14 
 Osteopontin 0.36 (0.04, 3.28) 0.37 
 SMRP 1.52 (0.48, 4.77) 0.47 
    
Final model - - - 
    
(*) Odds ratios given for 1-unit increase on log scale 
 
This analysis, as in the initial analyses which did not exclude the metastatic cancer group 
demonstrated that none of the four biomarkers in combination were strongly associated with 
MPM, and therefore no variables were included in the final model. 
2.4.7 Pleural fluid data– MPM vs. BPE 
Pleural fluid fibulin-3, HMGB-1, osteopontin and SMRP levels in the MPM and BPE groups were 
then compared and are summarised in Table 16. No significant difference was seen in fibulin-3, 
HMGB-1 and osteopontin values (Figure 17). However, the SMRP value was significantly higher 
3170nmol/L in patients with MPM compared to patients with benign disease whose SMRP value 
was 210nmol/L.  The ROC curves for the four biomarkers are also included (Figure 18). 
 
Table 16: Summary of biomarker concentrations in pleural fluid for MPM and BPE. 
Test BPE 
Median (IQR) 
MPM 
Median (IQR) 
P-value AUC 
(95% CI) 
     
Fibulin-3 (ng/ml) 58 (32, 85) 47 (31, 86) 0.550 0.56 (0.37, 0.74) 
HMGB-1 (pg/ml) 1783 (1219, 2650) 1788 (1329, 2115) 0.650 0.54 (0.36, 0.72) 
Osteopontin (ng/ml) 63 (50, 78) 67 (52, 81) 0.800 0.52 (0.34, 0.70) 
SMRP (nmol/L) 210 (110, 599) 3170 (2253, 4026) <0.001 0.94 (0.86, 1.00) 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 17: Boxplot depicting fibulin-3, HMGB-1, Osteopontin and SMRP values in pleural fluid of patients 
with MPM and BPE. 
 
The predictive ability of SMRP in pleural fluid for detecting MPM when patients with metastatic 
cancer were excluded was further examined, by evaluating the diagnostic ability at specific cut-
points. Two different cut points were considered. The chosen cut-off points and diagnostic 
performance are summarised in Table 17. The analysis suggested that the first cut-off gave a 
slightly higher specificity (96%) than sensitivity (90%). The second cut-off gave a higher sensitivity 
(95%), although specificity was still high at 91%. 
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(a) Fibulin-3 
 
(b) HMGB-1 
 
(c) Osteopontin 
 
(d) SMRP 
 
Figure 18: ROC curves for fibulin-3, HMGB1, osteopontin and SMRP in pleural fluid for MPM compared to 
BPE. 
 
Table 17: Cut-points and diagnostic performance of SMRP in pleural fluid for MPM compared to BPE. 
Statistic 
 
Cut-off 1 Cut-off 2 
  
1440 
 
90% 
96% 
94% 
91% 
 
1150 
 
95% 
91% 
90% 
95% 
Cut-off 
 
Sensitivity (%) 
Specificity (%) 
Positive Predictive Value (%) 
Negative Predictive Value (%) 
 
 
Again logistic regression was used to examine the effect of the four biomarkers in combination on 
MPM in the absence of metastatic cancers. A backwards selection approach was used to retain 
only the statistically significant variables.  There were mathematical problems fitting the full 
model with all four variables included in same model. Therefore the full model was not 
formulated and omitted from the analysis. The final model from the selection procedure is shown 
in Table 18. Only SMRP was significantly associated with MPM. The final model suggested that a 
one-unit increase in SMRP on the log scale was associated with the odds of MPM increasing by a 
factor of 11. 
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Table 18: Summary of analysis; logistic regression of biomarker concentrations in pleural fluid for MPM 
compared to BPE. 
Model 
 
Test Odds Ratio (95% CI) (*) P-value 
    
Full model (+)    
    
    
    
Final model SMRP 11.4 (2.71, 48.3)   0.001 
    
(*) Odds ratios given for 1-unit increase on log scale 
(+) Full model not formulated and omitted from analysis to model fitting problems 
 
2.5 Discussion 
In this study we carried out a head-to-head comparison of the diagnostic ability of 4 biomarkers, 
SMRP, osteopontin, fibulin-3 and HMGB-1 in both pleural fluid and serum for MPM. In addition to 
attempting to clarify the most superior biomarker we also explored for any synergistic benefit 
from combining the biomarkers together. 
The data on pleural fluid SMRP was promising, demonstrating a high specificity and sensitivity for 
differentiating patients with MPM from non-MPM. Although no formal sample size calculation 
was performed the high statistically significant difference in pleural fluid SMRP between the two 
groups would suggest the study was adequately powered to demonstrate this effect. The 
diagnostic accuracy was further improved when pleural fluid SMRP was used to differentiate 
between MPM and benign disease. Cut-off values were established and the ROC analysis revealed 
an AUC of 0.93 and 0.94 respectively. This backs up previous work by Cui et al whose group also 
demonstrated that the diagnostic performance of SMRP for discriminating MPM from healthy 
controls was best, followed by that for discriminating MPM from other cancers or from asbestos 
exposed patients (Cui et al., 2014).  
A limitation of this study was the lack of sarcomatoid or biphasic mesothelioma sub-types among 
the MPM samples analysed. Therefore our findings can only be applied to epithelioid 
mesothelioma. It has been reported that SMRP levels are higher in epithelioid mesothelioma 
compared to sarcomatoid and biphasic mesothelioma (Luo et al., 2010). However as epithelioid is 
by far the most commonly encountered histological sub-type our findings remain very relevant. 
A study previously investigating HMGB1 in MPM demonstrated excellent specificity but low 
sensitivity for differentiating between MPM and benign asbestos related disease (Tabata et al., 
2013). Another study (Napolitano et al., 2016) evaluated total HMGB1 and its isoform 
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hyperacetylated HMGB1. Hyperacetylated HMGB1 is thought to be actively secreted by malignant 
mesothelioma cells while the non-acetylated isoform is passively released by mesothelial cell in 
response to asbestos exposure. It is believed that the hyperacetylated form to be superior in 
differentiating between malignant and benign asbestos disease. The study demonstrated that 
while total HMGB1 had a specificity of 100% and sensitivity of 73% for differentiating 
mesothelioma from asbestos related disease and healthy controls, as expected hyperacetylated 
HMGB1 was superior with both a specificity and sensitivity of 100%. Furthermore the study 
concluded that both total and hyperacetylated HMGB1 were helpful in differentiating between 
mesothelioma and benign non-asbestos effusion and effusions caused by metastatic disease. 
In this study total HMGB1 was evaluated and did not replicate the results described above. No 
significant difference could be demonstrated in either serum or pleural fluid HMGB1 levels 
between any of the groups studied. The lack of difference in biomarker concentrations observed 
between the MPM group and the metastatic cancer group or non-MPM group is likely explained 
by the fact that HMGB1 is expressed by a host of other metastatic cancers which of course were 
included in both these groups. Furthermore, HMGB1 levels can be elevated in asbestos related 
disease and although HMGB1 has been demonstrated to have the ability to differentiate between 
MPM and benign asbestos disease (Napolitano et al., 2016; Tabata et al., 2013).  
Similarly unlike in some previously published studies championing fibulin-3 as a biomarker for 
MPM this work was unable to replicate these findings. There are a number of possible 
explanations for this. Many of the studies on biomarkers for mesothelioma have shown a 
significant heterogeneity between the study populations with wide variations in the comparison 
groups in terms of the type of control group, disease stage as well as histological subtype. The 
major study which demonstrated significantly elevated fibulin-3 concentrations in plasma and 
pleural fluid collated 2 populations with a notable variation in fibulin-3 cut off values between the 
2 different geographical populations for patients with mesothelioma (H. I. Pass et al., 2012). The 
population observed in this study were from the Portsmouth area which has a high prevalence of 
disease. The lower fibulin-3 concentrations seen may simply reflect a different MPM population 
which has not been previously explored.  
A major limitation to this work was the relatively small study population sampled for biomarker 
testing. The difference in serum SMRP in patients with MPM and non-MPM did not reach 
statistical significance (p=0.06). This could well be due to the result of the study being 
underpowered to detect a difference for this outcome. A retrospective power calculation based 
on the observed data was performed to inform potential future work. This was done on the log 
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scale due to the highly positively skewed distribution of the SMRP values. The difference between 
the groups on the log scale was 0.39 with a standard deviation of 0.7. A sample size of 160 
patients was calculated with a 5% significance level, 80% power and allowing for non-MPM being 
four times more prevalent than MPM. An inadequate sample size may well also explain the less 
than promising results seen for the other 3 biomarkers, HMGB-1, fubulin-3 and osteopontin in 
pleural fluid and serum. 
Biomarker concentrations may be influenced by tumour stage. The earliest SMRP prognosis study 
showed a relationship between baseline SMRP concentration and tumour size (B. W. Robinson et 
al., 2003). Osteopontin to date has failed to show any correlation with tumour stage (Hollevoet et 
al., 2011). Pass et al 2012 suggested a relationship between fibulin-3 and tumour stage (H. I. Pass 
et al., 2012), however subsequent work failed to show any relationship between fibulin-3 and 
tumour stage (Creaney et al., 2014). Due to the nature of the disease the presence of a malignant 
effusion in the non-MPM cancer group will signify more advanced disease and as demonstrated 
may be associated with higher biomarker levels. This is likely to have been a further confounding 
factor when attempting to differentiate biomarker values between the three groups examined in 
this study. 
Biomarker levels may also be correlated to burden of disease. In addition to SMRP levels 
correlating with tumour bulk, levels have also been shown to fall after treatments such as extra 
pleural pneumonectomy. Wheatley-Price et al demonstrated changes in SMRP correlated with 
radiological response with treatment (Wheatley-Price et al., 2010). SMRP levels have also been 
found to decline in patients with good response to chemotherapy compared to in those with 
progressive disease (Woolhouse et al., 2018). Chemotherapy has also been shown to affect 
fibulin-3 levels. Hooper et al measured fibulin-3 levels at baseline, during and after standard 
pemetrexed and cisplatin chemotherapy for MPM and demonstrated that serum fibulin-3 levels 
were higher at baseline (C. E. Hooper et al., 2015). While this evidence demonstrates the potential 
role for biomarkers in prognosticating in MPM as this study population was not stratified for prior 
chemotherapy it is possible that biomarker concentrations measured could have been influenced 
by previous chemotherapy especially in the metastatic cancer group. This needs to be considered 
as a limitation of this study. 
There is a school of thought that asbestos induced benign pleural effusions may eventually 
progress to mesothelioma leading to these patients often undergoing a prolonged period of 
surveillance in clinical practice. This would suggest that some of the higher biomarker values 
measured in the benign disease group could be the consequence of an asbestos related malignant 
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process in evolution rather than a benign process. This is a further potential factor that may have 
hindered differentiating between the sub-groups. 
2.6 Conclusion 
This chapter attempts to investigate the suitability of four biomarkers, fibulin-3, HMGB1, 
osteopontin and SMRP for clinical use in the diagnosis of MPM. The results demonstrated pleural 
fluid SMRP to be highly predictive of MPM. Importantly our work also demonstrated that 
combining biomarkers did not improve their diagnostic ability beyond that of SMRP alone. This 
suggests that future work should focus on SMRP with adequately powered robust research to 
evaluate pleural fluid SMRP as a biomarker for MPM. 
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3. Predicting prognosis in Malignant Pleural Mesothelioma in a local 
population 
3.1 Review of the literature 
3.1.1 Current prognosis in malignant pleural mesothelioma 
The prognosis with MPM is generally regarded as poor with a median survival of between 8-12 
months being reported (F. H. Brims & Maskell, 2013). Despite this poor prognosis rare cases of 
long survivors are recognised with 3-5% of patients surviving more than 5 years (F. H. Brims & 
Maskell, 2013). 
The ability to predict prognosis is important as it will help clinicians to plan treatments better 
tailored to individual patients. Prognostic factors will influence outcomes such as response to 
treatments and survival. Prognostic factors may include clinical and biological characteristics of 
the patient or tumour. Recognising these enables clinicians to predict response to treatments and 
explain the reasons for different outcomes in different patients. Patients and their families have 
the opportunity to make more informed decisions regarding treatments, enabling patients and 
their families to have more realistic expectations of their condition and likely progression. 
Predicting prognosis also enables clinicians to stratify patients for research which is vital 
particularly in diseases such as mesothelioma which are currently incurable and have relatively 
limited treatment options. Portsmouth is a city with a close proximity to a dockyard which has a 
historically large ship building industry where significant amounts of asbestos were used. As a 
result the local population has a high prevalence of asbestos-related respiratory disease including 
MPM (B. M. Robinson, 2012). PHT sees approximately 30 to 40 new cases of MPM each year and 
local audit data demonstrates that this number is increasing. This makes optimal prognostication 
ever more important in order to be able to respond to the needs of the local population.  
To date there is a large body of evidence including national and regional population based studies 
examining prognostic factors in MPM. These are summarised in the Table 19 and discussed in 
more depth in section 3.1.2. These prognostic factors include numerous clinical factors relevant to 
the prognosis of MPM including basic epidemiologic variables, clinical condition, imaging 
assessments, and tumour features.  
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Table 19: Recent population-based studies of MPM examining survival. (CI = confidence interval, MPM = malignant pleural mesothelioma, ECOG = European Cancer 
Oncology Group, CRP = C-reactive protein, RDW = red cell distribution width, KPS = Karnofsky performance score). 
Location  Years  N  Description  Prognostic variables identified for survival Hazard ratio (95 % 
CI)  
Reference 
Netherlands  2005–
2008  
1353 Median age 69 years; 1-year 
survival 47 %; 91.1 % male 
Increasing age, 1.04 (1.03–1.06); Sarcomatoid histology, 2.45 
(2.06–2.90) 
(van der Bij et al., 2012)  
USA  
 
1973–
2006  
 
8128  
 
Median age 72 years; 1-year 
survival 33 %; 81 % male 
Increasing age, 1.02 (1.019–1.023); Male gender, 1.23 (1.16–
1.31); Local disease, 0.80 (0.75–0.86); Treatment: surgery, 
0.66 (0.63–0.70) 
(Milano & Zhang, 2010)  
Japan  1996–
2006  
347 Median age 67 years; median 
survival 308 days; 87 % male 
Age > 70 years, 2.17 (1.36–3.46); Non-epithelioid histology, 
1.58 (1.15–2.18); ECOG performance score = 4, 3.22 (1.19–
8.74) 
(Nojiri et al., 2011)  
Italy  1990–
2001  
4100 62 % aged between 55–74 years; 
median survival 9.8 months; 73 % 
male 
Age > 75 years, 1.9 (1.7–2.1); Non-epithelioid histology, 1.8 
(1.6–2.0); Male gender, 1.1 (1.0–1.2) 
(Montanaro et al., 2009)  
Germany  1987–
2000  
498 Mean age 63.1 years; 87 % male Age > 60 years, 1.29; Sarcomatoid histology, 1.89;  
Male gender, 1.72 (No CIs presented) 
(V. Neumann, Rutten, 
Scharmach, Muller, & 
Fischer, 2004)  
Italy  1997–
2001  
429 Median survival 275 days; 
71.6 % male 
Age > 75, 1.82 (1.16–2.86); MPM “suspected”, 1.85 (1.16–
2.94); Sarcomatoid histology, 2.96 (1.28–6.81) 
(Marinaccio & Nesti, 
2003)   
Australia 1999-
2009 
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119 chemotherapy naïve & 54 
treated; median age 61.5 years; 
median survival 10.6 months; 82% 
male 
Non-epithelioid histology, 2 (1.3-2.9); NLR≥5, 2.7 (1.8-3.9) (Kao et al., 2010) 
Turkey 2003-
2012 
155 Mean age 58.2 years; mean 
survival 13.9 months; 42% male 
Non-epithelioid histology, 1.52 (1.07-2.31); NLR≥3, 11.67 
(1.14-2.46); RDW≥20%, 12.77 (1.28-6) 
(Abakay, Tanrikulu, 
Palanci, & Abakay, 2014) 
Turkey 1989-
2010 
363 Mean age 50.6 years; 
60% male 
Low KPS (<60), 2.25; Pleural fluid glucose, 1.73; CRP, 1.56 
Serum LDH, 2.24; Presence of effusion, 2.9; Pleural thickening 
on CT, 2.15; Platelet count >420x103/uL, 1.33 (No CIs 
presented) 
(Tanrikulu et al., 2010) 
Belgium 1989-
2003 
394 Mean age 64 years; 68.5% male KPS (<80), 1.7 (1.24-2.33); Platelet count >400 x103/uL, 1.64 
(1.15-2.33); Sarcomatoid histology, 3.78 (2.34-6.11); 
Biphasic histology, 1.6 (1.11-2.31); Diffuse involvement of 
pleural cavity, 2.73 (1.53-4.87) 
(Borasio et al., 2008) 
70 
 
3.1.2 Factors affecting prognosis 
3.1.2.1  Clinical factors 
Age is a potential prognostic factor with increasing age considered a poor predictor of survival as 
highlighted by several population based studies (Marinaccio & Nesti, 2003; Milano & Zhang, 2010; 
V. Neumann et al., 2004; Nojiri et al., 2011; van der Bij et al., 2012). Male gender is also 
considered a predictor of poor prognosis. This is likely due to the fact that men have a greater 
exposure to asbestos through occupations which traditionally have predominantly employed a 
male workforce.  This exposure in turn results in aggressive disease (Wolf et al., 2010). It has been 
considered that a longer duration and higher intensity exposure may lead to more aggressive 
forms of mesothelioma with worse prognosis (Hodgson & Darnton, 2000). A review article on 
prognostic factors for mesothelioma stated non-exposure to asbestos was associated with longer 
survival as did a no smoking history (Steele, 2005). 
Symptom severity is usually a reliable clue with regards to prognosis and particularly the presence 
of breathlessness, chest pain and weight loss have been shown to be linked to worse survival 
(Gonlugur & Gonlugur, 2010; Meniawy, Creaney, Lake, & Nowak, 2013; Steele, 2005). Weight loss 
and anorexia are also included as negative factors in the European Organisation for Research and 
treatment of Cancer (EORTC) prognostic score (Curran et al., 1998). 
Presence of comorbidities is another potential prognostic factor and the results of a multicentre 
survey demonstrated worse survival in elderly MPM patients with comorbidities such as diabetes, 
peripheral vascular disease and chronic liver disease (Ceresoli et al., 2014). Contrary to this a 
single Turkish study of a 100 patients concluded that the presence of comorbidity was a factor 
influencing better survival, although the reasons for this were not clear (Gonlugur & Gonlugur, 
2010). 
The literature has previously identified patient PS as an independent prognostic variable for poor 
outcome (Borasio et al., 2008; Nojiri et al., 2011; Tanrikulu et al., 2010). National lung cancer audit 
(NLCA) data in England for 2009 and 2010 suggests that in patients with a confirmed diagnosis of 
mesothelioma, PS stages 0 or 1 would expect to have an 80% survival at 6-months, whilst patients 
with a PS stage of 2, 3 or 4 are likely to have a 45% survival. This data is further backed up by a 
recently published report on 8740 mesothelioma patients from between 2008 and 2012 (NLCA, 
2014) which showed that worse PS was associated with worse median, 1 year and 3 year survival 
(Table 20).  
71 
 
Table 20: Overall median, 1 year and 3 year survival and based on patient performance status (NLCA, 
2014). 
Performance status Median survival 
(interquartile range) 
1 year survival % 3 year survival 
% 
0 12.1 months (7-20) 57 13 
1 9.8 months (5-16) 46 8 
2 5.8 months (3-11) 26 4 
3 2.8 months (1-7) 13 4 
4 1.0 month (0-3) 6 0 
 
3.1.2.2  Tumour factors 
The histological subtype is a strong predictor of survival in MPM according to several national 
studies and national audit data (NLCA, 2014) demonstrating a slower progression with longer 
survival in patients with the epithelioid histological sub-type of MPM (Table 21). 
Table 21: Median, 1 year and 3 year survival based on histological sub-type (NLCA, 2014). 
Histological subtype Median survival 
(interquartile range) 
1 year survival % 3 year survival 
% 
Epithelioid 11.1 months (6-18) 52 10 
Unspecified 7.9 months (3-15) 38 8 
Biphasic 7.3 months (4-12) 29 3 
Sarcomatoid 3.9 months (2-8) 13 1 
 
Biomarkers may have a role in determining prognosis as a result of their potential ability to assess 
tumour expression and response to treatments such as chemotherapy. These may be either 
commonly used assays or more specific biomarkers.  
Haematological markers such as haemoglobin (Hb), white cell count (WCC) and platelet count 
(PLT) have also shown to be associated with prognosis in mesothelioma (Herndon et al., 1998). A 
study validating the effectiveness of 2 pre-exiting mesothelioma prognostic scoring systems, 
EORTC and Cancer and Leukaemia Group B (CALGB) demonstrated a Hb >14g/dl, WCC >8.3x109/l 
and a PLT of >400x109/l were all poor prognostic factors and for each rise in Hb of 1 g/dl there 
was a fall in risk of 21%, whereas each rise in WCC of 1x109/l increased the risk of death by 11% 
(Edwards et al., 2000). 
The red blood cell distribution width (RDW) has also been suggested to have prognostic potential 
and a Turkish study retrospectively reviewing a 155 patients showed a RDW ≥20% was associated 
with a 2.77 fold increased mortality rate (Abakay et al., 2014). 
Neutrophil-to-lymphocyte ratio (NLR) is another factor which has been identified with prognostic 
potential. A NLR less than 5 (HR=2.7; 95% CI=1.8–3.9; P < 0.001) was an independent predictor of 
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length of survival, and the 1-year survival rate was 60% versus 26%, for a NLR less than 5 and 5 or 
greater, respectively (Kao et al., 2010).  Another study examining NLR suggested differences in 
prognosis may be observed at lower cut-offs and a NLR ≥3 was associated with a 1.67 fold 
increased mortality rate (Abakay et al., 2014). 
A smaller regional study from Japan identified high C-reactive protein (CRP) levels as a significant 
independent prognostic variable for poor outcome, with high WCC approaching significance 
(Nojiri et al., 2011). A study of 115 patients receiving multimodality treatment for mesothelioma 
which reviewed pre-treatment serum CRP levels concluded that CRP was an independent negative 
prognostic marker (Ghanim et al., 2012). 
Lactate dehydrogenase (LDH) has been associated with prognosis in mesothelioma and a large 
population based study of 363 MPM patients showed that a serum LDH value of more than 500 
U/L was linked to worse survival (Tanrikulu et al., 2010). This association between serum LDH and 
survival has also been noted in other studies (Metintas et al., 2001; Suzuki et al., 2012). A 
retrospective study of 284 patients with MPE examining the effects biochemical properties of 
pleural fluid on survival showed that rises in LDH values were associated with worse survival 
(Bielsa et al., 2008).  
More specific biomarkers such as SMRP, osteopontin and many others have also shown potential 
as markers of prognosis as well as diagnosis of MPM. These are currently under further 
exploration (C. E. Hooper et al., 2015; Wheatley-Price et al., 2010) and have already been 
described in depth in the previous chapter (Chapter 2). 
3.1.2.3  Prognostic tools for MPM 
To date several prognostic scoring systems have been developed for mesothelioma by combining 
some of the above described prognostic variables. The EORTC and the CALGB prognostic scoring 
systems were derived through the statistical analyses of large series of patients from 
chemotherapy trials. The EORTC found that performance status, WCC, gender, histologic subtype, 
and whether the histologic diagnosis was definitive or not were significant prognostic factors. 
Based on these variables from 204 patients two risk groups were identified by multivariate 
analysis. These were a good prognosis group with a 1 year survival of 40% (95% CI 30-50%) and a 
poor prognosis group with a 1 year survival of 12% (95% CI 4-20%) (Curran et al., 1998). 
The CALGB system which is derived from 337 patients was a more complex analysis with 
prognostic variables of performance status, age, WCC count, Hb, presence or absence of weight 
loss, and chest pain. The CALGB used an exponential survival tree analysis and defined 6 groups of 
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patients with varying median survival times ranging from 1.4 to 13.9 months (Herndon et al., 
1998).  
Although both the EORTC and CALGB systems were recently validated in a large study (Meniawy 
et al., 2013) 62% of patients in this study received chemotherapy which is significantly higher than 
non-trial populations suggesting perhaps that these results should be interpreted with caution. 
A major shortcoming of these systems is that they are relatively unwieldy and are therefore not 
used routinely in clinical practice. Thus their use is largely confined to the clinical trial setting to 
stratify patient cohorts so that treatment results can be appropriately interpreted and compared. 
Furthermore as these scoring systems have been based on clinical trial populations their 
applicability to the larger population is somewhat limited. 
The LENT score is a recently developed prognostic scoring system (Clive et al., 2014) for patients 
with malignant pleural effusions including mesothelioma. It is able to risk stratify patients into 
low, moderate and high mortality groups with associated median survival based on four chosen 
variables. These were pleural fluid LDH, ECOG PS, NLR and tumour type. These were chosen due 
to their clinical applicability after multivariate analysis identified six variables which were 
independently associated with prognosis.  Again this system has a number of limitations. It was 
developed using patients with different tumour types and was therefore not specific for 
predicting survival in MPM. Also as the system was developed for predicting survival in patients 
with malignant pleural effusions, it may not be applicable to MPM patients without evidence of 
an effusion. Factors such as disease stage, time from diagnosis and whether these patients had 
received previous treatments such as chemotherapy, which may be life prolonging were not taken 
into account in the analysis even though they are known to have an impact on survival (Clive et 
al., 2014).  
Another prognostic model using classification and regression tree analysis from an unselected 
Australian population which was subsequently validated in a UK population has been designed to 
predict the risk of death from MPM at 18 months (F. J. Brims et al., 2016). 
Despite this large body of evidence many of the studies are retrospective case series and 
therefore of limited quality. Although some data is more robust as gathered from clinical trial 
populations these patients were carefully selected and therefore unlikely to reflect the 
characteristics of unselected incident cases as seen in normal clinical practice. 
Although the prognosis for MPM is poor in general there is a wide variation in survival, response 
to treatment, and disease progression among individuals based on local expertise and services 
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available (NLCA, 2016). This highlights the importance of clinically useful prognostic factors that 
can be directly applied to the local population with MPM.   
Routine data collected in hospital refers to demographic and clinical information from healthcare 
episodes which have a bearing on clinical disease severity. The use of this routinely collected data 
for prognosticating at time of diagnosis is attractive as the data is a potentially rich source of 
information with large numbers of patients from the local population. The data is also readily 
available making the gathering of data less demanding.   
Thus the increasing availability of patient and disease specific information from medical databases 
now allows a wealth of information from which clinicians may draw from in order to improve 
planning for outcomes and risks of diseases. Such prognostic data should be used by the bedside 
to plan both acute and long term care as well as be helpful in local health planning.  
3.2 Aim 
The aim of this single institution study was to identify clinical and pathological characteristics 
gathered routinely as part of the standard care pathway in order to predict patients’ risk of death 
at 6 months from diagnosis with MPM. 
3.3 Method 
This section outlines the methodology used to predict prognosis for MPM at time of diagnosis. 
3.3.1 Study design 
This was a retrospective cohort design constructed from data gathered from a 100 consecutive 
patients referred to and diagnosed with MPM at Queen Alexandra Hospital, Portsmouth.  
I designed study protocol for this study. I liaised closely with the REC, the study sponsor, and the 
study statistician. 
3.3.2 Source of data 
The data source for this work was a pre-existing database consisting of a 100 consecutive patients 
who had presented over approximately a four year period and been diagnosed with MPM at QAH 
between December 2009 and September 2013. This database had been designed to evaluate the 
clinical services and patient pathway provided by the MPM service at Portsmouth. I entered 
individual patient information into a specific anonymised data form with a unique study number 
and patient initials which I designed. The patient's name, date of birth, hospital number and other 
identifiable information was not used on any of the study paperwork. 
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3.3.3 Eligibility criteria 
All patients of 18 years and above diagnosed with MPM at QAH, Portsmouth between December 
2009 and September 2013 were included in the study. 
3.3.4 Study variables 
The outcome variable was risk of mortality at 6 months from the time of diagnosis with MPM. 
Potential predictor variables were chosen based on routinely available data and therefore 
collected from the MPM service evaluation data forms. The variables extracted from this data 
source included demographic characteristics and laboratory tests and are listed in Table 22. 
Table 22: Potential predictor variables for survival in patients diagnosed with MPM at Portsmouth. 
 
Group 
 
Variable 
Demographics Age at diagnosis 
Gender 
Weight 
BMI 
Asbestos exposure 
Smoking status 
Performance status (PS) 
Comorbidities 
Symptoms Dyspnoea 
Chest pain 
Cough 
Weight loss 
Loss of appetite 
Night sweats 
Fever 
Pathology Histological subtype 
Cytology- presence of malignant cells  
Haematology Hb 
RDW 
PLT 
Systemic inflammation WCC 
NLR 
CRP 
Renal function Urea 
Na 
K 
Creatinine 
Liver function Total protein 
Albumin 
ALP 
Bone profile Adjusted Calcium 
Phosphate 
Pleural fluid biochemistry Total protein 
LDH 
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3.3.5 Data analysis 
Data was analysed using IBM SPSS statistical package 22.0. A description of the study cohort for 
all potential risk factors was provided using means and standard deviations for continuous 
variables and frequencies and percentages for categorical variables. 
3.3.6 Statistical analysis 
A statistician performed all statistical analyses. The outcome variable was patient survival time. As 
some patients in the study were still alive at time of data collection, it was necessary to analyse 
the data using survival analysis methods. Survival times were measured as the time from the date 
of diagnosis to the date of death. Patients who did not die were censored at the last time they 
were known to be alive. 
Due to the nature of the outcome, all analyses were performed using Cox regression. Cox 
regression is a survival analysis regression model which describes the relationship between the 
covariates and event incidence, in this case survival at 6 months was expressed by the hazard 
function which is the event probability at that point in time. 
The analysis was performed in two stages. Firstly the separate association between each factor 
and survival was assessed separately in a series of univariate analyses. Subsequently the joint 
association between the variables and the outcome was assessed in a multivariate analysis. This 
allowed for the effect of each predictor variable upon the outcome to be assessed independently 
of the other variables included in the analysis. To reduce the number of variables in the 
multivariate analyses, only variables showing some evidence of an association with survival from 
the univariate analyses (p<0.1) were included. Additionally variables with too much missing data 
were also excluded from this stage of the analysis, as missing values for a single variable meant 
that that particular patient was excluded from the analysis completely. 
For continuous predictor variables, the shape of the relationship between the variable and risk of 
death was examined. Where a linear relationship was not found to be appropriate, a non-linear 
relationship between the variable and the risk of death was assumed. 
The variables identified to be significant in the multivariable regression analysis were then used to 
create a risk model to predict the probability of death within 6 months of diagnosis for each 
patient. Broadly two aspects of the model performance were evaluated. The discrimination of the 
model examined the ability of the model to distinguish from high and low risk cases, whilst the 
calibration of the model examined how close. 
77 
 
Firstly the discrimination of the model was evaluated. This was assessed using the same dataset 
on which it was created and using Harrell's C-statistic. This measure is broadly equivalent to the 
area under the ROC curve. 
Secondly, both the discrimination and calibration of the model was examined by dividing the 
predicted risk into three categories. The categories were chosen to give a reasonably similar 
number of patients in each category. The observed percentage of graft loss within each of these 
three categories was calculated and this compared to the predicted risk. The calibration of the 
model was also examined by the use of the Hosmer-Lemeshow test. This compared the observed 
and predicted number of events (and non-events) in the same categories. The significance of this 
difference was assessed by comparing it to a Chi-square distribution with one degree of freedom. 
3.3.7 Consent 
In view of the poor prognosis associated with this disease at the time of data collection many 
patients were likely to be deceased and therefore individual patient consent for this study was 
not possible. The medical research council (MRC) has stated that the use of anonymous data from 
deceased persons is lawful, and that consent is not legally required in these circumstances (MRC, 
2018). As all patients in this study remained anonymous we did not require individual consent as 
described by the MRC. 
3.3.8 Ethical considerations an research approval 
Ethical approval for this research was granted on the 7th of July 2014 by the NRES Committee 
South Central - Berkshire (REC reference number: 14/SC/1139) (Appendix 7). The project was 
granted local site approval by Portsmouth Hospitals NHS Trust, Research and Development 
Department on the 8th of August 2014 (reference number PHT/2014/51) (Appendix 8). 
3.4 Results  
Patient demographics are summarised in Table 23. Categorical variables were summarised by the 
number and percentage. Continuous variables with a normal distribution were summarised by the 
mean and standard deviation. Continuous variable with a skewed deviation were summarised by 
the median and inter-quartile range. 
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Table 23: Demographics of 100 consecutive patients diagnosed with MPM at QAH between December 
2009 and September 2013. 
Variable N Data summary 
Age at diagnosis (years) 100 73.2 ± 7.8 
Gender 
    Male 
    Female 
100  
85 (85%) 
15 (15%) 
Weight (kg)                       70 74.8 ± 16.8 
BMI (kg/m2) 48 26.0 ± 4.9 
Asbestos exposure 
     Yes 
     No 
89  
69 (78%) 
20 (22%) 
Smoking status 
     Non-smoker 
     Ex-smoker 
     Current smoker 
94  
25 (27%) 
57 (61%) 
12 (13%) 
Performance status (PS) 
                0 
                1 
              +2 
95  
24 (25%) 
43 (45%) 
28 (29%) 
Comorbidities 
    Respiratory comorbidity 
    Other comorbidity 
    Number of comorbidities 
                0 
                1 
              +2 
98  
17 (17%) 
69 (70%) 
 
24 (24%) 
39 (40%) 
35 (36%) 
Dyspnoea 99 84 (85%) 
Chest pain 99 43 (43%) 
Cough 99 55 (56%) 
Weight loss 99 51 (52%) 
Loss of appetite 99 45 (45%) 
Night sweats 99 13 (13%) 
Fever 99 2 (2%) 
Histological subtype 
     Epithelioid 
     Sarcomatoid 
     Unclassified 
94  
63 (67%) 
21 (22%) 
10 (11%) 
Malignant cells (cytology) 65 18 (28%) 
Hb g/dl 99 13.3 ± 1.7 
RDW % 99 14.1 [13.2, 15.3] 
PLT *109/L 99 340 ± 114 
WCC *109/L 99 9.2 [8.1, 11.7] 
NLR % 99 5.2 [3.4, 7.6] 
CRP mg/L 66 48 [15, 80] 
Urea mmol/L 98 4.7 [4.0, 6.2] 
Na mmol/L 98 136 ± 3 
K mmol/L 96 4.4 ± 0.4 
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Creatinine µmol/L 98 81 [67, 94] 
Total protein g/L 92 66.9 ± 6.1 
Albumin g/L 92 32.9 ± 5.0 
ALP IU/L(+) 92 73 [56, 92] 
Adjusted Calcium mmol/L 80 2.32 [2.26, 2.39] 
Phosphate mmol/L 77 1.16 ± 0.23 
Pleural fluid protein g/L 49 43.7 ± 8.9 
Pleural fluid LDH IU/L(+) 52 701 [488, 1376] 
(+) International units per litre 
3.4.1 Overall survival 
The outcome of interest was patient survival. A graphical illustration of the survival times of the 
patient group as a whole is given in the next Kaplan-Meier plot (Figure 20). 
  
Figure 19: Kaplan-Meier plot of survival times of the patient group as a whole. 
3.4.2 Univariate analysis 
Factors associated with survival were examined. Firstly the separate association between each 
factor and survival was examined separately in a series of univariate analyses (Table 24).  
The size of the association between each predictor variable and survival was quantified using 
hazard ratios, along with corresponding confidence intervals. These give the relative difference in 
the hazard (or risk) of death at any time in one situation compared to another. For the categorical 
predictor variables, the hazard ratios give the risk of death in each category relative to the risk in a 
baseline category. For the continuous predictor variables, the hazard ratios give the relative 
change in the risk of death at any time for an increase in that variable. P-values indicating the 
significance of the results are also reported.  
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Table 24: A summary of the univariate analysis results for the association between the various prognostic 
factors and survival. 
Variable N Category / term Hazard Ratio (95% CI) P-value 
Age at diagnosis (*) 100 Linear term 
Squared term 
1.34 (1.15, 1.54) 
1.07 (1.00, 1.14) 
<0.001 
Gender 100 Male 
Female 
1.00 
1.03 (0.59, 1.79) 
0.930 
Weight (**) 70 - 0.82 (0.70, 0.95) 0.009 
BMI (*) 48 - 0.71 (0.52, 0.96) 0.030 
Asbestos exposure 89 No 
Yes 
1.00 
1.27 (0.76, 2.14) 
0.360 
Smoking status 94 Non-smoker 
Ex-smoker 
Current smoker 
1.00 
1.53 (0.93, 2.53) 
2.20 (1.07, 4.51) 
0.080 
Performance status 
(PS) 
95 0 
1 
2+ 
1.00 
1.32 (0.79, 2.22) 
3.21 (1.80, 5.74) 
<0.001 
Respiratory  
Comorbidity 
98 No 
Yes 
1.00 
1.22 (0.72, 2.07) 
0.470 
Other comorbidity 98 No 
Yes 
1.00 
1.18 (0.75, 1.86) 
0.470 
Number of  
Comorbidities 
98 0 
1 
2+ 
1.00 
1.10 (0.64, 1.87) 
1.65 (0.96, 2.84) 
0.120 
Dyspnoea 99 No 
Yes 
1.00 
0.49 (0.27, 0.86) 
0.010 
Chest pain 99 No 
Yes 
1.00 
1.60 (1.05, 2.43) 
0.030 
Cough 99 No 
Yes 
1.00 
0.93 (0.61, 1.40) 
0.720 
Weight loss 99 No 
Yes 
1.00 
2.37 (1.55, 3.62) 
<0.001 
Loss of appetite 99 No 
Yes 
1.00 
1.35 (0.90, 2.04) 
0.150 
Night sweats 99 No 
Yes 
1.00 
1.32 (0.73, 2.38) 
0.360 
Fever 99 No 
Yes 
1.00 
0.59 (0.14, 2.40) 
0.460 
Histological  
Subtype 
94 Epithelioid 
Non-epithelioid 
Unclassified 
1.00 
1.20 (0.71, 2.02) 
1.44 (0.73, 2.83) 
0.510 
Malignant cells 
(cytology) 
65 No 
Yes 
1.00 
1.13 (0.63, 2.00) 
0.680 
Hb 99 - 0.77 (0.68, 0.88) <0.001 
RDW 99 - 1.12 (0.99, 1.26) 0.070 
PLT (***) 99 Linear term 
Squared term 
1.02 (0.91, 1.14) 
1.04 (1.01, 1.07) 
<0.001 
WCC 99 - 1.00 (0.94, 1.07) 0.910 
NLR (*) 99 - 0.97 (.078, 1.20) 0.790 
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CRP (***) 66 - 0.94 (0.379, 1.12) 0.510 
Urea (*) 98 - 1.31 (1.03, 1.67) 0.030 
Na (*) 98 - 1.00 (0.73, 1.38) 0.980 
K  96 Linear term 
Squared term 
1.45 (0.91, 2.29) 
2.21 (1.09, 4.49) 
0.030 
Creatinine (†) 98 Linear term 
Squared term 
0.71 (0.11, 0.57) 
40042 (9.2, 1768852) 
0.006 
Total protein (*) 92 - 0.98 (0.83, 1.17) 0.830 
Albumin (*) 92 - 0.70 (0.55, 0.88) 0.003 
ALP (†) 92 - 2.21 (0.70, 6.98) 0.180 
Adjusted Calcium (+) 80 - 1.37 (1.10, 1.70) 0.005 
Phosphate (+) 77 - 0.92 (0.81, 1.05) 0.210 
Pleural fluid protein (*) 49 - 0.96 (0.80, 1.13) 0.600 
Pleural fluid LDH (†) 52 - 4.26 (1.66, 11.0) 0.003 
(+)     Hazard ratios reported for a 0.1-unit increase in variable 
(*)     Hazard ratios reported for a 5-unit increase in variable 
(**)   Hazard ratios reported for a 10-unit increase in variable 
(***) Hazard ratios reported for a 50-unit increase in variable 
(†)     Variable analysed on the log scale (base 10) 
 
The results suggested that, when examined separately, a number of the variables were 
significantly associated with patient survival. Significant associations with survival were observed 
for age, weight, BMI, performance status, dyspnoea, chest pain, weight loss, haemoglobin, 
platelet count, urea, potassium, creatinine, albumin, adjusted calcium and pleural fluid LDH and 
are described in more detail below. Although there was a trend towards an association between 
smoking status and survival, the result for this factor was not quite statistically significant. 
The results for age suggested a non-linear relationship with the risk of death. As such, it is difficult 
to interpret the two hazard ratios for this variable. So instead the results for age are shown 
graphically. The graph (Figure 9) shows the relationship between age and the relative hazard (or 
risk) of death at any time. The hazard is shown relative to a patient of mean age (mean age =73).  
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Figure 20: Relationship between age and the relative hazard of death at any time. 
 
The graph shows a relatively small effect of age for patients less than 80 years old. However, 
there is a sharp increase in the risk of death with increasing age for patients over the age of 80 
years. 
A greater weight and BMI were both associated with a lower risk of death. A patient with a weight 
10kg higher than the mean weight of 75kg was associated with around a 30% reduction in the risk 
of death at any time. 
Unsurprisingly higher PS scores were associated with an increased risk of death, and thus shorter 
survival times. The risk of death at any time was over 3 times higher for those with performance 
status of 2 or higher compared to those with performance status of 0. 
The occurrence of dyspnoea was associated with a lower risk of death. This was an unexpected 
finding which may be explained by patients experiencing dyspnoea being more likely to seek 
assistance from medical teams sooner. Conversely chest pain and weight loss were associated 
with a higher risk. Patients with weight loss had a risk of death at any time that was 2.4 times 
higher than those with no weight loss. 
Higher values of Hb were associated with a lower risk of death, and thus longer survival times. A 
one-unit increase in Hb was associated with almost a 25% lower risk of death.  
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PLT count was also found to be significant. The results for this variable suggested a non-linear 
relationship with survival. Therefore as it was difficult to interpret the two hazard ratios for this 
variable as with the age variable the relationship between platelet count and survival have been 
presented as a graph in Figure 22. This shows the relative risk of death for different PLT count 
values relative to a patient with an average value (mean PLT = 340*109/L). The results suggest 
little effect in raised platelet count values below 500*109/L. However, for values above this point, 
there is an increased risk of death with further increasing PLT count. 
 
Figure 21: Relative risk of death for different platelet count values relative to a patient with an average 
value (mean PLT = 340). 
Higher Urea values were also associated with a higher risk of death. A 5-unit increase in Urea was 
associated with a 31% increase in the risk of death. 
The results for Potassium showed a non-linear relationship between this factor and the risk of 
death. The results for this variable are thus shown graphically. The next plot (Figure 23) illustrates 
the relative risk of death at any time relative to a patient with an average Potassium value (mean 
= 4.4mmol/L).  The graph indicated little association between Potassium and the risk of death for 
values below 5mmol/L. However, patients with values above this point had an increased risk of 
death. 
(*109/L) 
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Figure 22: Relative risk of death at any time relative to a patient with an average potassium value (mean 
= 4.4mmol/L). 
 
The results for Creatinine also showed a non-linear relationship between this factor and the risk 
of death. The results for this variable are again shown graphically. The next plot (Figure 24) 
illustrates the relative risk of death at any time relative to a patient with an average creatinine 
value (mean on log scale equates to a Creatinine of 79). The results suggested an increased risk of 
death for patients with higher Creatinine values. The risk increased sharply for those with very 
high Creatinine values, above 200µmol/L. 
(mmol/L) 
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Figure 23: Relative risk of death at any time relative to a patient with an average creatinine value (mean 
on log scale equates to a creatinine of 79µmol/L). 
 
Higher Albumin values were found to be associated with a lower risk of death which is likely 
explained by less systemic inflammation or perhaps even by a better nutritional state. Higher 
Adjusted Calcium and pleural fluid LDH values were found to be associated with a higher risk of 
death and likely reflective of level of tissue damage. 
3.4.3 Multivariate analysis 
The second stage of the analysis process examined how survival was affected by the variables 
jointly in a multivariate analysis. As BMI and pleural fluid data was only available for 48 and 52 
patients respectively, both BMI and pleural fluid LDH were omitted from the analysis. A 
backwards selection procedure was performed to retain only the statistically significant variables, 
and the final model is summarised in Table 25. This final model was based on data from 74 
patients. 
  
 
 
 
 
(µmol/L) 
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Table 25: A summary of the multivariate analysis results for the association between selected prognostic 
variables and survival. 
Variable 
 
Category / term Hazard Ratio (95% CI) P-value 
Age at diagnosis (*) 
 
- 1.31 (1.09, 1.56) 0.004 
Smoking status Non-smoker 
Ex-smoker 
Current smoker 
           1.00 
2.16 (1.09, 1.56) 
3.42 (1.11, 4.20) 
0.030 
Chest pain No 
Yes 
           1.00 
2.14 (1.23, 3.72) 
0.007 
Weight loss No 
Yes 
           1.00 
2.13 (1.18, 3.86) 
0.010 
PLT (***) Linear term 
Squared term 
1.05 (0.91, 1.20) 
1.05 (1.00, 1.10) 
0.010 
Urea (*) - 2.73 (1.31, 5.69) 0.008 
Adjusted Calcium (+) - 1.47 (1.10, 1.94) 0.008 
(+)    Hazard ratios reported for a 0.1-unit increase in variable 
(*)     Hazard ratios reported for a 5-unit increase in variable 
(***) Hazard ratios reported for a 50-unit increase in variable 
 
The multivariate results suggested that the predictor variables age, smoking status, chest pain, 
weight loss, PLT count, Urea and Adjusted Calcium were independently associated with patient 
survival.  
After adjusting for the variables in the final model, there was no longer a significant effect of 
weight, PS, dyspnoea, Hb, Potassium, Creatinine or Albumin on the outcome. 
The univariate analysis suggested a non-linear relationship for age. However, after adjusting for 
the other factors, there was a steady increase in the risk of death with increased age. A 5-year 
increase in age was associated with a 31% increase in the risk of death.  
Smoking status was only of borderline significance in the univariate analysis. This was now found 
to be more strongly significant. Ex-smokers and current smokers were at increased risk. The risk of 
death at any time was 3.4 times greater for current smokers and 2.16 times greater for ex-
smokers than for non-smokers. 
As in the univariate analyses, in the multivariate analysis patients with chest pain and weight loss 
were both at increased risk with a 2.14 and 2.13 times greater risk of death at any time 
respectively. Higher Urea and Adjusted Calcium values were also associated with increased risk. 
The hazard ratios for PLT count were broadly similar to those observed in the univariate analyses, 
suggesting a similar pattern between this factor and survival times than was seen previously. 
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3.4.4 Development of risk model to predict prognosis 
3.4.4.1  Model summary 
Regression coefficients which are the log value of the hazard ratios for the prognostic factors 
identified from the multivariate analysis were then calculated for the risk model. These factors 
were used as they were found to be independently most significantly associated with patient 
survival. A summary of the regression coefficients for all variables in the final model are given in 
the next table (Table 26). 
 
Table 26: Summary of the regression coefficients for chosen variables. 
Variable 
 
Coefficient 
  
Age at diagnosis 0.053 
Ex-smoker 0.772 
Current smoker 1.230 
Chest pain 0.759 
Weight loss 0.757 
PLT -0.0115 
PLT2 0.000018 
Urea 0.201 
Adjusted calcium 3.830 
  
 
The linear combination of the coefficients was initially calculated. For categorical variables the 
coefficient was added to the total if that factor was present. For continuous variables the 
coefficient was multiplied by the value for that factor. Once the linear combination was 
calculated, a transformation was required to obtain the predicted probability. 
 
The predicted probability was calculated using the following formulae; 
1)  y = Σ coefficients 
2)  p  =  1 -   0.99999944 exp(y)       [this is 0.99999944 to the power of exp(y) 
where: 
Σ = mathematical sum  
p = Predicted risk of death at 6 months 
exp = exponential function. 
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3.4.4.2  Model evaluation  
The performance of the risk model was then evaluated. The discrimination of the model was 
examined using Harrell's C-statistic. This model was found to have a c-statistic of 0.76 for this 
dataset. This was a reasonable value suggesting the model had some ability to discriminate 
between low and high risk patients. 
Patients were split into one of three groups based on their predicted risk of death within 6 
months. A comparison of the predicted risk of death at 6 months and the actual observed 
occurrence of death at 6 months was made, and the results are summarised in Table 27. 
 
Table 27: Comparison of the predicted risk of death at 6 months and actual observed occurrence of death 
at 6 months. 
Risk group Number subjects Predicted deaths at 6 
months 
Observed deaths at 6 
months 
    
≤ 25% 23 13.8% 17.4% 
26 - 60% 25 37.9% 32.0% 
> 60% 26 83.6% 80.8% 
    
 
The results demonstrated that the percentage of deaths predicted at 6 months increased 
proportionally with increased risk group suggesting that the model had good discrimination. The 
results showed good calibration as the actual percentage of observed deaths at 6 months also fell 
within the risk group boundaries, and was similar to the predicted values.  
The Hosmer-Lemeshow test was also used to examine the calibration of the model in terms of the 
predicted of cases of death within 6 months. A summary of the observed and predicted number 
of deaths is shown in Table 28 along with the results of the test. 
 
Table 28: Summary of the observed and predicted number of deaths. 
Risk group Observed number of 
deaths at 6 months 
Predicted number of 
deaths at 6 months 
Chi-square statistic / 
p-value 
    
≤ 25% 4 3.2  = 0.8 
26 - 60% 8 9.4 p = 0.38 
> 60% 21 21.7  
    
 
The non-significant result suggests good agreement between observed and predicted numbers of 
cases of death at 6 months for each of the risk groups. Thus this result suggests a good calibration 
of the model. 
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3.5 Discussion 
This was a retrospective analysis of prognostic factors in patients newly diagnosed with MPM. 
These factors were then utilised to develop a risk prediction model for death at 6 months. A 6 
month cut off was used as it would allow for better treatment planning in a patient group were 
median survival is considered to be 8-12 months (Brims FJ, 2013).  
The data from this study examining the local population demonstrated a steady increase in the 
risk of death with increasing age. Age is widely accepted as a significant determinant of life 
expectancy. However age in determining prognosis in patients in mesothelioma has been 
contentious. Although studies have previously reported age as a significant variable (Milano & 
Zhang, 2010; Nojiri et al., 2011; van der Bij et al., 2012) there are numerous studies which suggest 
age has no prognostic significance (Curran et al., 1998). A single study showed young age to be 
favourable at time of diagnosis but no longer significant when considered from the date of 
starting chemotherapy (Chahinian et al., 1982).  
Smoking status was found to be of value in predicting risk and although not significant in the 
univariate analysis smoking was significant with increased risk of death in ex-smokers and current 
smokers in the multivariate analysis.  
To date there is limited data available on biological variables. Previous work has showed certain 
cancer types including mesothelioma to produce large amounts of interleukin-6 (IL-6) (Gastl et al., 
1993; Higashihara, Sunaga, Tange, Oohashi, & Kurokawa, 1992). It has been shown that high 
levels of IL-6 are highly correlated to platelet count, suggesting that IL-6 may have a role in 
tumour associated thrombocytosis (Gastl et al., 1993). Data on platelet count as a predictor of 
survival is conflicting with some evidence showing no prognostic relevance (Spirtas, Connelly, & 
Tucker, 1988). However two more recent studies showed a significant association with higher 
platelet counts and worse survival (Borasio et al., 2008; Tanrikulu et al., 2010) which was 
demonstrated in this study in both the univariate and multivariate analyses.  
The multivariate analysis here identified raised serum urea and adjusted calcium to be associated 
with an increased risk of death at 6 months. While there is limited data on urea as a prognostic 
marker for mesothelioma a recent retrospective analysis of a 114 patients also identified a raised 
urea to be a predictor of worse outcome (Marshall et al., 2015) which is supportive of our 
findings. 
Chest pain and weight loss were associated with worse outcomes. Few studies have previously 
looked for a direct correlation between baseline symptoms and prognosis. A previous study 
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examining quality of life in MPM patients identified pain as a symptom significantly associated 
with worse global quality of life (Hollen et al., 2004) and further work in this field has identified 
that baseline quality of life is a significant prognostic factor for survival (Langendijk et al., 2000; 
Montazeri, Milroy, Hole, McEwen, & Gillis, 2001). An American study (Temel et al., 2010) 
evaluating the role of early specialist symptom control delivered by palliative care specialists in 
advanced lung cancer reported better quality of life and improved survival. This work has 
identified a so far unmet need for research investigating the benefits of better symptom control 
on improving survival in mesothelioma and is explored further in chapter four. 
Surprisingly variables such as PS and histological subtype and patient gender which in previous 
literature have been associated with prognostic outcome (Montanaro et al., 2009; V. Neumann et 
al., 2004; Nojiri et al., 2011; van der Bij et al., 2012) were not found to be significant. PS was 
significant in the univariate analysis but not found to be so in the multivariate analysis. It is 
possible that in some cases patients with suspected MPM and worse performance states may not 
have been included in the database as their frailty may have limited the ability to confirm 
diagnosis of MPM. This may explain why performance status which is generally accepted as a 
strong predictor of mortality was not significantly associated with risk of death in this study. While 
this could be considered a shortcoming of our study arguably it is reflective of clinical practice 
where a more pragmatic approach to patient care is sometimes necessary.   
A limitation to this work was, like many other studies evaluating prognosis, this analysis was 
tested on a retrospective population limiting the quality of evidence. Another shortcoming was 
the proportion of missing data encountered for certain variables and attributed to the 
retrospective nature of the study. This incomplete data is likely to have clouded the reliability of 
the results and therefore certain variables had to be completely excluded from the analysis.  
Another consideration is that no formal sample size calculation was performed thus potentially 
missing certain prognostic factors of clinical significance. 15 different prognostic factors were 
identified as statistically significant in the univariate analysis. Although it is possible that if a larger 
sample size had been used further factors may have been found to be statistically significant, the 
large number of significant results identified in the univariate analysis would suggest the study 
was suitably powered to pick out the prognostic factors most strongly associated with survival. 
Therefore the study is unlikely to be underpowered. 
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The performance of the risk model was evaluated using the same dataset on which it was created. 
As a result, it is not surprising that it performs reasonably well. A fairer test would be to evaluate 
the performance of the model on a separate dataset and so needs further validation. 
3.6 Conclusion 
Retrospective analysis of our database identified age, smoking status, symptoms of chest pain and 
weight loss at presentation, and raised platelet count, urea and creatinine as markers of poor 
prognosis in mesothelioma. These prognostic predictors which are readily available in clinical 
practice make them an attractive aid for disease management. Although these prognostic factors 
alone cannot be used in isolation to predict prognosis, their presence may provide clinical teams 
with additional information when discussing life-expectancy with patients and their families. 
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4.0 A multi-centre non-blinded randomised controlled trial to assess the 
impact of regular early specialist symptom control treatment on quality of 
life in malignant mesothelioma: RESPECT-Meso 
4.1 Background 
MPM is an incurable cancer with a very limited prognosis. MPM has a significant symptom burden 
with pain, dyspnoea, weakness, sense of poor well-being and anorexia being commonly reported 
(Mercadante et al., 2016). A study examining health related quality of life (HRQoL) in MPM 
patients receiving chemotherapy demonstrated that 92% of patients have three or more physical 
symptoms at presentation (Hollen et al., 2004). Fatigue (94%), dyspnoea (89%), appetite loss 
(87%) and pain (85%) were the most common, with fatigue, dyspnoea and pain associated with a 
worse global HRQoL. Aggressive treatment strategies to prolong life include combinations of 
surgery, radiotherapy and chemotherapy, but remain controversial with no sound evidence base. 
At present, the fittest patients with MPM are offered chemotherapy with palliative intent, which 
has been shown to improve survival by two to three months in clinical trials (Vogelzang et al., 
2003). For less fit patients, best supportive and palliative care remains the mainstay of treatment. 
The fundamental aim of palliative care is to achieve the best quality of life (QOL) for patients and 
their carers. This is achieved with specialist symptom control and provision of psychological, social 
and spiritual support. Specialist palliative care (SPC) services are typically delivered by a MDT of 
staff with qualifications, expertise and experience to care for patients with progressive life limiting 
illnesses where the focus of care is on QOL. SPC is often delayed until disease focused treatments 
are no longer effective. There is evidence to suggest that even in high income countries up to 80% 
of people who die could have benefited from palliative care earlier (Murray et al., 2017).  
Several studies have reported that baseline quality of life is a significant prognostic factor for 
survival in non-small cell lung cancer (NSCLC) patients (Langendijk et al., 2000; Montazeri et al., 
2001). An American un-blinded single centre randomised controlled trial of 151 patients with 
advanced lung cancer assessed regular early SPC treatment in addition to standard care versus 
standard care alone, and demonstrated improved HRQoL, fewer symptoms of depression at 12 
weeks with reduced utilisation of aggressive end of life care measures (Temel et al., 2010). The 
same study reported improved survival in the intervention arm, although this was not a priori 
outcome, and the study was not adequately powered to demonstrate such an effect. More 
recently there is evidence from one randomised controlled trial that early integrated palliative 
care improved symptoms and potentially survival in patients with respiratory disease including 
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lung cancer (Higginson et al.), and another concluded that early SPC might improve HRQoL and 
patient satisfaction with care in patients with a large range of solid tumour malignancies 
(Zimmermann et al., 2014). A recent Cochrane review in 2017 which included seven RCTs 
evaluating early palliative care interventions in adults with advanced cancer indicated potential 
benefits to HRQoL and symptom intensity compared to when standard care alone (Haun MW, 
2017). However caution was advised in interpreting these results in view of the very low level of 
certainty of current evidence. 
Both patients with MPM and advanced lung cancer have very similar symptoms and both 
conditions have a poor prognosis. However, there are considerable differences in oncology and 
SPC services between America and many other countries including the UK, limiting the 
generalisability of these study results. In order to better address this a randomised controlled 
multicentre trial was designed to assess if regular early SPC alongside standard care had an effect 
on HRQoL in patients with newly diagnosed MPM compared to standard care alone provided by 
the NHS in the UK. This was a significantly large undertaking involving collaboration with many 
parties from different disciplines and from across the country.  
I was responsible for setting up of the trial and trial design including the development of the study 
protocol, standard operating procedures (SOP), study case reporting forms (CRF) and patient 
information leaflets. As the trial co-ordinator I liaised with the REC, the study sponsor, the British 
Lung Foundation (BLF) who was the study funder, the local finance department and the trial 
statistician. I also worked closely with patient and public facing organisations including 
Mesothelioma UK and Hampshire Asbestos and Support Awareness Group (HASAG) which are 
both mesothelioma charities and the Oxford Respiratory Trials Unit (ORTU). I led on recruitment 
of study sites and facilitated their set-up. I co-ordinated trial management group (TMG) and trial 
steering committee (TSC) meetings. Finally I was responsible for the co-ordination and day-to-day 
running of the trial and also interviewed and appointed a trial manager to later assist me in this 
role.  
4.2 Method 
4.2.1 Study objectives 
Primary aim 
The primary aim of our trial was to determine whether regular early SPC in newly diagnosed MPM 
patients results in improved quality of life 12 weeks after diagnosis, as compared to standard 
care.   
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Secondary aims 
The secondary aims included assessing the impact of regular early SPC on patient HRQoL at 24 
weeks. Patient mood was assessed at 12 and 24 weeks. Primary caregiver’s HRQoL and mood was 
assessed at 12 and 24 weeks, and additionally at 24 weeks following patient death.  
Collation of healthcare resource use was considered to assess cost-effectiveness of the study 
intervention and although included in the study protocol this data was not analysed. The rationale 
for this is explained in section 4.2.3.4 
4.2.2 Study design and setting 
This was a multi-centre randomised, un-blinded, parallel group controlled trial comparing early 
referral to a specialist palliative care team for regular early SPC versus standard care. A summary 
of the study design is illustrated in Figure 24. Study recruitment commenced in March 2014 and 
the final patient was recruited in October 2016. The study ended in April 2017. The study protocol 
had initially planned to recruit from 10 centres across the UK. However, due to falling behind on 
the projected recruitment target following TSC recommendation the trial was rolled out across a 
total of 22 centres including Perth, Australia. The study timeline and recruitment of centres is 
depicted in Figure 25.  
4.2.2.1  Selection of participants 
Recruitment and informed consent 
All new patients discussed at thoracic cancer MDT meetings were screened for eligibility as 
outlined in the study Screening and Randomisation SOP (Appendix 9) and those who met study 
inclusion criteria were approached by the study team in conjunction with the Lung Cancer Clinical 
Nurse Specialists (LCCNS). Suitable patients were asked to nominate a main carer and both the 
patients and carers were provided with verbal and written explanation of the study in the form of 
a Patient Information Sheet (Appendix 10) and Carer Information Sheet (Appendix 11). If the 
patients were unable to identify a main carer or the carers declined to participate, the patients 
could still participate. The patients and carers were then invited to a research clinic and asked to 
complete a patient consent form (Appendix 12) and a carer consent form (Appendix 13). This 
informed consent was obtained by a member of the research team. Informed consent procedures 
were carried out in accordance with Good Clinical Practice (GCP). The study team informed all 
participating patients’ and carers’ general practitioner (GP) about trial participation by letter 
(Appendix 14 and 15). 
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  Proven diagnosis of Mesothelioma 
ECOG PS=0-1, no exclusion criteria 
Written Informed Consent  
(patient and main carer) 
 
 
(patient and main carer) Baseli e questio n i s 
Patient: EORTC C30, EuroQuol 5-D, GHQ-12 
Main caregiver: FAMCARE-2, SF-36 Health Survey, GHQ-12 
Minimisation with random element 
Strata: ECOG PS, Centre, Plan for 
chemotherapy, histology 
 
STANDARD THERAPY 
INTERVENTION 
REGULAR EARLY SPECIALIST SYMPTOM CONTROL 
TREATMENT (RESSCT)  
AND STANDARD THERAPY 
CONTROL 
SPC review within 3 weeks and every 4 weeks thereafter. 
Patient has all other appropriate standard treatment 
All appropriate, standard treatment. Referral to SPC at 
discretion of lead physician / MDT anytime as required. 
TELEPHONE INTERVIEWS (S) 4-WEEKLY 
(WEEKS 4, 8, 16, 20) 
All patients complete EORTC C30 & LC13 
questionnaire 
12 & 24 WEEKS 
All patients and caregivers complete 
questionnaires (as above) 
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End of trial / Death 
24 Weeks after death 
Caregivers complete FAMCARE-2, SF-36 
& GHQ-12 
PRIMARY ENDPOINT: Comparison 
of the mean value across post-
baseline measures over 12 weeks 
of EORTC C-30 
Figure 24: Flow diagram outlining patient and carer trial pathway. 
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Figure 25: RESPECT-Meso study timeline. Timing of centres recruited is demonstrated. Each centre was an 
alphabetical letter. Code is available in Table 30. 
 
The following inclusion and exclusion criteria were used. 
Inclusion criteria 
1.  Histological or cytological confirmation of MPM. 
2. ECOG PS of 0-1. (Asymptomatic patients score 0; symptomatic but fully ambulatory 
patients score 1). 
3. The diagnosis of MPM received within the last 6 weeks. 
4. Ability to provide written informed consent in English and comply with trial procedures. 
Exclusion criteria 
1. Other known malignancy within five years (excluding localised squamous cell carcinoma 
of the skin, cervical intraepithelial neoplasia, grade III and low grade prostate cancer (Gleason 
score <5, with no metastases)). 
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2. Significant morbidity which the lead physician or MDT felt would unduly confound or 
influence HRQoL. 
3. Patients the MDT judge required referral to SPC at the point of diagnosis.  
4. Concurrent, or less than three months, since participation in another clinical trial that may 
have affected HRQoL. 
5. Referral at the time of recruitment for cytoreductive, tumour de-bulking, radical 
decortication or extrapleural pneumonectomy surgery for MPM. (Video Assisted Thoracoscopic 
Surgery or ‘mini’ thoracotomy for pleurodesis and diagnosis attempts was permissible.) 
6. Chemotherapy treatment for MPM initiated prior to consent. 
7. A significant history of depression / anxiety / psychiatric illness requiring specialist 
hospital care within the last twelve months. 
4.2.2.2  Randomisation and blinding 
Following completion of the baseline assessment, eligible patients and their carers were 
randomised with a random element in a 1:1 ratio between the intervention and control groups. 
Randomisation was via a computer generated centralised randomisation database which was 
managed by the ORTU, Oxford, UK. Participants were minimised according to; 
1) Centre  
2) Plan for chemotherapy (yes / no)  
3) ECOG PS (0 or 1) 
4) Histological sub-type (epithelioid versus non-epithelioid (biphasic, sarcomatoid, not defined)) 
Due to the nature of the intervention it was not possible to blind participants or the immediate 
research team to the allocated intervention. Interventions and outcome assessments were 
therefore non-blinded. Although the protocol stated that the data analyst would be blinded, this 
was not feasible since the dataset contained data which indirectly revealed treatment allocations. 
4.2.2.3  Control group: Standard Treatment 
The control group received all appropriate, routinely provided treatment for MPM currently 
available within the NHS. This was initiated by the patient’s General Practitioner (GP), the cancer 
MDT or lead respiratory physician as required. No treatment was withheld. Patients in the control 
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group could be referred to SPC based on clinical need at the discretion of the patient’s medical 
team. This occurred according to local timings and practice. 
Both, trial participants, referring physicians and SPC teams were instructed to inform the study 
team whenever a SPC referral was made from the control group. In order to capture this data 
accurately all participants in the control group were given a letter requesting that if the patient 
was seen by a healthcare professional in a SPC capacity that the trial team be immediately 
notified of the consultation (Appendix 16).  
4.2.2.4  Study intervention group: Regular Early Specialist Symptom Control 
Treatment(RESSCT) 
Patients randomised to the intervention group were referred in line with the SPC referral SOP 
(Appendix 17) and seen within three weeks by the SPC team. Carers were encouraged to 
accompany the patient for these visits. Both patients and carers continued to be seen by SPC 
teams regularly at four weekly intervals until the end of the trial. This was in addition to all 
standard care.  
Consultations included an assessment of physical, psychological, social and spiritual needs of the 
participant, with appropriate provision of additional medicine (e.g. analgesia) and referral to 
additional support services as required. By the nature of this care, it was bespoke and 
individualised according to each patients need. Inevitably services provided by SPC teams varied 
across centres depending on local resources. In order to standardise the approach to SPC 
consultations across the different trial centres, the study team adopted the use of the Sheffield 
Profile for Assessment and Referral to Care (SPARC) tool (Lidstone et al., 2003) (Appendix 18) and 
the revised Edmonton Symptom Assessment System (ESAS-r) (Watanabe et al., 2011) (Appendix 
19). Both these tools were utilised at the initial consultation for all intervention group patients 
and control group patients if and when referred. The SPARC and r-ESAS tools enabled the 
identification and signposting of complex palliative care needs which could then be adequately 
addressed. Participants were free to decline any interventions at any point. 
4.2.2.5  Participant reported outcome measures 
Patient and carer HRQoL and mood were measured using validated pre-specified questionnaires. 
HRQoL was measured using the global health status (GHS) subscale of the European Organization 
for Research and Treatment of Cancer Quality of Life questionnaire Core 30 (EORTC QLQ–C30) 
(Appendix 20), specifically developed to assess the quality of life in cancer patients (Fayers PM, 
2001). The EORTC QLQ-C30 has been widely used in clinical trials and been validated in patients 
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with MPM. The lung cancer supplement (LC13) adjunct (Appendix 21) is a further assessment of 
specific symptoms associated with lung cancer, which are relevant to MPM (Fayers PM, 2001; 
Nowak, Stockler, & Byrne, 2004).  
Caregiver HRQoL was assessed using the one-week recall short form-36 (SF-36) health survey 
(Appendix 22) which measures eight domains of HRQoL (Jenkinson, Wright, & Coulter, 1994). As it 
does not target a specific population, age or disease state it was appropriate for measuring 
HRQoL of care givers of patients. Another measure of care giver HRQoL was the family satisfaction 
with advanced cancer care-2 (FAMCARE-2) questionnaire (Appendix 23) which has sound 
psychometric properties and measures family/carers satisfaction with end-of-life care received by 
both the patient and their carers (Aoun, Bird, Kristjanson, & Currow, 2010). 
Patient and care giver mood was assessed using the 12 item General Health Questionnaire (GHQ-
12) (Appendix 25) The GHQ-12 is the most widely-used measure for screening for psychiatric 
morbidity in adults in the UK (Pevalin, 2000). 
4.2.2.6  Study visit schedule 
The patient and carer study visit schedule consisted of a combination of face to face and 
telephone contacts as described in the text below and Table 29. After consent, the following 
information was collected from all patients at the baseline assessment prior to randomisation; 
patient demographics, date and type of diagnostic pleural procedure, histological subtype of 
mesothelioma, current performance status (from MDT) and co-morbidities, previous treatments 
and pleural procedures, treatment plan, medication use, patient HRQoL and mood questionnaires 
(EORTC-QLQC30, EORTC-LC13, GHQ-12), neutrophil and lymphocyte values at time of diagnosis, 
IMIG stage of disease (Rusch, 1995) at time of diagnosis (staging data was only collected from 
selected sites). For designated main carers the following information was obtained; carer current 
health utilisation, work status (full or part time, retired), HRQoL and mood questionnaires (SF-36, 
FAMCARE-2, GHQ-12). This information was recorded in the Baseline visit CRF (Appendix 25). 
Patients randomised to the intervention group to receive RESSCT were seen by SPC at 4 weekly 
intervals. Carers were strongly encouraged to accompany the patient to these visits. The following 
information was collected; outcome of the consultation with SPC, specific referrals made on 
behalf of the patient. This information was recorded in the SPC Intervention CRF (Appendix 26).  
At 12 weeks (primary end point) and 24 weeks both patients and carers were seen in clinic and 
the following information on the patient was documented; patient history including recent 
treatments received and hospital / healthcare utilisation, medication use, patient HRQoL and 
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mood questionnaires (EORTC-QLQC30, EORTC -LC13, GHQ-12). For carers the following data was 
gathered; healthcare resource utilisation, carer HRQoL and mood questionnaires (SF-36, 
FAMCARE-2, GHQ-12). Clinic visits ensured better quality, more complete data for the primary 
end point. Patient specific data at 12 and 24 weeks and carer specific data at 12 and 24 weeks was 
recorded in the Patient Clinic Follow-Up Visit CRF (Appendix 27) and Carer Clinic Follow-Up Visit 
CRF (Appendix 28) respectively. 
Telephone consultations with patients were performed on a four-weekly basis (at 4, 8, 16 and 20 
weeks) to obtain the following information; recent treatments and hospital usage, medication 
use, completion of HRQoL questionnaires (EORTC-QLQC30, EORTC -LC13). The information was 
documented in the Telephone Follow-Up CRF (Appendix 29). Telephone rather than clinic 
consultations were utilised at these time points to minimise the burden of study procedures 
placed on the patients. 
The patient’s vital status was tracked for the duration of the study. In the event of patient death 
during the study the following information was documented; prior hospital / healthcare utilisation 
and treatments, medication use, date and place of death. This information was entered into the 
Post-mortality CRF (Appendix 30). After patient death, the research team approached the carer by 
written communication (Appendix 31) to complete the final questionnaires, 24 weeks after 
bereavement. Carer responses on the following was gathered over the telephone; healthcare 
utilisation, carer HRQoL and mood questionnaires (SF-36, FAMCARE-2, GHQ-12) and recorded in 
the Carer 24 week post-mortality CRF (Appendix 32). If this process identified psychological 
morbidity that required treatment, liaison with the individual’s GP and direct referral to more 
formal bereavement support services was considered.  
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Table 29: Study visit schedule (EOT= End of trial, SPC= Specialist Palliative Care). 
 Baseline SPC 
within 3 
weeks 
4 weeks 8 weeks 12 weeks 16 weeks 20 weeks 24 weeks Monthly 
SPC until 
death/EOT 
24 weeks 
after death 
Intervention 
 
Patient 
 
 
QLQ-C30, LC13, 
GHQ-12 
X    X   X   
SPC review 
 
 X X X X X X X X  
Telephone 
interview (QLQ-
C30, LC13) 
  X X  X X    
Carer GHQ-12, SF-36, 
FAMCARE-2 
X    X   X  X 
Control 
 
Patient* QLQ-C30, LC13, 
GHQ-12 
X    X   X   
Telephone 
interview (QLQ-
C30, LC13) 
  X X  X X    
Carer GHQ-12, SF-36, 
FAMCARE-2 
X    X   X  X 
*All patients in the control group could be referred to SPC at any time based on clinical need.
102 
 
4.2.3 Data analysis 
All analyses were undertaken using Stata version 15.1 (StataCorp, College Station, TX).  
4.2.3.1  Data quality 
The study was reported in accordance with the Consolidated Standards of Reporting Trials 
statement and ICH Guidelines for GCP. All data was recorded on specifically designed study CRFs 
and a CRF completion SOP (Appendix 33) was available to all investigators in order to ensure 
optimal data recording. The study data including data entry and validation was managed by the 
ORTU using a bespoke database created using OpenClinica Enterprise Edition software 
(OpenClinica LLC, Waltham MA, USA). Confidentiality of participant data was assured according to 
GCP. 
4.2.3.2  Data cleaning  
Data cleaning was performed on the total number of enrolled patients taken from data lock on 
10th May 2017 (after the end of the trial). Data cleaning was focussed on CRFs that contained 
critical data for analyses. This included baseline, randomisation, patient clinic and telephone 
follow-up, SPC review, death and SAE CRFs as well as data from the following questionnaires; 
EORTC QLQ-C30, GHQ-12, SF-36 health survey and FAMCARE-2. Consequent data locks on 16th 
June 2017, 23th June 2017 and 05th July 2017 were checked to see if previous queries were 
resolved. Any inconsistencies and queries identified were raised with the trial team. The final data 
lock was taken on 14th Aug 2017.  
4.2.3.3  Validation of data manipulation and derived data  
For the purposes of the analyses, data manipulation was checked on a small sample of patients 
visually to ensure it was done successfully and data derivation was hand-checked on a small 
sample of observations to ensure successful derivation, where appropriate.  
4.2.3.4  Questionnaire scoring and missing data  
EORTC QLQ-C30 
A total of 1042 questionnaires were collected, GHS score was calculated for 1037 (99.5%) of 
received questionnaires. Five questionnaires (0.5%) could not be scored because they were 
missing both items 29 & 30. The GHS score was calculated using the QLQ-C30 package on STATA. 
Each questionnaire was also scored using the formula specified in Section 7.1 of the Statistical 
Analysis Plan (SAP) for checking purposes. Scores derived from both methods were in agreement.   
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GHQ-12 for patients 
Four patients had duplicated questionnaires, leading to uncertainty over which form to include in 
the analysis. Two of those patients had two baseline questionnaires, one had two questionnaires 
at 12 weeks and one had two questionnaires at 24 weeks. We removed all four duplicated 
questionnaires (8 entries out of a total of 447) from the data before analysis.  
Questionnaires were scored using the GHQ scoring method (0-0-1-1) i.e. for each of the 12 items, 
the two options which indicated ‘better/healthier than normal’ and ‘same as usual’ were given a 
score of 0 and the two options which indicated ‘worse/more than usual’ and ‘much worse/ more 
than usual’ were given a score of 1. Each of the 12 items were summed to give a total score 
ranging from 0 to 12. Missing items were assumed a score of 0. When all items were missing, the 
questionnaire was not scored. Only 11 questionnaires (2.6%) out of a total of 439 were 
incomplete; 9 were missing just one item, two were missing all items and not scored (those two 
questionnaires were not treated as missing because the field GHQ-12 done in the clinic follow-up 
CRF was marked Yes and a date was recorded for form completion). 
GHQ-12 for carer  
One carer had a duplicated questionnaire at 12 weeks. These duplicated questionnaires were 
deleted (2 entries out of a total of 397) from the data before analysis.  
Questionnaires were scored in the same way and missing items were handled in the same way as 
for GHQ-12 for patients. Only 8 questionnaires (2.1%) out of a total of 395 were incomplete; one 
questionnaire was missing 5 items, five questionnaires were missing just one item and two 
questionnaires were missing all items. 
FAMCARE-2 
Questionnaires were scored by taking the sum of all 17 items to give a score ranging from 17 to 
85, where a higher score implied greater satisfaction with end of life care. For each questionnaire, 
missing items or items marked N/A were imputed with the mean score of available responded 
items (where the responses were 1-5). Questionnaires with ≥9 missing items were not scored. 
Items marked N/A were not considered missing but questionnaires where all items were marked 
N/A were not able to be scored.  
A total of 399 questionnaires were collected, a score was calculated for 341 (85.5%) of those 
received. Six questionnaires (1.5%) were missing ≥9 items and 52 questionnaires (13.0%) had 
responded N/A to all questions so could not be scored (this is due to a high proportion of 
questionnaires at baseline with N/A responses to all questions).   
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SF-36 health survey 
Questionnaires were scored using the QualityMetric Health Outcomes™ Scoring Software Version 
5.1 supplied by Optum. All SF-36v2 survey data collected in the study were imported into the 
software, and only questionnaires with complete data were scored. Missing data estimation was 
not used.  
A total of 404 questionnaires were collected, mental component scores (MCS) and physical 
component scores (PCS) were generated for 375 (92.9%) of those collected. Of the 29 
questionnaires with missing items, 19 were missing just one item, 9 were missing 2 to 7 items and 
one was missing 31 items. 
EuroQol-5D (EQ-5D) 
The use of the EQ-5D questionnaire was initially considered to measure patient HRQoL and then 
enable the calculation of Quality-Adjusted-Life-Years (QALY) (Whitehead & Ali, 2010). This would 
have allowed an economic analysis of healthcare use informing on the cost benefit of the study 
intervention.  
However, the primary outcome data demonstrated no treatment effect with the study 
intervention, RESSCT. In the absence of clear benefit with RESSCT any cost saving would be 
unlikely as this would involve a new pathway with a multitude of resource requirements. In view 
of this and the limitations on study funding the trial steering committee opted not to pursue the 
economic analysis as initially planned. Therefore EQ-5D questionnaires were not analysed. 
4.2.3.5  Sample size 
Assuming a population mean of 55 and a common standard deviation of 22 in GHS/HRQoL for 
mesothelioma patients (Fayers PM, 2001), a sample size of 78 patients in each arm was required 
to detect a 10-point difference in the mean scores between the two groups, with a power of 90% 
at a 5% two-sided significance level, assuming an autocorrelation  of 0.25.  
UK National Lung Cancer Audit data demonstrate approximately a 6% mortality at 12 weeks for PS 
0-1 patients – therefore we factored a 10% dropout before the primary endpoint at 12 weeks. 
Therefore, the sample size allowing for a power of 90%, a 5% two-sided significance level, a 
minimally clinically  important difference (MCID) of 10 units in the GHS/HRQoL and a dropout of 
10% (n=16) was 174 patients. 
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4.2.4 Statistical analysis 
The primary outcome was initially analysed on all participants with baseline and 12 week data. 
This was done using a linear regression model with baseline score added as a covariate (i.e. 
analysis of covariance (ANCOVA)) resulting in an adjusted mean difference in GHS score between 
randomised groups at 12 weeks. The same linear regression was performed with adjustment for 
the minimisation variables (centre, plan for chemotherapy, ECOG performance status and 
histological sub-type), as well as baseline score and treatment group. It was hypothesised that 
some data would be missing at 12 weeks due to early mortality. It was also hypothesised that 
treatment may affect both quality of life and survival and that analysing quality of life alone may 
lead to bias. Therefore, a joint modelling approach combining linear mixed effects models for 
repeated measurements and Cox models for censored survival outcomes was performed. The 
model incorporated all follow-up measurements of the outcome (i.e. at 4, 8, 12, 16, 20 and 24 
weeks) and survival time (with surviving patients censored at their last visit). Covariates included 
treatment group, baseline measurement of the outcome and measurement time.  
The intervention may have influenced the presence (or absence) of missing data. Therefore as the 
missing data was not random instead of employing multiple imputation or a mixed effects model 
a joint modelling approach was used to assess the robustness of any assumptions with missing 
data. For all patient reported secondary outcomes, ANCOVA models were used. Median survival 
times were obtained from the date of randomisation to date of death with the use of the Kaplan–
Meier method. Patients who were alive at the end of the trial were censored at that point. A Cox 
proportional hazards model was used to assess the effect of early SPC compared to standard care 
on survival with adjustment for treatment group.  
Pre-specified sub-group analyses comparing the EORTC QLQ-C30, GHS at 12 and 24 weeks were 
performed on the following subgroups: neutrophil/lymphocyte ratio (NLR <5/>5), International 
Association for Study of Lung Cancer Mesothelioma radiological stage (1 to 4), country of 
recruitment (UK/Australia), Age at recruitment (<75/>75 years), baseline ECOG PS (0/1), 
nominated carer at recruitment (yes/no). For each subgroup, a regression model was fitted for 
the GHS score on the baseline GHS score, treatment group, subgroup and the subgroup-
treatment group interaction for week 12 and week 24 separately.  
4.2.4.1  Deviations from the original randomisation and statistical analysis plan 
The SAP specified that ANCOVA models would be used for secondary outcomes. However at 
baseline 24.6% (35 out of 142) of available FAMCARE-2 questionnaires with >50% completion had 
responded N/A to all responded items and therefore could not be scored. This reduced the 
106 
 
number of carers with both outcome and baseline data for analysis. Consequently we decided to 
carry out analysis unadjusted for baseline for FAMCARE-2 outcomes at all time points i.e. a t-test 
was used instead.  
4.2.5 Safety reporting 
Given the nature of MPM, it was assumed that many of the patients involved in the study would 
have complications from their disease or other treatments (e.g. radiotherapy) during the follow 
up period, which were unrelated to study participation, and death was also a predicable 
occurrence during this study. Never the less to monitor safety during this trial and ensure there 
were no unexpected consequences of the intervention, investigators adhered to the risk-adapted 
safety monitoring procedures outlined below;  
• Recording of all Serious Adverse Events (SAEs) unless judged by the Investigator to be part 
of the patient’s natural disease progression or related to standard treatment.  
• Any SAE judged by the Investigator to be (possibly, probably or definitely) related to the 
intervention that was also unexpected, be expedited immediately to the Chief Investigator and 
the Sponsor, following instructions for expedited reporting within 24 hours of first becoming 
aware of the event. 
• Reporting of any observed quality change in events, or any safety concerns judged to be 
clinically significant and any clinical incident concerning study participants or with an impact on 
the study. 
A Data Monitoring Committee was not deemed necessary for this study as the study was not 
delivering a new intervention and there were no anticipated SAEs or risks from simply changing 
the timing of this intervention for subjects. 
4.2.6 Ethical considerations 
The study intervention was RESSCT which was carried out by SPC teams and was considered to 
have no additional safety risk compared with usual clinical practice. This study simply provided 
the same care, delivered at an earlier time point. The key ethical issues considered were as 
follows; no treatments or care would be withheld at any point in the study, with all subjects (in 
either group) able to receive any care considered appropriate by the treating physicians. The 
additional RESSCT input would continue beyond the end of trial (EOT) until death, with remaining 
subjects being integrated into existing palliative care services. 
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A favourable ethical approval for this study was granted by the NRES Committee, London-
Hampstead, reference: 12/LO/0078 (Appendix 34). The trial was conducted according to the 
Declaration of Helsinki(World Medical, 2013).  
4.2.7 Funding source, Sponsor and Trial oversight 
This study was funded through a competitive grant award from the British Lung Foundation (BLF) 
(Appendix 35). The sponsor for the trial was Portsmouth Hospitals NHS Trust (reference number: 
PHT/2013/46) (Appendix 36). In collaboration with the Sponsor, ORTU oversaw quality assurance 
and trial conduct with routine and for-cause audit performed in accordance GCP guidelines as 
appropriate. 
4.2.8 Dissemination policy 
The trial protocol was published (Gunatilake et al., 2014) and the full trial results will be published 
in a high impact medical journal. Lay summaries were developed with public patient involvement 
members and disseminated through respiratory and cancer charities and support groups. Lay and 
scientific summaries were published on the study website www.respect-meso.org. 
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4.3 Results 
4.3.1 Study participants 
Participants were recruited from a total of 22 centres including Perth, Australia (Table 30). Four 
centres were prematurely closed due to poor recruitment.  
Table 30: Participating centres with numbers patients and carers recruited. Centres (H)Royal Brompton 
Hospital, London; (I)St George’s University Hospital, London; (L)Royal Gwent Hospital, Wales; (Q)City 
Hospital, Birmingham prematurely closed as these centres were unable to recruitment. 
 
Centre ID 
 
Centre 
 
Months open 
 
Patients recruited 
 
Carers recruited 
A Portsmouth 31 35 31 
B Norfolk & Norwich 27 9 8 
D Durham & Darlington 27 5 4 
E North Manchester 26 10 4 
F South Tyneside 26 5 4 
G Wolverhampton 25 1 1 
J Essex 21 4 3 
K North Bristol 20 7 3 
M Swindon 19 3 2 
N Taunton 19 5 5 
O South Manchester 19 22 20 
P Basildon 17 7 6 
R Southampton 16 3 3 
S Perth, Australia 15 36 34 
T Winchester & Basingstoke 15 9 7 
U North Tyneside & Wansbeck 15 6 5 
V Ipswich 10 3 1 
W Nottingham 3 4 4 
                                              Total Recruited            174           145 
 
Patient recruitment and follow up took place between April 2014 and October 2016. 687 patients 
were screened for eligibility and 174 patients were randomised and included in the intention to 
treat (ITT) population. Progress of the patients through the trial is outlined in a CONSORT flow 
chart (Figure 26). Reasons for screening failure are summarised here. 87 patients were then 
allocated to RESSCT and 87 allocated to standard therapy.  
There were three protocol deviations. 1 patient randomised to RESSCT had already received 
chemotherapy and referred to palliative care prior to their baseline visit. However this patient 
withdrew two weeks after randomisation and therefore no data on the primary outcome was 
available for this patient. 1 patient randomised to receive RESSCT did not attend for his 
appointments with specialist palliative care and therefore by default received only standard care. 
For 1 patient the date of the baseline visit was 4 days outside the 6 week period from time of 
109 
 
diagnosis. All analyses were ITT unless otherwise specified, and so these patients with protocol 
deviations were analysed in the treatment group they were randomised to.   
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o Withdrew before 12 weeks 
(n=2)3 
o Died before 12 weeks (n=5) 
o Withdrew before 12 weeks 
(n=4) 
o Died before 12 weeks (n=6) 
Screening 
(n=687) 
Failed screening n=513 
o Patient declined/refused (n=170) 
o Did not meet inclusion criteria (n=343); 
 ECOG>2: (n=96) 
 Referral to SPC needed at point of diagnosis (n=39) 
 Other known malignancy within last 5 years (n=31) 
 Diagnosis of MPM >6weeks (n=35) 
 Patient is participating/participated (< 3 months ago) 
in another trial that may affect QOL (n=40) 
 Patient started chemotherapy prior to consent 
(n=11)  
 Significant co-morbidity which will unduly or 
confound QOL (n=14) 
 Significant history of depression/anxiety/psychiatric 
illness (n=6) 
 Not MPM (n=42) 
 Died <2 months (n=5) 
 Out of area(n=22) 
 Other (n=2) 
 
Consented (n=174) 
Eligible1 (n=172)  
 
STANDARD THERAPY (n=87) REGULAR EARLY SPECIALIST 
SYMPTOM CONTROL TREATMENT 
(RESSCT) (n=87) 
Randomised 
(n=174) 
Followed-up at 12 weeks (n=80)  
o Did not attend 12 week visit (n=3)  
o Unable to score EORTIC C30: form not done 
or insufficient data (n=2) 
EORTIC C30 scored at 12 weeks (n=75) 
No. analysed in ITT primary analysis 
Followed-up at 24 weeks (n=67)  
o Did not attend 24  week visit (n=6)  
o Unable to score EORTIC C30: form not done or 
insufficient data (n=1) 
EORTIC C30 scored at 24 weeks (n=60) 
Followed-up at 24 weeks (n=68)  
o Did not attend 24 week visit (n=2)  
o Unable to score EORTIC C30: form not done or 
insufficient data (n=1) 
EORTIC C30 scored at 24 weeks (n=65) 
Followed-up at 12 weeks (n=77)  
o Did not attend 12 week visit (n=3)  
o Unable to score EORTIC C30: form not done 
or insufficient data (n=1) 
EORTIC C30 scored at 12 weeks (n=73) 
o Withdrew before 24 
weeks (n=1) 
o Died before 24 weeks 
(n=12) 
o Withdrew before 24 
weeks (n=1) 
o Died before 24 
weeks (n=8) 
Received at least one session 
of RESSCT (n=84). Did not 
receive at least one session of 
RESSCT (n=3)2 
Figure 26: Consort flow chart: 1Two patients out of the 174 who consented were not eligible but were randomised to 
RESSCT, these were protocol deviations. 2Out of the three patients randomised to RESSCT and did not receive at least 
one session, two were the above mentioned protocol deviations: Two were ineligible but randomised and one was 
treated with standard therapy as was unable to travel for palliative care. 3One of the two patients who withdrew 
before week 12 on the RESSCT arm was again the same patient who was ineligible but randomised. 
111 
 
4.3.2 Baseline characteristics 
Table 31 demonstrates the key demographic and clinical characteristics at baseline for RESSCT 
and standard care groups.  
Table 31: Baseline characteristics by randomisation arm. 
  
Standard Care (N=87)  
 
RESSCT (N=87) 
Numbers included  n  n  
Age Mean (SD)  
median (LQ, UQ) 
87 73.2 (8.2)  
72.8 (69.0, 78.9) 
87 72.4 (7.8)  
72.1 (66.7, 77.7) 
Gender Male (%)  87 72 (82.8) 87 67 (77.0) 
Radiological stage 1/2/3/4  
(%1/2/3/4)   
53 20/8/16/11 
(36.4/14.5/29.1/20.0) 
45 15/3/16/14  
(31.3/6.3/33.3/29.2)  
Neutrophil to Lymphocyte Ratio 
Median (LQ, UQ)  
86 4.1 (2.9, 7.4)  87  3.6 (2.7, 5.3)  
Co-morbidities Yes (%) 
Underlying respiratory 
disease  
87 9 (10.3) 87 12 (13.8) 
Cardiac failure 87 0 (0.0)  87 0 (0.0) 
Ischaemic heart disease 87 9 (10.3) 87 8 (9.2) 
Chronic renal impairment 87 1 (1.2) 87 2 (2.3)  
Diabetes 87 7 (8.1) 87 9 (10.3)  
Other  87 28 (32.2)  87 19 (21.8) 
Designated carer Yes (%) 87 72 (82.8)  87 73 (83.9) 
Previous treatment received Yes (%)  
Cordotomy 87 0 (0.0) 87 1 (1.2) 
Nerve block  87 0 (0.0) 87 0 (0.0) 
Radiotherapy  87 1 (1.2) 87 1 (1.2) 
Analgesia Yes (%) 
Suffers pain  87 46 (52.9)  87 54 (62.1)  
Pain due to 
mesothelioma  
46 28 (60.9) 54 27 (50.0) 
Analgesia use  87 56 (64.4) 87 55 (63.2) 
Pleural procedures Yes (%) 
Pleural procedures  87 69 (79.3) 87 67 (77.0)  
Therapeutic tap 69 28 (40.6) 67 26 (38.8) 
Chest Drain 69 20 (29.0) 67 19 (28.4) 
Chest Drain and 
pleurodesis 
69 16 (23.2) 67 21 (31.3) 
Indwelling pleural 
catheter 
69 12 (17.4) 67 7 (10.4) 
Medical thoracoscopy  69 27 (39.1) 67 26 (38.8) 
VATS 69 21 (30.4) 67 28 (41.8) 
Mini thoracotomy 69 1 (1.4) 67 0 (0.0) 
 
Table 32 shows the baseline patient data used for minimisation, by treatment group. There was 
good overall balance between the randomised groups for all four minimisation factors; plan for 
chemotherapy, ECOG performance status, histological subtype and study centre.  
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Table 32: Minimisation variables at baseline by randomisation arm. *Note the plan for chemotherapy was 
available for only 173 out of 174 patients at baseline. 
  
Standard Care (N=87) 
 
RESSCT (N=87) 
Numbers included  n  n  
Minimisation factors  
Plan for chemotherapy Yes (%) 86* 45 (52.3) 87 47 (54.0) 
ECOG performance status 0/1  
(% 0/1)  
87 32/55 
(36.8/63.2) 
87 34/53 
(39.1/60.9) 
Histological subtype  
Non-epithelioid/epithelioid  
(% Non-epithelioid/epithelioid) 
87  
19/68 
(21.8/78.2)  
87  
19/68 
(21.8/78.2) 
Centre: 87  87  
Basildon Hospital  3 (3.5)  4 (4.6)  
Broomfield Hospital  2 (2.3)   2 (2.3) 
City & Sandwell Hospital  0 (0.0)  0 (0.0) 
Ipswich Hospital  1 (1.2)   2 (2.3)  
Kings Mill Hospital  2 (2.3)  2 (2.3) 
Musgrove Park  2 (2.3)  3 (3.5) 
North Durham   2 (2.3)  3 (3.5) 
North Manchester  5 (5.8)   5 (5.8)  
North Tyneside General  1 (1.2)  1 (1.2) 
Perth Hospital  18 (20.7)   18 (20.7) 
Royal Brompton  0 (0.0)  0 (0.0) 
Royal Gwent Hospital  0 (0.0)  0 (0.0) 
South Tyneside  1 (1.2)  4 (4.6) 
Southampton General  2 (2.3)  1 (1.2) 
Southmead Hospital  3 (3.5)  4 (4.6) 
Basingstoke  1 (1.2)  0 (0.0) 
Great Western Hospital  0 (0.0)  3 (3.5) 
New Cross Hospital  1 (1.2)  0 (0.0) 
Norfolk & Norwich  6 (6.9)  3 (3.5)  
PHT – Portsmouth Hospitals 
NHS Trust 
 18 (20.7)  17 (19.5)  
RHCH, Winchester  3 (3.5)   5 (5.8)  
St Georges Hospital  0 (0.0)  0 (0.0) 
UHSM, Wythenshawe  13 (14.9)  9 (10.3)  
Wansbeck General  3 (3.5)   1 (1.2) 
 
Table 33 demonstrates the patient questionnaire scores at baseline for primary and secondary 
outcomes, by treatment group. Baseline values were similar between randomised groups for all 
outcomes. Only 107 questionnaires were available for carers at baseline. 
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Table 33: Questionnaire scores at baseline by randomisation arm. 
  
Standard Care (N=87, 
carer N=72)  
 
RESSCT (N=87, carer 
N=73) 
Numbers included  n  n  
QLQ-C30 Mean (SD) Median (LQ, 
UQ)    
87 66.9 (22.6) 
66.7 (50.0, 83.3) 
86 66.1 (20.0)  
66.7 (50.0, 83.3) 
Patient GHQ-12 Mean (SD) 
Median (LQ, UQ)    
86 2.8 (3.2) 
2 (0, 4) 
85 3.1 (3.3)  
2 (1, 4)  
Carer GHQ-12 Mean (SD) Median 
(LQ, UQ)    
71 3.9 (3.2) 
4 (1, 6)  
72 4.7 (3.8)  
4 (1, 8)  
FAMCARE-2 Mean (SD) Median 
(LQ, UQ)    
50 76.5 (8.6) 
77.9 (70.8, 85.0) 
57 76.0 (9.6)  
80.8 (69.0, 85.0) 
SF-36: PCS Mean (SD) Median 
(LQ, UQ)    
65 54.4 (8.9) 
55.9 (49.1, 61.4) 
69 54.3 (9.5)  
56.5 (49.3, 60.8) 
SF-36: MCS Mean (SD) Median 
(LQ, UQ)    
65 43.2 (11.6)  
44.1 (34.6, 52.6)  
69 40.8 (13.3)  
42.3 (33.1, 52.6)  
 
4.3.3 Numbers analysed (Description of available data) 
4.3.3.1  Primary analysis: Global health status score on the EORTC QLQ-C30 at 12 
weeks adjusting for baseline 
The primary analysis was ITT. 148 (85%) out of 174 randomised patients had a GHS score at week 
12 and at baseline. The reasons for missing scores for the remaining patients are shown in Table 
34. Figure 27 shows the raw data at baseline and 12 weeks for those 148 patients included in the 
primary analysis. 
Table 34: Reasons for exclusion from the primary analysis of the GHS score at week 12. 
 
ITT population 
 
Standard Care (N=87)  
 
RESSCT (N=87) 
Died before week 12 6 (6.9) 5 (5.7) 
Withdrew before week 12 4 (4.6) 2 (2.3) 
Missing week 12 questionnaire  3 (3.4) 3 (3.4) 
Unable to calculate score form 
week 12 questionnaire due to 
missing items  
1 (1.1) 2 (2.3) 
Number analysed (%) 73 (83.9) 75 (86.2) 
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Figure 27: Distribution of GHS scores on the EORTC QLQ-C30 at baseline and 12 weeks by treatment arm 
for the 148 patients included in the primary analysis. 
 
4.3.3.2  Secondary analyses: Global health status score on the EORTC QLQ-C30 at 
12 weeks adjusting for baseline and minimisation factors  
147 out of 174 (84%) randomised patients were included in this analysis. The number of patents 
with week 12 and baseline GHS scores were the same as for the primary analysis (Table 33). For 
one patient in the standard care group, the chemotherapy plan was unknown at randomisation. 
Therefore 72 (82.8%) patients in the standard care group and 75 (86.2%) patients in the RESSCT 
group were included in the analysis.  
4.3.3.3  Secondary analyses: Global health status score on the EORTC QLQ-C30 at 
24 weeks adjusting for baseline 
125 patients (72% of randomised) had a GHS score at 24 weeks. Reasons for missing scores for 
the remaining patients are shown in Table 35. One patient did not have a QLQ-C30 measured at 
week 24. Although the reason stated was death the recorded date of death was after the 
recorded date of the week 24 clinic visit which the patient did not attend. Therefore this patient 
was included in the row Missing week 24 questionnaire in Table 35 rather than recorded as having 
died before week 24.  
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Table 35: Reasons for exclusion from the ANCOVA analysis of the GHS score at week 24. 
 
ITT population 
 
Standard Care (N=87)  
 
RESSCT (N=87) 
Died before week 24 14 (16.1) 17 (19.5) 
Withdrew before week 24 5 (5.7) 3 (3.4) 
Missing week 24 
questionnaire  
3 (3.4) 6 (6.9) 
Unable to calculate score 
from week 24 
questionnaire due to 
missing items  
0 (0.0) 1 (1.1) 
Number analysed (%) 65 (74.7) 60 (69.0) 
 
4.3.3.4  Joint modelling of global health status score at all time points and 
mortality 
A total of 864 scores were available across all post-baseline study time points (i.e. week 4 to 24), 
432 from the standard care arm and 432 from the RESSCT arm. These 864 scores were from 169 
patients (97.1% of randomised), 85 from the standard arm and 84 from the RESSCT arm, all of 
whom had a score at baseline. So data from 169 patients were analysed in the mixed model 
component of the joint model. For the survival component of the joint model, all 174 patients 
were included. 
4.3.3.5  Secondary analyses: GHQ-12 for patients at 12 and 24 weeks 
GHQ-12 questionnaire scores were available for 144 patients at 12 weeks. The baseline score 
from one patient in the RESSCT group was not available as two baseline forms were entered for 
this patient. Therefore this data was excluded and so 143 patients (82.2% of randomised) were 
included in the ANCOVA, 69 from the standard care group (79.3% of randomised) and 74 from the 
RESSCT group (85.1% of randomised).  
Scores were available for 122 patients at 24 weeks. Again the baseline score for the above 
mentioned patient was excluded and so 121 patients (69.5% of randomised) were included in the 
ANCOVA. 64 from the standard care group (73.6% of randomised) and 57 from the RESSCT group 
(65.5% of randomised). 
4.3.3.6  Secondary analyses: GHQ-12 for carers at 12 and 24 weeks and 24 weeks 
post mortality  
Scores were available for 121 carers at 12 weeks, but one carer score was missing at baseline. 120 
carers were included in the ANCOVA (82.8% of carers randomised), 57 from the standard care 
group (79.2%) and 63 from the RESSCT group (86.3%).  
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Scores were available for 96 carers at 24 weeks, but again the same carer score was missing at 
baseline. 95 carers (65.5% of randomised) were included in the ANCOVA, 51 (70.8%) from the 
standard care group and 44 from the RESSCT group (60.3%).  
Out of the 145 patients whose carers consented to participate in the study, 56 died before 25 
weeks prior to the study end date, 26 and 30 on the standard care and RESSCT groups, 
respectively. Therefore although 56 carer questionnaires at 24 week post mortality were 
expected, scores were only available for 33 carers at 24 weeks post mortality. 17 (~65.4% of 
expected) from the standard care group and 16 (~53.3% of expected) from the RESSCT group. 
Baseline scores were available for all of these 33 forms.  
4.3.3.7  Secondary analyses: FAMCARE-2 at 12 and 24 weeks and 24 weeks post 
mortality  
114 questionnaires (78.6% of carers randomised) were scored at 12 weeks, 51 from the standard 
care group and 63 from the SSCT group (70.8% and 86.3% of randomised, respectively). Of the 
114 patients with data at 12 weeks, 21 did not have data at baseline (20 of which answered N/A 
to all items), therefore a T-test was performed instead of ANCOVA as outlined in the SAP. Due to 
non-normality of residuals, a non-parametric test (Wilcoxon Mann-Whitney) was performed to 
compare consistency of conclusions. In addition, the distribution of patients with scores 
1/2/3/4/5 in each treatment group were tabulated and compared between groups using the 2-
sided Fisher’s Exact test for each of the 17 items on the questionnaire. These analyses did not 
require missing/NA values to be imputed so were performed on the available raw data only.  
The analysis procedures performed for week 12 data was repeated for data at 24 weeks and 24 
weeks post-mortality. Scores were available for 88 carers at 24 weeks (60.7% of carers 
randomised), 43 from the standard care group (59.7%) and 45 from the RESSCT group (61.6%).  
Out of the 145 patients whose carers consented to participate in the study, 56 died before 25 
weeks prior to the end of the study, 26 and 30 on the standard care and RESSCT groups, 
respectively. However scores were only available for 32 carers at 24 weeks post mortality, 16 
(~61.5% of expected) from the standard care group and 16 (~53.3% of expected) from the RESSCT 
group.  
4.3.3.8  Secondary analyses: SF-36 at 12 and 24 weeks and 24 weeks post 
mortality  
116 questionnaires (80.0% of carers randomised) were scored at 12 weeks, 55 from the standard 
care arm and 61 from the RESSCT group (76.4% and 83.6% of randomised, respectively). Out of 
117 
 
the carers with data at 12 weeks, 8 did not have data at baseline. Therefore 49 carers from the 
standard care group and 59 carers from the RESSCT group were analysed.  
Data for 94 carers were available at 24 weeks (64.8% of carers randomised), 47 from each arm 
(65.3% and 64.4% of carers randomised to standard care and RESSCT, respectively). Out of these 
94 carers, 7 did not have baseline data. Therefore 42 carers from the standard care arm and 45 
carers from the RESSCT group were analysed.   
Of the 56 carer questionnaires expected at 24 weeks post mortality, data was only available for 31 
carers at 24 weeks post mortality (~55.4% of expected). 16 were from the standard care group 
and 15 from the RESSCT group (~61.5% and 50.0%% of expected). Out of these 31 carers, 3 did 
not have a score at baseline, and so only 14 carers from each arm were included in the analysis. 
4.3.4 Compliance  
4.3.4.1 Treatment compliance 
Standard care group 
Out of the 87 patients randomised to receive standard care, 85 patients had at least one 
telephone or clinic follow-up visit (week 4 to week 24). Prior to the primary endpoint at week 12, 
15 patients (17.2%) had been referred to SPC. Out of the 73 patients with data for the primary 
analysis, 11 were referred to SPC before week 12 (12.6% of randomised and 15.1% of those 
analysed). By week 24, 30 patients (34.5%) had been referred to palliative care.  
RESSCT group  
Of the 87 patients randomised to receive RESSCT, 3 patients did not attend any SPC visits. 1 
patient had no data at any time point and withdrew around 12 weeks after randomisation (week 
12 QLQ-C30 not done), 1 patient was randomised in error as they were ineligible and withdrew 2 
weeks after randomisation, and 1 patient was treated with standard therapy as they were unable 
to travel to see the palliative care team. Taking this into account 84 patients (96.6%) had at least 
one SPC consultation. Out of those 84 patients, 68 had attended all three SPC consultations 
before the primary endpoint at week 12.  
Table 36 shows the number of SPC visits all randomised patients on the RESSCT group had 
attended prior to week 12 and the number of number of SPC visits patients with the primary 
endpoint data on the RESSCT group had attended before week 12.  
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Table 36: Number of SPC consultations attended by patients on the RESSCT group: all randomised 
patients and those with primary endpoint data to contribute to the primary analysis.   
 
Number of SPC consultations 
attended before 12 weeks 
 
Total randomised RESSCT 
(N=87) 
 
Numbers analysed for the 
primary analysis (N=75)  
0 3 (3.5)  1 (1.3) 
1 6 (6.9) 2 (2.7)  
2 10 (11.5) 9 (12.0) 
3 68 (78.2)  63 (84.0)  
 
Table 37 shows the number of SPC review CRFs received at each scheduled time point up to 24 
weeks. Also shown are the number of patients who attended the SPC consultations and the 
number of patients who did not attend. Reasons for non-attendance are also included.  
 
Table 37: Number of patients randomised to the RESSCT group that attended/ did not attend the SPC 
consultation for visits up to 24 weeks post randomisation. Reasons for non-attendance at listed for each 
time point.  
Visit SPC done Total 
CRFs 
received 
Reasons for SPC not done 
 Yes No   
Within 3 weeks 
of 
randomisation 
82 1 83 Too unwell to complete paperwork 
4 weeks 74 6 80 Patient forgot  
Patient too unwell to attend 
Patient declined follow up 
Unable to contact patient 
Admitted to Hospice 
Unknown 
8 weeks 74 6 80 Patient didn't think they had to attend 
Patient too unwell to attend (n=3)  
Patient in hospital 
Patient declined follow up 
12 weeks 67 10 77 miscommunication ward appointment 
Patient too unwell to attend (n=2) 
Patient and SPC nurse both on holiday 
Unable to contact patient (n=3) 
Patient has died (n=2) 
Patient forgot. Appointment rescheduled to 
next week (no additional form for 12 week 
appointment recorded)  
16 weeks 64 5 69 Patient admitted to hospital 
Patient declined follow up  
Unable to contact patient (n=3) 
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Visit SPC done Total 
CRFs 
received 
Reasons for SPC not done 
 Yes No   
20 weeks 62 2 64 Patient has died 
Patient currently inpatient in Leicester 
24 weeks  52 8 60 Patient too unwell to attend (n=3) 
Patient declined follow up (n=2) 
Appointment cancelled 
Patient on holiday 
Conflicting appointment 
 
SPC visits were due every 4 weeks for patients randomised to receive RESSCT. Figure 28 shows the 
number of SPC visits attended at each time point and the category of deviation for the date of 
each visit i.e. whether the visit occurred within a window of +/- 7/10/14 days of the date the visit 
was due (visit due date was 4 weeks after the date of the previous visit).  
 
 
Figure 28: Number of SPC visits attended by patients randomised to receive RESSCT at each time point, 
and the category of deviation. 
 
 
All SPC visits before week 24 attended by patients randomised to RESSCT 
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4.3.4.2  Data availability  
The graphs in this section show the number of questionnaires received and the proportion of 
questionnaires that had 0-<20%, 20-<40%, 40-<60%, 50-<60%, 60-<80% and 100% responses at 
each time point by treatment allocation, for each questionnaire collected in the study (Figures 29-
33). 
  
 
Figure 29: Total number of questionnaires received and % completion of questionnaires at each time 
point by treatment group. 
 
 
Figure 30: Total number of questionnaires received and % completion of questionnaires at each time 
point by treatment group. 
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Figure 31: Total number of questionnaires received and % completion of questionnaires at each time 
point by treatment group. 
 
 
Figure 32: Total number of questionnaires received and % completion of questionnaires at each time 
point by treatment group. 
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Figure 33: Total number of questionnaires received and % completion of questionnaires at each time 
point by treatment group.  
 
Figure 34 shows the total number of questionnaires with more than 50% of items completed i.e. 
questionnaires to be included in the analysis at each time point, by the category for % of items 
marked N/A.  
 
 
Figure 34: Total number of questionnaires for each time point and treatment arm with % of items marked 
N/A. 6 questionnaires had less than 50% completion and were not included in the analysis.  
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4.3.4.3  Withdrawals & Protocol Violations 
9 patients (5.2% of randomised) withdrew from the study. Of those 5 patients (5.7% of 
randomised) were from the standard care group and 4 patients were (4.6% of randomised) from 
the RESSCT group.  
4.3.4.4  Blinding 
This was an un-blinded study due to the nature of the intervention. The study protocol stated that 
the data analyst would be blinded. However, this was not feasible as the dataset contained data 
which indirectly revealed treatment allocations. 
4.3.5 Results 
4.3.5.1  Primary analysis: Global Health Status on the EORTC QLQ-C30 at 12 
weeks  
Table 38 shows the result of the primary analysis. The estimated difference in the GHS score 
between the RESSCT group and standard care group was 1.8 (95% CI: -4.9, 8.5). Therefore there 
was no evidence (p=0.59) to suggest that there was any significant difference between the 
treatment groups in effect on GHS.  
Table 38: ANCOVA of the global health status (GHS) score on the EORTC QLQ-C30 collected from 
randomised patients at the 12 week visit.  
 
 
 
Standard Care (N=87) 
 
RESSCT (N=87) 
Number analysed  73 75 
Mean score at 12 weeks (SD) 59.5 (21.2) 60.2 (23.6) 
Mean difference, adjusted for 
baseline score (95% CI) 
1.8 (-4.9, 8.5) 
P-value  0.59 
 
4.3.5.2  Secondary analyses: Global Health Status on the EORTC QLQ-C30 at 12 
weeks, adjusted for baseline 
The primary analysis was repeated with the minimisation variables as additional covariates i.e. a 
linear regression model for the GHS score at 12 weeks for centre, plan for chemotherapy, ECOG 
performance status and histological sub-type in addition to the baseline score and treatment 
group was calculated. Results are shown in Table 39. The estimated difference in score between 
treatment groups was 2.2 (-4.8, 9.3), and was very similar to the result of the primary analysis.  
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Table 39: Linear regression of the GHS score on the EORTC QLQ-C30 collected from randomised patients 
at the 12 week visit.  
  
Standard Care (N=87) 
 
RESSCT (N=87) 
Number analysed 72 75 
Mean score at 12 weeks (SD) 59.6 (21.3) 60.2 (23.6) 
Mean difference, adjusted for baseline 
score and minimisation variables* 
(95% CI) 
2.2 (-4.8, 9.3) 
P-value 0.50 
* Centre, plan for chemotherapy, ECOG performance status and histological sub-type 
4.3.5.3  Secondary analyses: Global Health Status on the EORTC QLQ-C30 at 24 
weeks  
The GHS scores for patients in both treatment arms were compared at week 24 after adjusting for 
GHS scores at baseline (Table 40). Consistent with previous results of the GHS score at week 12, 
there was no evidence of significant difference (p=0.54) between the treatment arms at week 
24.The estimated difference in score was -2.0 (95%CI:-8.6, 4.6).  
 
Table 40: ANCOVA of the global health status (GHS) score on the EORTC QLQ-C30 collected from 
randomised patients at the 24 week visit.  
  
Standard Care (N=87) 
RESSCT (N=87) 
Number analysed  65   60 
Mean score at 12 weeks (SD) 63.7 (19.84) 61.3 (20.75) 
Mean difference, adjusted for 
baseline score (95% CI) 
-2.0 (-8.6, 4.6) 
P-value  0.54 
 
4.3.5.4  Secondary analysis of the secondary outcome- global health status on the 
EORTC QLQ-C30 at all time points 
A more optimal approach to assess the effect of RESSCT on the GHS score was to consider all the 
data collected in the study. A common method would be to analyse GHS scores from all six post-
baseline time points using a mixed effects model. However this method made the assumption 
that the missing data is missing at random. However in this study most missing data points were 
due to the patient dying before their scheduled follow-up visit rather than missing at random. 
Therefore if the GHS score was related to survival time then performing a mixed effects 
regression alone could potentially lead to a biased result when assessing the relationship between 
RESSCT and GHS.  
Hence the association between the GHS score and mortality was investigated. 11 patients died 
before the primary time point at the 12 week clinic visit.  20 patients died before the 24 week 
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clinic visit. The remaining deaths (62 patients) occurred after the week 24 clinic visit (median time 
alive after week 24 was 20.6 weeks (LQ: 11.0 weeks, UQ: 39.0 weeks)).  Figure 35 shows the mean 
GHS score at each time point in the following four categories; patients who died before week 12, 
patients who died before week 24, patients who died after week 24 and patients who were alive 
at the end of the study. This demonstrates a clear association between survival and GHS scores 
with patients who died early having lower GHS scores across all available time points compared to 
those who survived until after the end of study.  
 
Figure 35: Mean GHS score at all time points for patients who died before their 12 week clinic visit/ died 
before their 24 week clinic visit/ died after their 24 week clinic visit/ were alive at the end of the study. 
The number of patients at each time point for each of the 4 categories are also demonstrated. 
 
To assess the effect of RESSCT on the GHS score by including data collected at all time points 
while accounting for informative (non-random) missing data, a joint model combining the linear 
mixed effects model with the Cox proportional hazard model was formed. In the joint model, 
dependence between the GHS score and survival was induced by a shared random intercept 
between the two “sub-models”. The mixed effects sub-model included data from all patients who 
had a baseline GHS score and at least one post-baseline GHS score. The Cox PH sub-model 
included all patients in the study. Time to death was calculated as the time from randomisation to 
death if death occurred before the 24 week clinic visit. The remaining patients were censored at 
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the date of the last recorded follow-up visit or the date of the last known contact if this was 
before week 24. The mixed effects sub-model had the following covariates; baseline score, 
treatment group, visit and a treatment visit interaction. The Cox PH sub-model had only 
treatment group as a covariate. Table 41 shows the estimated difference in the GHS score 
between the treatment groups at each study time point. There was no evidence of a significant 
difference at any time point. The association parameter, gamma, was -0.11 (95% CI: -0.16, -0.06, 
p<0.01), which implied a negative association between the GHS score and death times i.e. the 
lower the score, the higher the chance of death and provided strong evidence against missingness 
at random. This conclusion agrees with the observed association between GHS score and survival 
demonstrated in Figure 35.  The estimated HR from the joint model was 1.4 (95% CI: 0.6, 2.9, 
p=0.42) and so there was no evidence that survival significantly differed between the two 
treatment groups. 
Table 41: Joint modelling of the GHS score on the QLQ-C30 at all time points and survival time. 
 Number analysed  Mean score (SD) Mean difference 
(RESSCT-standard 
care), adjusted 
for baseline score 
(95% CI) 
P-value 
 Standard 
Care 
(N=87) 
RESSCT 
(N=87) 
Standard 
Care (N=87) 
RESSCT 
(N=87) 
  
4 weeks 84 83 64.8 (19.7) 64.9 (20.1) 0.4 (-5.3, 6.1) 0.90 
8 weeks 76 79 62.1 (22.5) 61.3 (19.3) -0.8 (-6.7, 5.1) 0.79 
12 weeks 73 75 59.5 (21.2) 60.2 (23.6)  2.3 (-3.7, 8.3) 0.45 
16 weeks 69 69 62.3 (21.7) 63.9 (19.0) 1.9 (-4.2, 8.0) 0.54 
20 weeks 65 66 62.6 (20.6) 60.2 (20.8) -2.6 (-8.9, 3.6) 0.41 
24 weeks 65 60 63.7 (19.8) 61.3 (20.7)  -1.3 (-7.7, 5.0) 0.68 
 
Figure 36 shows the mean GHS score at each time point by treatment group calculated from the 
data. Figure 37 shows the mean GHS score at each time point by treatment group predicted by 
the joint model. The observed and estimated mean profiles demonstrated by the two figures are 
very similar which is consistent with our conclusion from the joint model estimates i.e. that the 
study intervention had no significant effect on the GHS score throughout the 24 weeks of follow-
up. 
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Figure 36: Mean ± 95% CI of the mean global health status score (raw values) at all time points by 
treatment group. N(SC)=no. of available GHS scores in the standard care arm; N(RESSCT)=no. of available 
GHS scores in the RESSCT group. 
 
 
Figure 37: Mean ± 95% CI of the mean global health status score estimated by the joint mixed effects/ 
Cox PH model at all analysis time points by treatment group. The no. analysed at each time point is the 
same as the no. of available responses shown in Figure 36. 
RESSCT 
 
 
 
N(SC)=87            N(SC)=84                N(SC)=76               N(SC)=73                  N(SC)=69                N(SC)=65          N(SC)=65 
N(RESSCT)=86    N(RESSCT)=83        N(RESSCT)=79         N(RESSCT)=75          N(RESSCT)=69        N(RESSCT)=66     N(RESSCT)=60 
 
 
 
RESSCT 
 
Standard Care 
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4.3.5.5  Secondary analyses: Patient GHQ-12 score at 12 and 24 weeks 
Patients GHQ-12 scores in the RESSCT and standard care groups were compared at week 12 and 
week 24. The estimated difference in the GHQ-12 score between RESSCT and standard care 
groups was -0.6 (95% CI: -1.5, 0.4) at week 12 and -0.4 (95% CI: -1.2, 0.4) at week 24. Therefore 
there was no evidence to suggest that the treatment groups differed at either time points (Table 
42).  
 
Table 42: ANCOVA of patients GHQ-12 scores at week 12 and week 24.  
12 weeks 
 Standard Care (N=87) RESSCT (N=87) 
Number analysed 69 74 
Mean score at 12 weeks 
(SD) 
2.6 (3.2) 2.2 (3.0)  
Mean difference, adjusted 
for baseline score (95% CI) 
-0.6 (-1.5, 0.4) 
P-Value 0.23 
24 weeks 
Number analysed 64 57  
Mean score at 24 weeks 
(SD) 
2.1 (2.5) 
 
1.8 (2.5)  
Mean difference, adjusted 
for baseline score (95% CI) 
-0.4 (-1.2, 0.4) 
P-Value 0.27 
 
4.3.5.6  Secondary analyses: Carer GHQ-12 score at 12 and 24 weeks and 24 
weeks post mortality  
GHQ-12 scores for carers were measured at week 12, 24 and 24 weeks post patient mortality. The 
results of analysis for the three time points are demonstrated in Table 43. There was a between 
group difference in the GHQ-12 scores at week 24, which was -1.7 (95% CI: -2.9,-0.4) p=0.01. This 
suggested a more positive outcome in the RESSCT group.  
There was no significant difference at 12 weeks -0.3 (95% CI: -1.2, 0.6).  At 24 weeks post patient 
mortality the difference was 0.4 (95% CI: -1.7, 2.5) which again was not significant. However, the 
number of questionnaires available for analysis at this time point was only 33 and therefore very 
small. 
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Table 43: ANCOVA of carer GHQ-12 score at week 12, week 24 and 24 weeks post mortality. 
 Standard Care (N=72) RESSCT (N=73)  
GHQ-12 for carers at 12 weeks 
Number analysed 57 63 
Mean score at 12 weeks 
(SD) 
3.4 (3.1) 3.6 (3.4) 
Mean difference, adjusted 
for baseline score (95% CI) 
-0.3 (-1.2, 0.6) 
P-Value 0.5 
GHQ-12 for carers at 24 weeks 
Number analysed 51 44 
Mean score at 24 weeks 
(SD) 
3.7 (3.8) 2.5 (3.3)  
Mean difference, adjusted 
for baseline score (95% CI) 
-1.7 (-2.9,-0.4) 
P-Value 0.01 
GHQ-12 for carers at 24 weeks post mortality 
Number analysed 17 16 
Mean score at 24 weeks 
post mortality (SD) 
4.1 (4.1) 4.2 (3.7)  
Mean difference, adjusted 
for baseline score (95% CI) 
0.4 (-1.7, 2.5) 
P-Value 0.67 
 
4.3.5.7  Secondary analyses: FAMCARE2 score at 12 and 24 weeks and 24 weeks 
post mortality  
FAMCARE-2 scores for each group were measured at week 12, week 24 and 24 weeks post patient 
mortality. The results are shown in Table 44. FAMCARE-2 scores were significantly different in the 
RESSCT group compared to the standard care group with a difference in mean scores of 4.1(0.7, 
7.4), p=0.02 and 6.1(2.1, 10.1), p=0.003 for week 12 and week 24 respectively. p-values derived 
from non-parametric comparisons were in agreement of this conclusion. These results 
demonstrated a favourable outcome with RESSCT at these two time points.  There was however 
no significant difference between treatment groups at 24 weeks post mortality, although only 32 
patients were analysed at this time point.  
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Table 44: T-test of carer FAMCARE-2 score at week 12, week 24 and 24 weeks post mortality, also shown 
for each time point is the p-value from the Wilcoxen Mann Whitney test (a non-parametric comparison).  
FAMCARE-2 score at 12 weeks 
 Standard Care (N=72) RESSCT (N=73) 
Number analysed 51 63 
Mean score at 12 weeks (SD) 74.5 (9.0) 78.5 (8.9) 
Mean difference (95% CI) 4.1 (0.7, 7.4) 
P-Value 0.02 
Wilcoxen MW p-value 0.006 
24 weeks 
Number analysed 43 45 
Mean score at 24 weeks (SD) 73.3 (11.4) 79.5 (6.8) 
Mean difference, adjusted for 
baseline score (95% CI) 
6.1 (2.1, 10.1) 
P-Value 0.003 
Wilcoxen MW p-value 0.002 
24 weeks post-mortality 
Number analysed 16 16 
Mean score at 24 weeks after 
death (SD) 
69.9 78.3 
Mean difference, adjusted for 
baseline score (95% CI) 
8.5 (-0.5, 17.5) 
P-Value 0.06 
Wilcoxen MW p-value 0.12 
 
4.3.5.8  Secondary analyses: Carer SF-36 scores at 12 and 24 weeks and 24 weeks 
post mortality  
Table 45 demonstrates the results of the analysis of the perceived health status of the primary 
carers as assessed by the physical component scores (PCS) and mental component scores (MCS) 
on the SF-36 questionnaire. There was no evidence of a statistically significant difference in the 
PCS or MCS between treatment groups at week 12, week 24 or 24 weeks post patient mortality.  
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Table 45: ANCOVA of carer SF-36 physical component score and mental component score at week 12, 
week 24 and 24 weeks post mortality. 
SF-36:  Physical component score  Mental component score  
 Standard Care 
(N=72) 
RESSCT  
(N=73)  
Standard 
Care (N=72) 
RESSCT  
(N=73)  
12 weeks 
Number analysed 49 59 49 59 
Mean score at 12 
weeks (SD) 
51.8 (9.2) 53.4 (9.7) 45.1 (10.6) 43.7 (12.4) 
Mean difference, 
adjusted for baseline 
score (95% CI) 
1.8 (-0.7, 4.3) 0.5 (-2.8, 3.9) 
P-Value 0.16 0.75 
24 weeks 
Number analysed 42 45 42 45 
Mean score at 24 
weeks (SD) 
50.7 (8.8) 52.6 (10.0) 45.7 (11.8) 46.3 (9.8)  
Mean difference, 
adjusted for baseline 
score (95% CI) 
1.3 (-1.7, 4.4) 1.0 (-3.0, 4.9) 
P-Value 0.37 0.63 
24 weeks post mortality 
Number analysed 14 14 14 14 
Mean score at 24 
weeks post mortality 
(SD) 
54.2 (7.5) 51.8 (11.3)  42.9 (11.7) 41.1 (11.7)  
Mean difference, 
adjusted for baseline 
score (95% CI) 
-3.6 (-8.9, 1.7) 0.4 (-6.8, 7.6) 
P-Value 0.15 0.90 
 
4.3.5.9  Secondary analyses: Overall survival  
30 patients randomised, died prior to the secondary outcome (24 weeks post randomisation). A 
Cox PH regression on all patients censoring at this time point was performed. The estimated 
hazard ratio (HR) was 1.13(95% CI: 0.55, 2.31), p=0.74 suggesting there was no evidence that time 
to death differed between treatment arms (Table 46). This conclusion was in agreement with the 
log rank test (a non-parametric comparison) (chi2(1)=0.11, p=0.74). The Kaplan Meier graph of 
overall survival censored at 24 weeks is shown in Figure 38.  
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Table 46: Overall survival censored at 24 weeks after date of randomisation. 
 
 
 
 
 
 
  
 Figure 38: Kaplan Meier graph of overall survival by treatment arms, censored at 24 weeks after 
randomisation date. 
 
 93 patients (53.4% randomised) died during the study period. Another Cox PH regression analysis 
was performed on all patients, censoring at the last date of contact which was the end of the 
study. This analysis (Table 47) demonstrated a HR of 1.12(95% CI: 0.77, 1.73), p=0.51 which was 
very similar to the analysis censoring at week 24. This again suggests that time to death did not 
differ in either treatment arm during the course of the study. The median survival time was 54.7 
weeks (95% CI: 46.4, 85.4) for patients randomised to standard care and 50 weeks (95% CI: 42.43, 
69.0) for patients randomised to RESSCT. The Kaplan Meier graph of survival censored at the last 
date of contact is shown in Figure 39.  
 
 
 
  
Standard Care (N=87) 
 
RESSCT (N=87) 
Number analysed 87 87 
Number of deaths (%)  14 (16.09%)  16 (18.39%)  
Log rank test  chi2(1) = 0.11, p= 0.74 
Hazard ratio (95% CI)  1.13 (0.55, 2.31) 
P-Value 0.74 
RESSCT 
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Table 47: Overall survival censored at last date of contact. 
 
 
 
 
 
 
 
 
 
 
Figure 39: Kaplan Meier graph of overall survival by treatment arms censored at the last known date of 
contact in the study. 
 
Subgroup analyses, as pre-specified in the SAP, were carried out for the GHS score on the EORTC 
QLQ-C30 at weeks 12 and 24. For each subgroup, a regression model was fitted for the GHS score 
on the baseline GHS score, treatment group, subgroup and the subgroup-treatment group 
interaction for week 12 and week 24 separately. Results are shown on Table 48. As demonstrated 
there was no significant difference in HRQoL between the two study arms for any of the pre-
specified subgroups at either 12 or 24 weeks.  
 
 
Standard Care  
(N=87) 
RESSCT  
(N=87) 
Number analysed 87 87 
Number of deaths (%)  46 (52.87%)  47 (54.02%)  
Median survival time in 
weeks (95% CI) 
54.7 (46.4, 85.4)  50.0 (42.43, 69.0) 
 
Log rank test  chi2(1) = 0.45, p= 0.50 
Hazard ratio (95% CI)  1.12 (0.77, 1.73) 
P-Value 0.51 
RESSCT 
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4.3.5.10 Subgroup analysis  
Table 48: Subgroup analyses of the GHS score on the QLQ-C30 at weeks 12 and 24. n=no. of patients analysed. Also shown are: the raw means (SD) for each 
treatment group, the modelled difference in score (RESCCT-SC) for each category of the subgroup and the p-value of the interaction between treatment group and 
subgroup. *Difference (RESSCT minus standard care) adjusted for baseline GHS score, treatment group, subgroup and treatment-subgroup interaction.  
GHS score on the EORTC QLQ-C30 for patients at 12 weeks  
 Neutrophil/lymphocyt
e ratio (<5/>5)  
Radiological stage (1/2/3/4) Country 
(AUS/UK) 
Age at baseline 
(<75/≥75) 
ECOG at baseline (0/1) Presence of carer 
(Yes/No) 
 SC RESSCT SC RESSCT SC RESSCT SC RESSCT SC RESSCT SC RESSCT 
N 72 75 46 42 73 75 73 75 73 75 73 75 
Mean score at 
12 weeks (SD) 
59.6 
(21.3) 
60.2  
(23.6) 
59.1 (20.2) 59.1  
(27.5) 
59.5 
(21.2) 
60.2  
(23.6) 
59.5 (21.2) 60.2  
(23.6) 
59.5 
(21.2) 
60.2  
(23.6)  
59.5  
(21.2)  
60.2  
(23.6) 
Modelled 
mean 
difference 
(95% CI) 
<5 NLR 
(n=104): 
3.0  
(-5.0, 11.1) 
Stage 1 
(n=30):  
4.8  
(-11.5, 21.1) 
UK (n=114):   -0.31  
(-8.0, 7.3) 
<75 (n=90): 1.7  
(-7.0, 
10.3) 
ECOG 0 
(n=58): 
4.9  
(-5.9, 15.6) 
Carer did 
not 
Consent 
(n=23) 
-1.4  
(-18.7, 
15.9)  
 
Stage 2 
(n=9):  
17.6 
(-14.2, 49.4) 
>5 NLR 
(n=43): 
-1.7  
(-14.2, 
10.8) 
Stage 3 
(n=29):  
-5.7  
(-22.3, 10.8) 
AUS (n=34 ):  8.9  
(-5.1, 23.0)  
≥75 (n=58): 1.7  
(-9.1, 
12.5) 
ECOG 1 
(n=90):  
-0.1  
(-8.7, 8.5) 
Carer 
consented 
(n=125)  
2.3  
(-5.0, 9.7)  
Stage 4 
(n=20):  
-2.9 
(-22.8, 17.0) 
P-Value 0.52 0.51 0.24 1.00 0.47 0.69 
GHS score on the EORTC QLQ-C30 for patients at 24 weeks 
N 64 60 42 28 65 60 65 60 65 60  65 60 
Mean score at 
12 weeks (SD) 
63.9 
(19.9) 
61.3  
(20.7) 
64.7 (20.0) 62.5  
(24.1)  
63.7 (19.8) 
 
61.3  
(20.7)  
63.7 (19.8) 61.3  
(20.7) 
63.7 
(19.8)  
61.3  
(20.7)  
63.7 
(19.8) 
61.3 
(20.7) 
Modelled 
mean 
difference 
(95% CI) 
<5 NLR 
(n=90):  
-1.3  
(-9.1, 6.5) 
Stage 1 
(n=28):  
-6.7  
(-22.2,8.8) 
UK  
(n=96 ):   
-0.2  
(-7.8, 7.3) 
<75 (n=80): -2.3  
(-10.6, 
6.0)  
ECOG 0 
(n=54): 
-7.3  
(-17.3, 2.7)  
Carer did 
not 
Consent 
(n=22) 
-0.3  
(-16.2, 
15.5) Stage 2 
(n=7):  
17.2  
(-16.6, 50.9) 
>5 NLR 
(n=34):  
-4.3  
(-17.3, 8.8) 
Stage 3 
(n=22):  
-7.5 
(-24.8,9.8) 
AUS (n=29 ):  -7.1 
(-20.9, 6.8) 
≥75 (n=45): -1.5  
(-12.6, 
9.6)  
ECOG 1 
(n=71):   
2.0  
(-6.7, 10.8) 
Carer 
consented 
(n=103)  
-2.2  
(-9.5, 5.0) 
Stage 4 
(n=13):  
8.0 
(-14.9, 31.0) 
P-Value 0.70 0.38 0.38 0.90 0.16 0.83 
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4.3.5.11 Treatment by centre interaction  
To examine the consistency of the treatment effect across study centres, Figure 40 shows all the 
data included in the primary analysis for each of the participating centres. Scores from patients 
randomised to standard care are in blue and scores from patients randomised to RESSCT are in 
red. There appears to be an overlap of scores between the two treatment groups both along the 
GHS scoring scale and across all centres. Therefore there is no indication from visually examining 
the data, that the effect of receiving RESSCT compared to standard care was inconsistent across 
study centres.   
 
Figure 40: Transformed GHS score at 12 weeks for all patients, by centre. This graph shows the GHS 
scores of all patients included in the primary analysis. The number of patients with a score at week 12 
and the total patients randomised for each centre are shown in brackets next to the centre name. 
 
 
 
 
      SC                  RESSCT 
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4.3.5.12 Sensitivity analysis 
Analysis on protocol-compliant patients  
A sensitivity analysis on the primary outcome was performed. This was the GHS score on the QLQ-
C30 at 12 weeks on a per-protocol cohort which included all patients who;  
 
 Were randomised 
 Received the study intervention (i.e. received RESSCT for those in the RESSCT group) 
 Had at least one GHS score post baseline  
 Were protocol compliant, here defined as patients who received all three SPC visits 
before week 12, and the first visit was within 3 weeks of the date of the baseline visit 
and consequent visits (week 4 and 8) fell within the +/-7 day window of due date 
(based on the date of the previous visit).  
After the above exclusions, 128 patients were included in the per-protocol population. This 
consisted of 84 from the standard care group and 44 from the RESSCT group. 113 patients (88.3% 
of per-protocol cohort) had an available GHS score at 12 weeks. Results of the ANCOVA are shown 
in Table 49. The estimated difference between the treatment groups was 1.6 (-6.3, 9.6), and 
therefore there was no evidence that the GHS significantly differed between the two groups.  
 
Table 49: Sensitivity analysis of the primary outcome on a per-protocol cohort where only patients who 
complied to all three SPC visits before week 12 were included in the RESSCT group. 
 
EORTC C30 global health status score at 12 weeks: sensitivity analysis 
Number included in per-protocol 
cohort 
Standard Care 
(N=84) 
RESSCT  
(N=44) 
Number analysed 72 41 
Mean score at 12 weeks (SD) 59.1 (21.2) 60.2 (22.8) 
Mean difference, adjusted for 
baseline score (95% CI) 
1.6 (-6.3, 9.6) 
P-value  0.68 
 
A further post-hoc analysis on protocol-compliant patients excluding standard care patients who 
crossed over to the SSCT arm before the primary outcome measured at 12 weeks was performed. 
15 patients (17.2% of randomised) on the standard care arm were referred to palliative care 
before the clinic follow-up at week 12. These 15 patients who crossed over and received the 
intervention were excluded from the 128 patients from the initial per protocol analysis. Results of 
the ANCOVA are similar to the sensitivity analysis above and are shown in Table 50. Again no 
significant difference was demonstrated.  
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Table 50: Sensitivity analysis of the primary outcome on a per-protocol cohort of protocol-compliant 
patients, further excluding patients on the standard care arm who were referred to RESSCT before week 
12.  
 
EORTC C30 global health status score at 12 weeks: post-hoc sensitivity analysis 
Number included in per-protocol 
cohort 
Standard Care 
(N=69) 
RESSCT  
(N=44) 
Number analysed 61 41 
Mean score at 12 weeks (SD) 60.8 (20.0) 60.2 (22.8) 
Mean difference, adjusted for 
baseline score (95% CI) 
0.6 (-7.6, 8.8) 
P-value  0.89 
 
4.3.5.13 Exploratory analysis 
Prognostic modelling of symptoms in predicting survival  
Overall survival in patients with high/low symptom severity at baseline was compared for three 
reported symptoms on the EORTC QLQ-C30 questionnaire. These were; shortness of breath, pain 
and tiredness.  For each symptom, patients were grouped into two categories, those who 
answered “No” or “a little” (low severity) and those who answered “quite” or “very much” (high 
severity). For each of the three symptoms the number of patient deaths in the two severity 
categories, the estimated median survival time, the result of the log rank test and the estimated 
HR from fitting a Cox PH regression model (censored at the last known date of contact with the 
symptom as the only covariate) was calculated (Table 51).  
For each of the three symptoms, fewer patients (30-45%) answered in the high severity category. 
For all three symptoms, the estimated median survival times were higher in the low severity 
category and the log rank test suggested significant differences in survival between patients with 
high and low symptom severity. The estimated HR for both shortness of breath and pain was 1.7 
(95% CI: 1.1-2.6) i.e. the hazard was 70% higher in those in the high severity group. The HR for 
tiredness was 1.9 (95% CI: 1.3-3.0) i.e. the hazard in the high severity group was 90% higher than 
in the low severity group. In conclusion, the results of analysing the three reported symptoms 
suggested that patients who suffered these symptoms more severely at baseline died earlier 
compared to those with less severe symptoms.  
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Table 51: Survival by severity of symptoms reported for questions 8, 9 and 18 on the QLQ-C30 at baseline.  
Shown are the number of patients who answered the question, the number of deaths and the median 
survival time by severity category (No or a little/quite or very much), the log-rank and Cox PH regression 
results. 
Reported 
symptoms on the 
QLQ-C30 
Q8: Were you short of 
breath? 
Q9: Have you had 
pain? 
Q18: Were you tired? 
 
 No/a little quite/very 
much 
No/a little quite/very 
much 
No/a little quite/very 
much 
No. included in 
analysis 
120 53 130 40 125 47 
Number of 
deaths (%) 
59 (49.2) 34 (64.2) 66 (50.8) 26 (65.0) 60 (48.0) 32 (68.1) 
Median survival 
time in weeks 
(95% CI) 
65.3 
(49.1, 
78.3) 
41.0 
(28.1, 
69.0) 
59.4 
(46.4, 
77.6) 
45.1 
(22.4, 
67.3) 
67.3 
(49.3, 
78.3) 
42.7 
(24.0, 
54.7) 
Log rank test 0.01 0.03 0.002 
Hazard ratio (95% 
CI) 
1.7 (1.1-2.6) 1.7 (1.1-2.6) 1.9 (1.3-3.0) 
P-value (Cox PH) 0.02 0.03 0.003 
 
4.3.5.14 Safety (Harms) 
Nine serious adverse events (SAE) were reported during the study, three events were reported in 
1 patient randomised to the standard care group and six events were reported in 4 patients 
randomised to the RESSCT group. Therefore a total of 5 patients had at least one SAE (Table 522). 
There was no significant difference in the number of patients experiencing SAEs between the 
standard care and RESSCT groups (Fisher’s exact, P= 0.37).  
 
Table 52: Number of patients with reported SAEs by treatment group. 
 Standard Care  
(N=87) 
RESSCT  
(N=87) 
No. of patients with at least 
one SAE 
1 (1.1) 4 (4.6) 
No. of patients with no SAEs  86 (98.9)  83 (95.4)  
 P= 0.37 
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4.4 Discussion 
The WHO has recommended that all countries implement comprehensive palliative care 
programmes to improve quality of life for patients with cancer or other life threatening 
illnesses(Sepulveda, Marlin, Yoshida, & Ullrich, 2002). However palliative care services are fully 
integrated within health care in only a small proportion of countries (Lynch, Connor, & Clark, 
2013). Referrals to palliative care are usually late despite guidelines recommending earlier 
involvement (Wentlandt et al., 2012). This trial of 174 patients, assessing the benefit of regular 
early SPC treatment is to date the largest RCT to examine this question in patients with MPM. 
RESSCT delivered by SPC did not demonstrate any benefit to patient HRQoL at 12 weeks. A further 
per protocol analysis where all participants in the intervention group were fully compliant with 
the study intervention, and a post-hoc analysis where any patients in standard care group seeing 
SPC prior to the primary outcome measurement were excluded, did not show any treatment 
benefit. Neither was there any evidence of any benefit to patient HRQoL at 24 weeks or patient 
mood at either time points with RESSCT.  
When evaluating the study results the possibility of a type II error, leading to missing a real effect 
of the intervention was considered. As anticipated dropout before the primary outcome at 12 
weeks was 17 (9.77%) and completeness of data for the primary outcome was good. Therefore, it 
is unlikely the study was underpowered. The patient HRQoL and mood data at all time points 
failed to demonstrate any suggestion of a trend towards a positive effect of the intervention, 
suggesting a true negative result. There was some inevitable dilution of effect from the 
intervention with 19 (21.8%) of the intervention group not completing all SPC visits and 15 
(17.2%) of the standard care group receiving a SPC review before the week 12 outcome. It is 
possible that this crossover may have diluted any treatment effect. The primary outcome HRQoL 
measure (EORTC QLQ-C30 GHS) is a robust well validated measure for MPM and therefore 
unlikely to have failed to demonstrate a real effect (Fayers PM, 2001). Furthermore, our baseline 
estimates of GHS HRQoL were similar to two other mesothelioma studies, suggesting the validity 
of our findings (Clive et al., 2016; Zalcman et al., 2016). This would suggest that the study result is 
a true negative. 
Potential limitations of this study which should be considered in its interpretation include a high 
failure rate of screening predominantly due to patients not meeting study eligibility criteria. 
Another major limitation was that the intervention could not be masked due to its nature. 
Although attempts were made to analyse the data in a blinded fashion this was not feasible as the 
dataset contained data which indirectly revealed treatment allocations. As a result of trial 
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participation there may have also been increased awareness of the clinical teams to the potential 
benefits of earlier SPC. This may have influenced earlier referral of patients in the standard care 
group, potentially influencing the study outcome. Compliance with the protocol for monthly SPC 
visits should also be viewed as a weakness, however, this study was designed as a pragmatic study 
of an advanced cancer and this was an expected occurrence, as was the crossover from standard 
care to SPC care. Furthermore, the uniformity of the RECCST intervention provided across 
multiple sites may have varied. Inevitably there was some variation in SPC care provided across 
the different centres as is expected as the nature of palliative care is inherently bespoke to the 
patients’ and families’ needs. However to ensure that all patients had a standardised initial 
assessment two validated assessment questionnaires, SPARC (Lidstone et al., 2003) r-ESAS 
(Watanabe et al., 2011), were used. Thereafter the provision of care was directed by perceived 
patient and carer needs and the expertise of the palliative care specialist. 
The RESPECT-Meso study was designed to allow as pragmatic an approach as possible. This was to 
ensure best possible external applicability of the results, within the confines of ensuring internal 
validity and appropriate scientific rigor. One of the central difficult decisions made was to only 
include subjects with an ECOG PS of 0-1. This was based on UK National Lung Cancer Audit data 
demonstrating a ~24% mortality at 12 weeks for PS 2 patients with mesothelioma. Such attrition 
would have significantly increased the challenge of obtaining adequate data for the primary 
endpoint at 12 weeks. However, UK data demonstrate that 70-80% of patients with mesothelioma 
have a PS of 0-1 at the time of diagnosis (Bhatnagar, Earl, Lansdell, & Howell, 2010; F. J. Brims, 
Arif, & Chauhan, 2012; Chapman, Mulrennan, Ladd, & Muers, 2008; Jeyabalan et al., 2010) so our 
approach still allowed the inclusion of the majority of MPM cases at presentation. 
Finally, while this was a multicentre study, 40% of recruitment was from two sites, Portsmouth 
Hospitals NHS Trust which is a large general hospital in the UK and Sir Charles Gairdner Hospital 
which is a tertiary cancer centre for Western Australia. By way of being very different health care 
settings this is likely to have reduced a significant selection bias. Furthermore pre-specified sub-
group analysis did not demonstrate any difference in HRQoL measurements between the 
Australian centre and UK sites. 
Quality of life was chosen as the primary outcome of this trial as it is the main focus of palliative 
care. The Temel study (Temel et al., 2010) which recognised the potential importance of 
delivering early palliative care to patients with advanced lung cancer was a major contributor 
towards the rationale for the RESPECT-Meso trial. However the findings of the RESPECT-Meso trial 
are at odds with this study. A key difference between the two studies was the differing oncology 
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and palliative care services offered as standard care. The Temel study was conducted on an 
America population where oncology and palliative care services are less well integrated. 
Traditionally patients in America do not encounter palliative care services until much later in the 
course of their disease and usually after all other modes of therapy have been exhausted. UK 
practice is that all patients diagnosed with lung cancer or MPM have early access to a cancer 
clinical nurse specialists who are skilled in palliative care. There is also a strong culture within the 
NHS which encourages a more holistic approach when caring for these patients with much better 
integration between oncology and palliative care services. It is likely that this difference in 
baseline/standard care for patients diagnosed with cancer may have diluted any potential benefit 
with RESSCT in our patient population. However this interpretation should be viewed with caution 
as this study did not specifically test this supposition. 
The Temel study also reported an improved survival in with the intervention of early SPC, based 
on a secondary endpoint analysis with the effect size reported conferred an odds ratio of 0.82. 
The RESPECT-Meso study did examine the effect on survival but no difference in survival was 
observed based on the intervention. In any case a significant result was not anticipated as it was 
estimated that a study sample size of ~500 participants would have been required to demonstrate 
an effect on survival. However a post-hoc-analysis of all patients’ quality of life scores revealed 
that patients reporting worse quality of life at all time points including baseline had a higher 
mortality. This work consolidates on previous work that suggests worse symptoms and quality of 
life is a predictor of mortality (Langendijk et al., 2000; Montazeri et al., 2001). 
To date there is limited data on the impact of a life changing diagnosis such as cancer on patient’s 
carers. The results did not show a difference in carer HRQoL or mood at any time point including 
after the patient had died. There was however a significant albeit small improvement in carer 
mood at week 24 with RESSCT. This was not carried through to the next time point which was 24 
weeks post patient mortality. The bereavement process is complex and outside the remit of this 
study. It is possible that the small benefit in carer mood seen at week 24 may not have been 
sufficient to influence the significant emotional burden associated with bereavement. Care giver 
satisfaction with end of life care received by the patient (measured by the FAMCARE2 
questionnaire) was significantly better at weeks 12 and 24 with RESSCT. Carers assigned to the 
RESSCT group were actively encouraged to attend the 4 weekly consultations with SPC from the 
time the patient was given a diagnosis of MPM. It is likely that this additional SPC support given 
much earlier may have influenced this result. Although the higher satisfaction carers experienced 
with RESSCT up till week 24 was not seen at the 24 weeks post mortality time point only 32 
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questionnaires were available for analysis at this time point. It is possible that the small volume of 
data influenced this result and therefore should be interpreted with caution. 
4.5 Conclusion 
This study was designed to evaluate the implementation of a novel care pathway to care for 
patients with MPM, a disease with a high symptom-burden. While this study cannot advocate an 
immediate change to the existing care pathway in terms of incorporating early palliative care, 
further research is needed to evaluate whether certain patient groups would still benefit more 
from such an intervention. Although this intervention was not shown to be beneficial in this UK 
patient population the results may be of interest to health services in which palliative care 
services are less well integrated with oncology services. The result of the study will help inform 
clinicians and policy makers and enable a much better understanding as to the implications of this 
intervention. 
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5.0 Overall conclusion 
This thesis explores MPM which is an, aggressive cancer. It is caused by exposure to asbestos, and 
despite a ban on asbestos exports into the UK since 1999 the UK still boasts the highest death rate 
from MPM in the world (Rake et al., 2009). Portsmouth Hospitals NHS Trust which was where the 
majority of this this research was conducted serves the city of Portsmouth and is a busy district 
general hospital. It has a close proximity to the Portsmouth dockyards which has a historically 
large ship building industry where a significant amount of asbestos was used. As a result the local 
population has a high prevalence of asbestos-related respiratory disease including MPM and 
therefore with a real need MPM services to be further optimised. 
The insidious nature how MPM progresses, and its non-specific symptoms are key factors limiting 
the early diagnosis of MPM. The first study described in this thesis investigates four biomarkers, 
SMRP, osteopontin, fibulin-3 and HMGB-1 all of which have previously shown to have some 
promise for diagnosing MPM. This study has shown that pleural fluid SMRP can be utilised in a 
clinical setting to diagnose MPM from other causes of a pleural effusion with a high sensitivity. 
Importantly this study also demonstrated that combining pleural fluid or serum Fibulin-3, HMGB-1 
and Osteopontin to SMRP did not increase the sensitivity for detecting MPM above that of SMRP 
alone. In view of these findings any future research should be focused on SMRP as the biomarker 
of choice for diagnosing MPM. 
MPM is at present incurable regardless of the stage it is diagnosed. In the absence of a cure, being 
able to predict prognosis is particularly important so that patients and families may plan for their 
futures and also so that clinicians can ensure patient tailored care. The second study described 
here has attempted to identify predictors of survival from a retrospective cohort of patients newly 
diagnosed with MPM. Unlike previous prognostic studies examining patient populations which 
tend to have strict eligibility criteria (Curran et al., 1998) this study included all comers. Patient 
and disease factors evaluated were also readily available through routine clinical care making it a 
much more pragmatic study. A patient age of more than 73 years, the presence of symptoms of 
chest pain and weight loss, deranged biochemistry with raised serum urea and adjusted calcium 
as well as smoking status at presentation were found to independently adversely affect survival. 
While non-smokers had the lowest risk, current smokers had a much higher risk of death 
compared with ex-smoker with hazard ratios of 3.42 and 2.16 respectively. This is of particular 
relevance as it was the only modifiable risk factor to influence survival after diagnosis with MPM. 
Although this study is unable to directly comment on the potential survival benefit of smoking 
cessation the better comparative survival figures seen in ex-smokers would suggest smoking 
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cessation to be beneficial.  There is meta-analysis data (Parsons, Daley, Begh, & Aveyard, 2010) 
demonstrating a clear survival advantage with smoking cessation after a diagnosis of lung cancer. 
While this finding in lung cancer cannot be extrapolated to MPM, certainly more research is 
required to evaluate this further. The results from this study therefore further contribute to the 
importance of continuing to provide smoking cessation advice and nicotine replacement 
treatments even after diagnosis. 
 MPM is associated with a host of debilitating symptoms due to a combination of the nature of 
the disease, and also due to often presenting late for the reasons described previously. Except for 
chemotherapy which can prolong survival (Vogelzang et al., 2003) there is no other treatment for 
MPM which has a sound evidence base. The RESPECT-Meso trial describes a multicentre 
randomised controlled trial which evaluates a much more proactive symptom based care 
approach, tailored to the individual patient’s needs. This intervention did not appear to be of 
significant benefit in the NHS (UK) and Australia which has a similar health care service. A 
reasonable hypothesis for the negative result observed is that the health care setting where the 
trial was conducted already had well integrated SPC services which were already readily available 
to patients in the control group as part of standard care. This may have diluted any potential 
benefit. 
An exploratory analysis demonstrated an association between HRQoL and prognosis with worse 
HRQoL shown to be linked with worse survival. This further highlights the importance of focusing 
on patient outcomes such quality of life. The perceived increased carer satisfaction with SPC 
teams which was a separate priori outcome is also noteworthy and deserves further study. 
While this study was unable define a role for routine SPC in MPM patients without a high 
symptom burden, it confirms that most will require referral as their disease progresses. On one 
hand the study result is somewhat reassuring and suggests that any immediate changes to 
existing MPM care pathways in health care services similar to those which participated in this trial 
are unnecessary. On the other hand useful lessons may be learnt and applied to MPM care 
pathways which have less well integrated palliative care services. The results may also influence 
further work evaluating the potential benefits of early SPC in diseases other than MPM.  
Looking to the future there remains an ongoing need for further advances in all aspects of MPM 
care including diagnostics, prognostication and treatment. The biomarker study supports existing 
evidence on the potential role for SMRP as a biomarker for mesothelioma and would suggest that 
future work should focus on pleural fluid SMRP with adequately powered robust research. The 
145 
 
work done here evaluating prognosis in MPM identified several factors capable of independently 
influencing patients’ survival. A potential future direction for work should include investigating 
whether survival might now be positively influenced by modifying these prognostic factors. Finally 
as described MPM remains a disease with very limited treatment options and while many 
potential treatments such as chemotherapy continue to be investigated it is vital not neglect the 
importance of patient QOL as well as carer outcomes when considering developments to the care 
of patients with MPM. 
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7.0 Appendices 
Appendix 1: A prospective comparison of serum and pleural fluid biomarkers in the diagnosis of 
MPM, ethical approval by the NRES Committee London - Camberwell St Giles (REC reference 
number: 14/LO/0628). 
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Appendix 2: A prospective comparison of serum and pleural fluid biomarkers in the diagnosis of 
MPM, local site approval by PHT, R & D department (Reference number: PHT/2014/18). 
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Appendix 3: ELISA protocols adapted for the manufacturer’s instructions for SMRP. 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
Cal A       
0 nM 
066                          
Blood                          
Tube 1
085                                   
Pl Fl                     
Tube 1                
Cal B       
2 nM 
066                          
Blood                          
Tube 2
085                                   
Pl Fl                     
Tube 2                
Cal C       
4 nM 
066                          
Blood                          
Tube 3
085                                   
Pl Fl                     
Tube 3                
Cal D      
8 nM 
066                          
Blood                          
Tube 4
085                                   
Pl Fl                     
Tube 4              
Cal E       
16 nM 
066                          
Blood                          
Tube 5
085                                   
Pl Fl                     
Tube 5                
Cal F       
32 nM 
066                          
Blood                          
Tube 6
085                                   
Pl Fl                     
Tube 6                
High 
Cntrl 
13.5nM
066                          
Blood                          
Tube 7
085                                   
Pl Fl                     
Tube 7                
Low 
Cntrl 
4.5nM 
066                          
Blood                          
Tube 8
085                                   
Pl Fl                     
Tube 8                
Create dilutions of pl fl and serum samples by serially diluting using the sample diluent (starting with 1ml neat sample and pipetting 500ul across eppendorfs).
Add 100μL each of dilutions of standard, blank and samples into the appropriate wells. Cover with the Plate sealer. Incubate on plate shaker (700rpm) for 1 hour at room 
temprature (20-25°C).
Assay Procedure
Save Data to a memory Stick and transfer data into relevant Raw OD Data Tab section in Spread sheet.
 Export data with assigned Study name - Plate number - Date.
Check that the OD450 of the top and bottom standard are within working range to ensure assay sensitivity is not lost. 
Data Analysis
Aspirate the conjugate and wash x5.
Pipette 100μl of TMB Substrate into each well, apply plate cover and incubate on plate shaker for 15 mins.
Add 100µL of stop solution. Read on plate reader (450nm) within 30 minutes.
Aspirate the contents of the wells and wash x5 (350μL in each well, aspirate, repeat x4, then tap plate onto absorbent towel).
Pipette 100μl of conjugate into each well, apply plate cover and incubate on shaker (700rpm, 20-25°C) for 1 hour.
MPM SMRP ELISA Protocol Sheet
Plate 1 Layout
E
F
C
D
A
B
Bring all kit components and samples to room temperature (18-250C) before use.
Sample Preparation
Reagent Provided
Defrost sample by leaving at room temperature for > 30minutes.
Prepare Wash Buffer by diluting 1 part concentrate with 19 parts deionized water.
G
H
Calibrators and controls do not require dilutiuon before use.
Prepare 1:101 dilutions of patient serum samples using Diluent/Cal A.
Reagent Preparation
TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual solution into the vial again.
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Appendix 4: ELISA protocols adapted for the manufacturer’s instructions for Osteopontin. 
 
1 2 3 4 5 6 7 8 9 10 11 12
 Std 1 
40 
ng/mL
066                          
Blood                          
Tube 1
085                                   
Pl Fl                     
Tube 1                
 Std 2 
20 
ng/mL
066                          
Blood                          
Tube 2
085                                   
Pl Fl                     
Tube 2                
 Std 3 
10 
ng/mL
066                          
Blood                          
Tube 3
085                                   
Pl Fl                     
Tube 3                
 Std 4                
5 
ng/mL
066                          
Blood                          
Tube 4
085                                   
Pl Fl                     
Tube 4              
 Std 5 
2.5 
ng/mL
066                          
Blood                          
Tube 5
085                                   
Pl Fl                     
Tube 5                
 Std 6 
1.25 
ng/mL
066                          
Blood                          
Tube 6
085                                   
Pl Fl                     
Tube 6                
 Std 7 
0.625  
ng/mL
066                          
Blood                          
Tube 7
085                                   
Pl Fl                     
Tube 7                
 Std 8 
BLANK
066                          
Blood                          
Tube 8
085                                   
Pl Fl                     
Tube 8                
Create dilutions of pl fl and serum samples by serially diluting using the sample diluent (starting with 1ml neat sample and pipetting 500ul across eppendorfs).
Assay Procedure
Mix each tube thoroughly before continuing the dilution series. Prepare standards within 15 minutes of beginning the assay.
Save Data to a memory Stick and transfer data into relevant Raw OD Data Tab section in Spread sheet.
 Export data with assigned Study name - Plate number - Date.
Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water to prepare 600mL of Wash Solution (1×). Mix gently.
TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual solution into the vial again.
Add 50 µl of Stop Solution to each well. 
Add 90 µl of TMB Substrate to each well, cover with a plate sealer and incubate for 15-25 mins at 37°C. 
Wash Step- Aspirate the liquid and add 350μL of 1× Wash Solution to each well, let it sit for 1-2 minutes. X3 washes.
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper.
Add 100μL of Detection Reagent B working solution to each well, cover with new plate sealer and incubate for 30 minutes at 37oC.
Wash Step- Aspirate the liquid and add 350μL of 1× Wash Solution to each well, let it sit for 1-2 minutes. X5 washes.
MPM Osteopontin ELISA Protocol Sheet
Plate 1 Layout
E
F
C
D
A
B
Bring all kit components and samples to room temperature (18-250C) before use.
Sample Preparation
Reagent Provided
Defrost sample by leaving at room temperature for > 30minutes.
Use the diluted standard to produce a double dilution with the last tube as the blank 0 pg/mL (pipetting 250 µl across eppendorfs).
G
H
Reconstitute 1 tube of Standard with 0.5 mL of Standard Diluent, kept for 10 minutes at room temperature, shake gently (avoid foaming). 
The concentration of the standard in the stock solution is 40ng/mL. Prepare 7 eppendorf tubes containing 0.25 mL Standard Diluent.
Reagent Preparation
Briefly spin or centrifuge the stock Detection A and Detection B before use. 
Dilute Detection Reagent A and B stocks to the working concentration with Assay Diluent A and B, respectively (1:100).
Check that the OD450 of the top and bottom standard are within working range to ensure assay sensitivity is not lost. 
Aspirate the liquid of each well, Do not wash.
Add 100μL of Detection Reagent A working solution to each well, cover with a plate sealer, gently agitate and incubate for 1 hour at 37oC 
Data Analysis
Add 100μL each of dilutions of standard, blank and samples into the appropriate wells. Cover with the Plate sealer. Incubate for 2 hours at 37 oC.
Run the microplate reader and conduct measurement at 450nm immediately.
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper.
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Appendix 5: ELISA protocols adapted for the manufacturer’s instructions for Fibulin-3. 
 
1 2 3 4 5 6 7 8 9 10 11 12
 Std 1 
100 
ng/mL
066                          
Blood                          
Tube 1
085                                   
Pl Fl                     
Tube 1                
 Std 2 
50 
ng/mL
066                          
Blood                          
Tube 2
085                                   
Pl Fl                     
Tube 2                
 Std 3 
25 
ng/mL
066                          
Blood                          
Tube 3
085                                   
Pl Fl                     
Tube 3                
 Std 4 
12.5 
ng/mL
066                          
Blood                          
Tube 4
085                                   
Pl Fl                     
Tube 4              
 Std 5 
6.25 
ng/mL
066                          
Blood                          
Tube 5
085                                   
Pl Fl                     
Tube 5                
 Std 6 
3.12 
ng/mL
066                          
Blood                          
Tube 6
085                                   
Pl Fl                     
Tube 6                
 Std 7 
1.56 
ng/mL
066                          
Blood                          
Tube 7
085                                   
Pl Fl                     
Tube 7                
 Std 8 
BLANK
066                          
Blood                          
Tube 8
085                                   
Pl Fl                     
Tube 8                
Create dilutions of pl fl and serum samples by serially diluting using the sample diluent (starting with 1ml neat sample and pipetting 500ul across eppendorfs).
Add 100μL of Detection Reagent A working solution to each well, cover with the Plate sealer and Incubate for 1 hour at 37 oC 
Data Analysis
Add 100μL each of dilutions of standard, blank and samples into the appropriate wells. Cover with the Plate sealer. Incubate for 2 hours at 37 oC.
Run the microplate reader and conduct measurement at 450nm immediately
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper
Bring all kit components and samples to room temperature (18-250C) before use.
Sample Preparation
Reagent Provided
Defrost sample by leaving at room temperature for > 30minutes.
Use the diluted standard to produce a double dilution with the last tube as the blank 0 pg/mL (pipetting 250 µl across eppendorfs).
G
H
Reconstitute 1 tube of Standard with 0.5 mL of Standard Diluent, kept for 10 minutes at room temperature, shake gently (avoid foaming). 
The concentration of the top standard is 4000 pg/mL. Prepare 7 eppendorf tubes containing 0.25 mL Standard Diluent.
Reagent Preparation
Briefly spin or centrifuge the stock Detection A and Detection B before use. 
Dilute Detection Reagent A and B stocks to the working concentration with Assay Diluent A and B, respectively (1:100).
MPM Fibulin 3 ELISA Protocol Sheet
Plate 1 Layout
E
F
C
D
A
B
Assay Procedure
Mix each tube thoroughly before continuing the dilution series.
Save Data to a memory Stick and transfer data into relevant Raw OD Data Tab section in Spread sheet.
 Export data with assigned Study name - Plate number - Date.
Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water to prepare 600mL of Wash Solution (1×). Mix gently.
TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual solution into the vial again.
Add 50μl of Stop Solution to each well. Mix the liquid by tapping the side of the plate. 
Add 90μL of Substrate Solution and incubate for 15-25 mins at 37°C.
Wash Step- 350μL of 1× Wash Solution to each well, let it sit for 1~2 minutes. X3 washes
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper
Add 100μL of Detection Reagent B working solution to each well, cover and Incubate for 30 minutes at 37oC
Wash Step- 350μL of 1× Wash Solution to each well, let it sit for 1~2 minutes. X3 washes
Check that the OD450 of the top and bottom standard are within working range to ensure assay sensitivity is not lost. 
Remove the liquid of each well, Don’t Wash
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Appendix 6: ELISA protocols adapted for the manufacturer’s instructions for HMGB1. 
 
1 2 3 4 5 6 7 8 9 10 11 12
 Std 1 
4000 
pg/mL
066                          
Blood                          
Tube 1
085                                   
Pl Fl                     
Tube 1                
 Std 2 
2000 
pg/mL
066                          
Blood                          
Tube 2
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Pl Fl                     
Tube 2                
 Std 3 
1000 
pg/mL
066                          
Blood                          
Tube 3
085                                   
Pl Fl                     
Tube 3                
 Std 4 
500 
pg/mL
066                          
Blood                          
Tube 4
085                                   
Pl Fl                     
Tube 4              
 Std 5 
250 
pg/mL
066                          
Blood                          
Tube 5
085                                   
Pl Fl                     
Tube 5                
 Std 6 
125 
pg/mL
066                          
Blood                          
Tube 6
085                                   
Pl Fl                     
Tube 6                
 Std 7 
62.5 
pg/mL
066                          
Blood                          
Tube 7
085                                   
Pl Fl                     
Tube 7                
 Std 8 
BLANK
066                          
Blood                          
Tube 8
085                                   
Pl Fl                     
Tube 8                
Create dilutions of pl fl and serum samples by serially diluting using the sample diluent (starting with 1ml neat sample and pipetting 500ul across eppendorfs).
Add 100μL of Detection Reagent A working solution to each well, cover with a plate sealer, gently agitate and incubate for 1 hour at 37oC 
Data Analysis
Add 100μL each of dilutions of standard, blank and samples into the appropriate wells. Cover with the Plate sealer. Incubate for 2 hours at 37 oC.
Run the microplate reader and conduct measurement at 450nm immediately.
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper.
Bring all kit components and samples to room temperature (18-250C) before use.
Sample Preparation
Reagent Provided
Defrost sample by leaving at room temperature for > 30minutes.
Use the diluted standard to produce a double dilution with the last tube as the blank 0 pg/mL (pipetting 250 µl across eppendorfs).
G
H
Reconstitute 1 tube of Standard with 0.5 mL of Standard Diluent, kept for 10 minutes at room temperature, shake gently (avoid foaming). 
The concentration of the top standard is 4000 pg/mL. Prepare 7 eppendorf tubes containing 0.25 mL Standard Diluent.
Reagent Preparation
Briefly spin or centrifuge the stock Detection A and Detection B before use. 
Dilute Detection Reagent A and B stocks to the working concentration with Assay Diluent A and B, respectively (1:100).
MPM HMGB-1 ELISA Protocol Sheet
Plate 1 Layout
E
F
C
D
A
B
Assay Procedure
Mix each tube thoroughly before continuing the dilution series.
Save Data to a memory Stick and transfer data into relevant Raw OD Data Tab section in Spread sheet.
 Export data with assigned Study name - Plate number - Date.
Dilute 20mL of Wash Solution concentrate (30×) with 580mL of deionized or distilled water to prepare 600mL of Wash Solution (1×). Mix gently.
TMB substrate - Aspirate the needed dosage of the solution with sterilized tips and do not dump the residual solution into the vial again.
Add 50 µl of Stop Solution to each well. 
Add 90 µl of TMB Substrate to each well, cover with a plate sealer and incubate for 10-20 mins at 37°C. Monitor until optimum colour achieved. 
Wash Step- Aspirate the liquid and add 350μL of 1× Wash Solution to each well, let it sit for 1-2 minutes. X3 washes.
Remove the remaining liquid from all wells completely by snapping the plate onto absorbent paper.
Add 100μL of Detection Reagent B working solution to each well, cover with new plate sealer and incubate for 30 minutes at 37oC.
Wash Step- Aspirate the liquid and add 350μL of 1× Wash Solution to each well, let it sit for 1-2 minutes. X5 washes.
Check that the OD450 of the top and bottom standard are within working range to ensure assay sensitivity is not lost. 
Aspirate the liquid of each well, Do not wash.
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Appendix 7: Predicting prognosis in MPM in a local population, ethical approval by the NRES 
Committee South Central - Berkshire (REC reference number: 14/SC/1139). 
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Appendix 8: Predicting prognosis in MPM in a local population, local site approval by PHT, R & D 
department (reference number PHT/2014/51). 
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Appendix 9: RESPECT-Meso Screening and Randomisation SOP. 
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Appendix 10: RESPECT-Meso Patient Information Sheet. 
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Appendix 11: RESPECT-Meso Carer Patient Information Sheet. 
 
  
173 
 
Appendix 12: RESPECT-Meso Patient Consent Form. 
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Appendix 13: RESPECT-Meso Carer Consent Form. 
 
  
175 
 
Appendix 14: Letter informing GP of patient trial participation. 
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Appendix 15: Letter informing GP of carer trial participation. 
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Appendix 16: SPC reminder letter for patients in the control group. 
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Appendix 17: SPC referral SOP. 
 
 
179 
 
 
 
180 
 
 
  
181 
 
Appendix 18: The Sheffield Profile for Assessment and Referral to Care (SPARC) tool. 
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Appendix 19: The revised Edmonton Symptom Assessment System (ESAS-r) questionnaire. 
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Appendix 20: The European Organization for Research and Treatment of Cancer Quality of Life 
questionnaire Core 30. 
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Appendix 21: The lung cancer supplement (LC13) adjunct. 
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Appendix 22: The short form-36 (SF-36) health survey questionnaire. 
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Appendix 23: The family satisfaction with advanced cancer care-2 (FAMCARE-2) questionnaire. 
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Appendix 24: The 12 item General Health Questionnaire (GHQ-12). 
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Appendix 25: Baseline visit Case Reporting Form. 
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Appendix 26: SPC Intervention CRF. 
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Appendix 27: Patient Clinic Follow-Up Visit CRF. 
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Appendix 28: Carer Clinic Follow-Up Visit CRF. 
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Appendix 29: Telephone Follow-Up CRF.  
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Appendix 30: Post-mortality CRF. 
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Appendix 31: 6 month post mortality letter to carer. 
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Appendix 32: Carer 24 week Post-mortality CRF. 
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Appendix 33: RESPECT-Meso CRF completion SOP. 
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Appendix 34: RESPECT-Meso Trial ethical approval by NRES Committee, London- Hampstead 
(REC reference number: 12/LO/007). 
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Appendix 35: British Lung Foundation (BLF) grant award. 
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Appendix 36: RESPECT-Meso Trial local site approval by PHT, R & D department (reference 
number: PHT/2013/46). 
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Appendix 37: UPR16 form
 
